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Preterm birth (< 37 completed weeks of gestation) and impaired fetal growth are among 
the most frequent causes of perinatal morality worldwide, and are associated with numerous 
long-term health consequences among surviving infants. While the causes of preterm birth and 
its consequences are complex and likely interrelated, characterization of potentially modifiable 
risk factors –such as those posed by environmental exposure to phthalates – may help diminish 
the substantial public health burden associated with these adverse pregnancy outcomes. 
Increasing scientific evidence suggests that exposure to phthalates during pregnancy may be 
associated with increased risks of deleterious birth outcomes such as preterm birth. Maternal 
endocrine disruption in gestation may be one pathway mediating some of these relationships. 
This dissertation research focuses on subclinical maternal thyroid hormone disruption as a 
potential biological pathway by which prenatal phthalate exposure influences adverse birth 
outcomes because (1) maintaining homeostatic maternal thyroid hormone levels throughout 
pregnancy is crucial for normal fetal growth and development; (2) few data are available on the 
direct effects of subclinical thyroid hormone changes in gestation on the risk of preterm birth; 
and (3) phthalate-associated thyroidal disturbances in pregnancy is a largely understudied area of 
environmental and reproductive epidemiology. 
 In the first aim of this dissertation research, we observed that repeated measures of 
urinary phthalate metabolites were associated with altered maternal thyroid hormone levels in 
two qualitatively disparate populations of pregnant women in Northern Puerto Rico and Boston, 
MA. The second and third aims were conducted among the main dissertation cohort (a nested 
case-control study of preterm birth in Boston, MA), and explored the associations between 
subclinical changes in maternal thyroid function parameters and preterm birth as well as 
ultrasound and delivery indices of fetal growth. Our findings from Aim 2 suggest that subclinical 
alterations in individual maternal thyroid hormones, specifically free T4 (FT4) and total T3 (T3), 
influence the risk of preterm birth and the strength of these associations vary by gestational age. 
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Additionally, we observed differences in the temporal hormonal patterns across gestation 
between women who delivered preterm and those who delivered at term, and these variations 
were most evident in the first trimester of pregnancy. Finally, our results from Aim 3 support 
findings from previous studies showing inverse associations between subclinical changes in FT4 
and fetal growth indices including birth weight in generally euthyroid pregnant women. Overall, 
the public health implications of this research need to be determined. Additional human health 
and animal studies are required to confirm these observed relationships and to determine the 
potential biological mechanisms that underlie the effects of phthalate-induced thyroidal 
disturbances on pregnancy and birth outcomes. 
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CHAPTER I. Introduction 
 
BACKGROUND 
Preterm birth (< 37 completed weeks of gestation) and impaired fetal growth are among 
the most frequent causes of perinatal morality.1-5 In 2015, the rate of preterm birth in the United 
States was 9.62%, a marginal increase from the 9.57% rate recorded in 2014.6 This marks the 
first rise in the preterm birth rate since at least 2007, the earliest year for which national data 
were available for the National Center for Health Statistics’ new measure for estimating 
gestational age of a newborn (named the obstetric estimate of gestation at delivery).6,7 The rate of 
babies born with low birth weight (< 2,500 grams), a potential consequence of both preterm 
delivery as well as fetal growth restriction (birth weight < 10th percentile for gestational age), has 
followed a similar temporal trend.5,6 Subsequent to the decreasing rates observed between 2007 
and 2014, the low birth weight rate increased slightly to 8.07% in 2015 from the 8.00% rate 
documented in 2014.6 Although birth outcomes in the United States are arguably better than 
those observed in many developing countries, the United States still has one of the highest rates 
of infant mortality and preterm birth of developed nations.8 In 2010, the preterm birth rate in the 
United States (excluding births at less than 24 weeks) was 40% higher than England and Wales 
and over 69% higher than Finland, Ireland, and Sweden; and ranked last out of the 19 European 
countries studied.9 
Although recent medical advances have improved survival among both preterm and 
growth-restricted infants, the long-term health consequences associated with these adverse birth 
outcomes are significant.1,2 Babies born preterm or growth-restricted are at an elevated risk for 
lasting physical and neurodevelopmental complications such as hearing and vision impairment, 
cerebral palsy, mental retardation, learning difficulties, and non-communicable disease.2,10-13 
These life-long complications, coupled with neonatal and maternal care at delivery, have a 
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profound societal economic impact.10 In 2007, the Institute of Medicine (IOM) estimated that the 
annual economic cost associated with preterm birth in the United States was at least $26 
billion.11 As a result of the persistent and deleterious consequences of preterm birth over the last 
two decades, the IOM assembled a committee to identify research gaps and priorities needed to 
address the risk factors contributing to the considerable preterm birth rate in the United States.11 
In its 2007 report, the IOM committee noted that the dearth of scientific knowledge pertaining to 
the environmental etiologies of preterm birth presented “a potentially significant shortcoming for 
the design of public health prevention strategies”.11 While the causes of preterm birth and fetal 
growth restriction are complex and interrelated,5,11,12 characterization of potentially modifiable 
risk factors, such as those posed by exposure to environmental contaminants, may help diminish 
the substantial public health and economic burdens associated with these adverse birth outcomes.   
Phthalate uses, metabolic patterns, and exposure assessment. The phthalate metabolites 
measured in this current dissertation research as well as their parent compounds are listed in 
Table I.1. Phthalate diesters are commonly used as plasticizers in industrial applications.12 
Additionally, many personal care products and cosmetics, such as fragrances, skin lotions, nail 
polish, and eye shadows, may contain some types of phthalates (e.g., diethyl phthalate [DEP], di-
n-butyl phthalate [DBP], diisobutyl phthalate [DiBP]) as a solvent, fixative or alcohol 
denaturant.13-17 DEP, DiBP and di(2-ethylhexyl) phthalate (DEHP) have been used as a 
component of food and pharmaceutical packaging.14,16,18-21 Other uses of phthalates have 
included vinyl flooring (butylbenzyl phthalate [BBzP]) and medical tubing and devices (DEHP). 
Importantly, over the last decade, alternative chemicals have been increasingly substituted for 
polyvinyl chloride and/or certain phthalates (e.g., DEHP and DBP) in some consumer products 
(e.g., cosmetics and children’s toys) and medical devices (e.g., blood storage bags).16,22,23 Thus, 
the above descriptions may not be entirely representative of the current phthalate content of these 
products. 
Following exposure and uptake, phthalates are rapidly metabolized and excreted in urine 
and feces.16 The biological half-lives of phthalate metabolites have been estimated to be between 
approximately 3 to 18 hours.16 Phthalates typically undergo phase I hydrolysis followed by phase 
II conjugation, but metabolism patterns can differ by phthalate 16,24. In phase I the phthalate 
diester is hydrolyzed into the potentially more bioactive monoester metabolite by lipases and 
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esterases in the intestinal epithelium, liver, blood and other tissues, and systemically distributed 
16,25,26. The monoester metabolites then: 1) undergo phase II biotransformation, catalyzed by 
UGTs (uridine 5’-diphosphate glucuronosyltransferases), to form glucuronide-conjugated 
monoesters that are excreted in the urine 27,28; 2) go through phase I biotransformation reactions 
(e.g., oxidation) to form more hydrophilic (and likely less bioactive) secondary oxidized 
metabolites prior to glucuronidation 29,30; and/or 3) a portion of the unconjugated (free) 
monoester and/or secondary metabolites may also be directly excreted in urine.16 The extent to 
which hydrolytic monoesters are further oxidized to secondary metabolites depends on the alkyl 
chain length of the parent compound.  For the shorter chained phthalates (DEP, DBP, DiBP, 
butyl benzyl phthalate [BBzP]), approximately 70-80% of an oral dose is excreted as the simple 
monoester metabolite in urine compared to less than 10% and 2% of long-chained phthalates 
DEHP and di-isononyl phthalate (DiNP), respectively. 16,27,31-36 
In epidemiology and human biomonitoring studies, urine is the most common biological 
matrix used to assess environmental exposure to phthalates. Although many different biological 
specimens have been used for assessing environmental exposure to chemicals in humans – such 
as blood (serum and plasma), saliva, sweat, semen, breast milk, amniotic fluid, and umbilical 
cord blood – urine offers several advantages in exposure assessment.16 These advantages 
include: ease of sample collection, larger sample volumes, greater concentrations of the 
metabolites, and reduced potential for contamination by the parent diester and subsequent 
formation of metabolites by enzymes present in blood.16,36 However, because phthalates are 
metabolized and excreted rapidly, concentrations in a single urine sample reflect exposure to the 
parent compound or the metabolite itself in the preceding hours or days depending on the 
phthalate.16 Thus, there is some concern as to whether a single urine sample can accurately 
capture longer term exposures (such as weeks to months). Additional urine samples collected 
serially over time, as was utilized in the present dissertation research, can help mitigate the 
potential exposure misclassification over longer periods of time.  
Environmental phthalate exposure is widespread. Due to their ubiquitous use, human exposure 
to phthalates is widespread.37 Because phthalates are not chemically bound to the plastics and 
other products that contain them, they can easily migrate into household dust, food and water 
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sources, and ambient air.12,38,39 Consequently, human exposure to phthalates can occur via 
ingestion, inhalation, and/or dermal absorption.12,40   
Biomonitoring studies have documented pervasive exposure to phthalates among the 
United States general population in the last decade.41,42 Urinary concentrations of monobenzyl 
phthalate (MBzP), monobutyl phthalate (MBP), and monoethyl phthalate (MEP) – metabolites of 
BBzP, DBP, and DEP, respectively – were detected in at least 98% of participants in each cycle 
of the National Health and Nutrition Examination Survey (NHANES) from 2001 to 2010.42 
Urinary concentrations of the oxidized metabolites of DEHP (e.g., mono(2-ethyl-5-oxohexyl) 
phthalate [MEOHP], mono(2-ethyl-5-hydroxyhexyl) phthalate [MEHHP], and mono(2-ethyl-5-
carboxypentyl) phthalate [MECPP]) were also detected in nearly all participants.42 Notably, 
females had consistently greater concentrations of certain urinary phthalate metabolites than 
males across the 10-year study.41,42  
Extensive exposure to phthalates has also been reported in pregnant women in the United 
States43,44 and Puerto Rico.45 The detection of several phthalates in amniotic fluid and cord blood 
indicate that phthalates or their metabolites can cross the placental barrier, resulting in fetal 
exposure.46-49 Given the reproductive and developmental toxicities of phthalates reported in 
animal studies, exposure to these chemicals during particularly vulnerable periods of 
development may pose significant health risks for pregnant women and their unborn babies.50,51 
Phthalate exposure and birth outcomes. Growing evidence suggests that environmental 
contaminants may influence gestational age at delivery as well as fetal growth.11,52-54 Until 
recently, epidemiology studies investigating the environmental factors associated preterm birth 
and fetal growth have focused predominately on prenatal exposures to organochlorine and 
organophosphate pesticides, lead, tobacco smoke, and air pollution.11,55 The contribution of low-
dose exposures to ubiquitous environmental contaminants such as phthalates is less understood.  
Animal studies have shown phthalate-induced adverse effects on pregnancy outcomes at 
exposure levels greater than those experienced by humans. In particular, rodents exposed in 
utero to phthalates had increased pregnancy loss, elevated fetal resorption and death, reduced 
fetal weight, and decreased gestational length.56-60 Results from available human studies 
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assessing the associations between prenatal phthalate exposure and adverse birth outcomes 
(including preterm birth) and fetal growth have been less conclusive.  
Pertaining to preterm birth, a nested case-control study conducted among Mexican 
mother-infant pairs found higher mean third-trimester urinary concentrations of MECPP, MBP, 
and mono(3-carboxypropyl) phthalate ([MCPP]; an oxidized metabolite of both DBP and di-n-
octyl phthalate [DOP]) in women delivering preterm (<37 weeks of gestation) compared with 
women delivering at term (≥37 weeks of gestation).61 Additionally, phthalates detected in cord 
blood samples collected from Chinese pregnant women were associated with an elevated odds of 
preterm delivery.62 In contrast to these findings, increased levels of urinary DEHP metabolites 
(e.g., mono(2-ethylhexyl)phthalate [MEHP], MEOHP, and MEHHP) in the latter half of 
pregnancy were associated with reduced odds of preterm birth among pregnant women 
participating in a multicenter birth cohort in the United States.63 Moreover, a subsequent 
investigation among pregnant women in the Netherlands reported a null association between 
maternal occupational exposure to phthalates and preterm birth.64 Several studies have 
investigated the role of prenatal exposure to phthalates in the length of gestation.47,62,65-68 
However, the results of these studies have been inconsistent, showing both positive, negative, 
and null associations. These discrepant findings related to preterm birth and gestational age at 
delivery may be consequent to study limitations related to exposure assessment (i.e., single spot 
urine samples collected at varying time points in pregnancy, self-reports of occupational 
exposure, and blood measurements of phthalate exposure), small sample sizes, ascertainment of 
outcomes (i.e., gestational age based on participant recall of last menstrual period), and/or 
residual confounding.  
In a case-control study nested within an ongoing prospective birth cohort in Boston – the 
main study population of the this dissertation research – urinary concentrations of MEHP, 
MECPP, and molar sum of DEHP metabolites were associated with significantly elevated odds 
of preterm birth compared with controls.69 In contrast to many of the previous aforementioned 
epidemiological investigations that assessed phthalate exposure via a single spot urine sample in 
late pregnancy, which may be an unreliable indicator of prenatal exposure,70 Ferguson and 
colleagues69 measured urinary phthalate metabolite concentrations using multiple urine samples 
collected longitudinally across pregnancy. To reduce potential outcome misclassification, the 
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authors used clinically and first trimester ultrasound validated gestational dates (in lieu of self-
reported dates of last menstrual period). While unequivocally additional epidemiological 
investigations are required to affirm these findings in qualitatively disparate populations of 
pregnant women, Ferguson and colleagues’ study69 nonetheless provides compelling evidence 
for a potential role of in utero phthalate exposure in the risk of preterm birth.  
A similar inconsistent pattern of results, likely due to the same study limitations 
explicated above for preterm birth, exists in the body of literature pertaining to prenatal phthalate 
exposure and ultrasound and delivery indices of fetal growth. In a multiethnic cohort of mother-
infant pairs in New York City, higher third trimester urinary concentrations of summed low 
molecular weight phthalates were significantly associated with increased head circumference at 
birth.67 In a subsequent nested case-control study in China, in utero DBP and DEHP exposure 
(assessed via parent compound concentrations in cord blood and metabolite concentrations in 
meconium) were significantly associated with low birth weight and shorter birth length among 
term babies, respectively.71 Similar findings were observed in a population-based cohort in the 
Netherlands, wherein occupational exposure to phthalates was associated with decreased fetal 
length and weight.72 However, positive associations have also been reported between phthalate 
metabolites and birth weight,73,74 and analyses among other, large birth cohorts have produced 
generally null associations between maternal urinary concentrations of phthalates and fetal 
growth parameters during pregnancy and at birth 54,65,75 and between maternal occupational 
exposure to phthalates and decreased weight at birth (< 3000 grams).64  
Ferguson and colleagues recently performed an additional analysis within the same 
nested case-control study as that mentioned previously for their work on preterm birth (i.e., the 
population of pregnant women included in the current dissertation research) wherein the authors 
investigated the extent to which maternal exposure to phthalates was associated with various 
indices of fetal growth.76 In their longitudinal analysis, utilizing repeated biomarker and 
ultrasound measurements in pregnancy, the authors observed inverse associations between 
urinary DEHP metabolites and head and abdominal circumferences, femur length, and estimated 
fetal weight.76 Results from this study provide suggestive evidence that maternal exposure to 
phthalates, specifically DEHP, in pregnancy may be associated with reduced fetal growth. 
Building upon these and previous findings related to preterm birth, the present study seeks to 
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augment the current mechanistic understanding of phthalate-induced adverse birth outcomes in 
this cohort of pregnant women.  
Thyroid hormone disruption as a biological mechanism. The biological mechanisms through 
which phthalates act to influence downstream adverse birth outcomes may involve inflammation, 
oxidative stress, and endocrine disruption. There is a well-established link between strong 
inflammatory responses in pregnancy (e.g., as a result of maternal infection), particularly those 
mediated by cytokine and chemokine activation, and preterm labor and preterm premature 
rupture of the membranes (PPROM).11,77-82 Research has also shown that elevated levels of 
oxidative stress in pregnancy, caused by an imbalance of free radical production and availability 
of antioxidants necessary for detoxification, is associated with various adverse pregnancy 
outcomes such as fetal growth restriction, preterm birth (involving intact membranes), and 
PPROM.83 Animal and cellular studies have shown that phthalates, in particular DEHP and its 
hydrolytic monoester (MEHP), may induce pro-inflammatory and oxidative stress processes.84-87 
Human studies have corroborated these findings in adult men and non-pregnant women.88-90 
Among pregnant women, a recent analysis performed among this study’s cohort in Boston 
showed that increases in urinary phthalate metabolites were significantly associated with 
elevated levels of urinary biomarkers of oxidative stress (8-hydroxydeoxyguanosine and 8-
isoprostane), each measured at multiple times points across gestation.91 Similar findings were 
reported in a subsequent longitudinal analysis conducted among Puerto Rican pregnant women, 
an additional prospective birth cohort among whom the present dissertation analyses were 
performed.92 
Phthalates may alter the hormonal milieu of pregnancy to induce downstream adverse 
birth outcomes as well. To date, much of the scientific literature has highlighted phthalate-
induced hormonal disruptions along the hypothalamic-pituitary-gonadal axes. Less is known 
about the role of phthalates in altering thyroidal function in particularly susceptible populations 
such as pregnant women.  
Thyroid hormones are essential for metabolism as well as growth and development.93 
Production of thyroid hormones are tightly regulated by the negative feed-back system that 
involves hypothalamus, pituitary, and thyroid gland (Figure I.1).94 Thyroid hormones (T3 and 
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T4) remain within narrow ranges due to the release of hypothalamic thyrotropin releasing 
hormone (TRH) and pituitary thyroid stimulating hormone (TSH).95 T4 is exclusively produced 
by the thyroid gland whereas ~80% of T3 is produced in extrathyroidal tissues through the 
conversion of T4 to T3 by deiodinase enzymes.96 The vast majority of thyroid hormones in 
circulation are bound to serum proteins; over 99.95% of T4 and 99.5% of T3 are bound to 
transport proteins.94,96 Although both free T4 (FT4) and free T3 (FT3) are unbound in circulation 
and are available for cellular uptake, FT3 binds more readily to nuclear receptors in thyroid-
responsive tissues (including placenta) where its binding initiates transcriptional regulation of 
target genes.94-96 Thus, FT3 is considered the primary bioactive hormone and FT4 is largely a 
prohormone. 94-96 In clinical practice, TSH has been recommended as the main screening test for 
thyroid dysfunction and often is tested in combination with FT4 to mitigate potential 
misdiagnosis. 95 
In pregnancy, the hormonal and metabolic demands increase and induce profound 
alterations in maternal thyroid physiology.97 During the first half of pregnancy, total T4 and 
T3 may increase by as much as 50% due to estrogen-stimulated increases in thyroxine-binding 
globulin (TBG), the major blood transport protein of thyroid hormones.98,99 Levels of T4 and T3 
eventually level off and the increased thyroidal output is maintained until term, owing in part to 
transplacental passage of maternal hormones and increased deiodinase activity of the placenta, 
which regulate circulating levels of thyroid hormones by metabolizing T4 to T3 and/or 
deactivating T4 to reverse T3 (rT3).98 A second major change of maternal thyroid parameters in 
pregnancy involves a transient decrease in maternal serum TSH during the first trimester.97,99,100 
The characteristic dip in TSH in early pregnancy is a result of the weak thyroid-stimulating 
activity of human chorionic gonadotropin (hCG), whose secretion by the placenta increases 
during this period of gestation, and the subsequent negative feedback on the thyroid gland by 
increases in total hormone levels 97,99,100 Also contributing to the elevated thyroidal activity 
during pregnancy is the increased renal clearance of iodine due to an increased glomerular 
filtration rate.98 Finally, in iodine sufficient pregnancies, free hormone levels in pregnant women 
remain within the non-pregnant reference ranges, although slight reductions in free T4 (FT4) and 
free T3 (FT3) concentrations occur during the latter half of pregnancy.98  
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Maintaining maternal euthyroidism throughout pregnancy is essential for embryogenesis 
as well as fetal growth and development, especially neurodevelopment.43,101-105 Thyroid 
hormones play an integral role in early placental development as well as fetal tissue accretion 
and differentiation.106,107 During the first trimester, the fetus relies solely on maternal thyroid 
hormones until the fetal thyroid gland becomes fully functional after 18 weeks of gestation.91,92 
In later pregnancy, maternal thyroid hormones are essential for fetal thyroid homeostasis.102   
Epidemiological investigations have shown that overt thyroid disease in early and late 
gestation is associated with various pregnancy complications such as preterm birth, low birth 
weight, and fetal growth impairment.108-112 Maternal subclinical thyroid disease, specifically 
subclinical hypothyroidism (elevated TSH with normal FT4), has also been linked to similar 
deleterious birth outcomes such as preterm birth and fetal growth impairment, although these 
data are not as conclusive.109 For example, several studies have shown associations between 
subclinical hypothyroidism and an increased risk of preterm birth in cohorts in the United States 
113,114 and China,112 whereas other investigations have reported null associations.115-117 The 
observed dissimilarities in the results of these studies may be due to limitations associated with a 
small number of cases consequent to a lack of sample size, differences in laboratory methods 
used for hormone measurements, variations in the classification of thyroid disease, and/or 
inconsistent ascertainment of outcome measurements (e.g., gestational age based on self-reported 
last menstrual period vs. ultrasound measurements). Additionally, each of the above studies 
assessed subclinical thyroid disease using a single blood sample taken in the first half of 
pregnancy. There is a lack of data pertaining to the effects of trimester-specific subclinical 
alterations in individual thyroid hormone parameters, especially in late gestation, on the risk of 
preterm birth. Furthermore, the extent to which these relationships vary by clinical presentation 
of preterm birth remains unknown.  
Inconsistent findings, likely for similar reasons as explicated above for preterm birth, 
have also been observed across studies investigating the effects of subclinical hypothyroidism on 
various indices of fetal growth: both positive 113,118,119 and null associations 115-117,120 have been 
reported. Additionally, in a prospective birth cohort study in the Netherlands, higher normal-
range FT4 concentrations were associated with low birth weight and an increased risk of small 
for gestational age at birth; no associations were observed for TSH.121 This inverse relationship 
10 
 
between higher FT4 concentrations within generally euthyroid pregnant women and birth weight 
have been corroborated by other studies.122-124 Notably, the majority of these studies restricted 
assessment of thyroid function to early pregnancy. While the fetus is unable to independently 
synthesize thyroid hormones until the second trimester, there is evidence that the fetus may rely 
on maternal thyroid hormones for growth and development even in late gestation.123,125 To our 
knowledge, only one longitudinal study has investigated the impact of subclinical alterations in 
thyroid hormone parameters across trimesters on fetal growth. Specifically, Nishioka and 
colleagues126 reported an inverse association between an increase in maternal TSH 
concentrations between the first and third trimester and low birth weight. This study’s small 
sample size (N=163 neonates) and thus limited number of low birth weight babies (N=10), 
precluded trimester-specific analyses (in lieu of examining absolute changes across the three 
trimesters) and likely contributed to the lack of variation in free hormone concentrations 
observed across the study population. In contrast to Nishioka and coauthors’ study,126 the present 
dissertation research includes nearly three times as many participants, permitting both 
longitudinal and cross-analyses that utilize thyroid hormone measurements and standardized 
growth measurements collected at multiple time points in pregnancy. 
Various biological mechanisms have been proposed through which phthalates may exert 
their action on thyroid function. It has been suggested that phthalates may bind to thyroid 
hormone receptors, consequently activating or inhibiting thyroid hormone action,127-129 although 
data overtly demonstrating the binding of phthalates to thyroid receptors are lacking. Available 
experimental studies have provided some evidence for these potential mechanisms of thyroid 
disruption. In vitro studies have shown that phthalates may alter the sodium/iodide symporter-
mediated uptake of iodide by thyroid follicular cells130,131,113,114 exhibit thyroid receptor 
antagonist activities,132-134 or displace thyroid hormones (e.g., T3) from distributor proteins.135 
Additionally, phthalates were found to alter the transcription of genes involved in the 
hypothalamic-pituitary-thyroid axis as well as the whole-body content of thyroid hormones in 
zebrafish.136 
Limited human health studies have examined the potential thyroid-altering effects of 
phthalates. In a cross-sectional study of men recruited from a U.S. fertility clinic, the urinary 
concentration of MEHP was inversely associated with FT4 and total T3.137 Urinary 
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concentrations of DEHP metabolites were also inversely associated with total T3 and total and 
free T4, and positively associated with TSH in a representative sample of U.S. adults (non-
pregnant women and men) participating in NHANES.138 Similar inverse relationships between 
urinary DEHP metabolites and total and free T3 were reported in a cross-sectional study of 
Danish children.139 While pervasive exposure to phthalates has been documented among 
pregnant women worldwide,48,62,123-126 human health studies investigating the effects of phthalate 
exposure during pregnancy on maternal thyroid function are scarce. Huang and colleagues 140 
reported an inverse association between urinary concentrations of MBP, and both free and total 
T4 in the second trimester among 76 Taiwanese pregnant women undergoing amniocentesis. In a 
more recent cross-sectional analysis conducted among a separate cohort of Taiwanese pregnant 
women (N=148), Kuo and colleagues141 observed significant inverse unadjusted associations 
between several urinary phthalate metabolites (MEOHP, MEHHP, and MBzP) and serum TSH 
in the third trimester. While these findings provide suggestive evidence for phthalate-induced 
thyroidal disturbances during pregnancy, these studies are limited by their small sample size and 
cross-sectional study designs. 
In conclusion, this dissertation research focuses on subclinical maternal thyroid hormone 
disruption as a potential biological pathway by which prenatal phthalate exposure influences 
adverse birth outcomes because (1) maintaining homeostatic maternal thyroid hormone levels 
throughout pregnancy is crucial for normal fetal growth and development; (2) few data are 
available on the direct effects of subclinical thyroid hormone changes in gestation on the risk of 
preterm birth; and (3) phthalate-associated thyroidal disturbances in pregnancy is a largely 




The present dissertation will focus on the effects of maternal subclinical thyroid hormone 
disruption in potentially mediating the relationships between maternal phthalate exposure and 
preterm birth and fetal growth. 
Aim 1. Examine the extent to which maternal urinary phthalate metabolite levels are associated 
with maternal thyroid hormones concentrations (including TSH, free and total T4, and/or free 
and total T3), each measured at multiple time points during pregnancy.  
Phthalate-associated thyroidal disturbances in pregnancy is a largely understudied area of 
environmental and reproductive epidemiology. These associations were initially explored in a 
relatively small, prospective cohort of pregnant women from Northern Puerto Rico, and were 
subsequently repeated among the main dissertation cohort consisting of pregnant women who 
planned to deliver at Brigham and Women’s Hospital in Boston, MA. 
I hypothesized that (1) urinary phthalate metabolites will be inversely associated with 
maternal thyroid hormone concentrations, including free and total T4 and T3, and (2) the 
relationships between urinary phthalate metabolite levels and plasma thyroid hormone 
concentrations vary by time point of sample collection during gestation, with stronger 
associations observed in the latter half of pregnancy. 
Aim 2. Assess the extent to which maternal thyroid hormone concentrations measured at 
multiple time points in pregnancy are associated with preterm birth, and to explore differences 
in the patterns of these hormones across pregnancy between women who delivered preterm and 
at term. 
Maternal thyroid hormones are essential for early placental development and for 
initiation and maintenance of the pregnancy state. Few data are available on are available on the 
direct effects of subclinical changes in maternal thyroid hormones in gestation on the risk of 
preterm birth, and no studies have investigated differences in hormonal patterns across 
pregnancy in women delivering preterm vs. term. 
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I hypothesized that (1) maternal plasma thyroid hormone associated are associated with 
an elevated odds of preterm birth, and (2) these associations vary by clinical presentation of 
preterm delivery (spontaneous preterm birth vs. preterm birth resulting from aberrant 
placentation) and by the time point of sample collection during gestation.  
Aim 3. Determine the extent to which maternal thyroid hormone concentrations are associated 
with ultrasound and delivery indices of fetal growth. 
 Results from available human health studies investigating the associations between 
subclinical thyroid dysfunction in pregnancy and fetal growth are conflicting. The majority of 
these studies assess fetal growth via birth weight or other anthropometric measurements at 
delivery. Few analyses have explored these associations using repeated measures of maternal 
thyroid hormone concentrations and fetal growth collected across pregnancy. 
 I hypothesized that maternal plasma thyroid hormone concentrations are inversely 




PROTECT cohort [Aim 1]. The Puerto Rico Testsite for Exploring Contamination Threats 
(PROTECT) project is an ongoing prospective birth cohort in the Northern Karst Region of 
Puerto Rico designed to investigate the relationship between phthalates and other environmental 
contaminants and adverse pregnancy outcomes such as preterm birth. The study population for 
the present dissertation research included data collected from the first 106 pregnant women with 
urinary phthalate metabolites and serum thyroid and sex hormones measures completed as of 
November 2012. Biomarker measurements were available at up to two time points in pregnancy. 
Additional information regarding subject recruitment and eligibility as well as data collection is 
provided in the subsequent dissertation data chapters. 
LifeCodes cohort [Aims 1-3]. Participants were part of a nested case-control study of preterm 
birth drawn from the LifeCodes cohort, a prospective birth cohort of pregnant women who 
planned to deliver at Brigham and Women’s Hospital in Boston, MA. Women were followed 
until delivery, and provided urine and blood samples for biomarker measurements and 
underwent ultrasound scans at up to four time points in pregnancy. Additional information 
regarding subject recruitment and eligibility as well as data collection is provided in the 
subsequent dissertation data chapters. From the prospective LifeCodes cohort, 130 women who 
delivered preterm (< 37 weeks) and 352 randomly selected controls were included in the nested 
case-control study. For the current dissertation research, an additional 41 women with self-
reported pre-existing or gestational thyroid disease/conditions (e.g., hyper- or hypothyroidism, 
Graves’ disease, or thyroid cancer) based on answers to medical questionnaires administered at 
each of the study visits were additionally excluded. Two women who did not provide plasma 
samples at any study visit were also excluded. The final study population included 116 cases of 
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Table I.1. Phthalate parent compounds and their metabolites 
Parent Compound,  
Abbreviation(s) 
Major Metabolite(s),  
Abbreviation(s) 
Diethyl phthalate  
 
DEP Mono-ethyl phthalate  MEP 










Di-isobutyl phthalate  
 























Di-isononyl phthalate DiNP Mono(carboxy-isooctyl) 
phthalate  
MCOP 
Diisodecyl phthalate DiDP Monocarboxyisononyl 
phthalate  
MCNP 
    












































CHAPTER II. Urinary Phthalate Metabolites in Relation to Maternal 
Serum Thyroid and Sex Hormone Concentrations during Pregnancy: A 
Longitudinal Analysis (PROTECT Cohort) 
 
ABSTRACT 
Background: Increasing scientific evidence suggests that exposure to phthalates during 
pregnancy may be associated with an elevated risk of adverse reproductive outcomes such as 
preterm birth. Maternal endocrine disruption across pregnancy may be one pathway mediating 
some of these relationships. We investigated whether urinary phthalate metabolites were 
associated with maternal serum thyroid (free thyroxine [FT4], free triiodothyronine [FT3], and 
thyroid-stimulating hormone [TSH]), and sex (estradiol, progesterone, and sex hormone-binding 
globulin [SHBG]) hormone levels at multiple time points during pregnancy.  
Methods: Preliminary data (n=106) were obtained from an ongoing prospective birth cohort in 
Northern Puerto Rico. We collected urine and serum sample at the first and third study visits that 
occurred at 18 +/- 2 and 26 +/-2 weeks of gestation, respectively. To explore the longitudinal 
relationships between urinary phthalate metabolites and serum thyroid and sex hormone 
concentrations, we used linear mixed models (LMMs) adjusted for prepregnancy body mass 
index (BMI) and maternal age. An interaction term was added to each LMM to test whether the 
effect of urinary phthalate metabolites on serum thyroid and sex hormone levels varied by study 
visit.  In cross-sectional analyses, we stratified BMI- and age-adjusted linear regression models 




Results: In adjusted LMMs, we observed significant inverse associations between mono-3-
carboxypropyl phthalate (MCPP) and FT3 and between mono-ethyl phthalate (MEP) and 
progesterone.  In cross-sectional analyses by study visit, we detected stronger and statistically 
significant inverse associations at the third study visit between FT3 and MCPP as well as mono-
carboxyisooctyl phthalate (MCOP); also at the third study visit, significant inverse associations 
were observed between FT4 and metabolites of di-(2-ethylhexyl) phthalate (DEHP). The inverse 
association between MEP and progesterone was consistent across study visits.  
Conclusions: In this group of pregnant women, urinary phthalate metabolites may be associated 
with altered maternal serum thyroid and sex hormone levels, and the magnitude of these effects 
may depend on the timing of exposure during gestation. 
INTRODUCTION 
Phthalate diesters are commonly used as plasticizers in industrial applications.1 
Additionally, many household and consumer products, including flooring and wall coverings, 
food packaging, and cosmetics such as lotions and fragrances, contain phthalates. 2-4 Due to their 
ubiquitous use, human exposure to phthalates is widespread.5 Because phthalates are not 
chemically bound to the plastics and other products that contain them, they can easily leach into 
household dust, food and water sources, and ambient air.1,6,7 Consequently, human exposure to 
phthalates can occur through ingestion, inhalation, or dermal absorption.1,3 
Growing evidence suggests that urinary concentrations of phthalate metabolites during 
pregnancy are associated with adverse reproductive outcomes including preterm birth and 
pregnancy loss.8,9 Hormonal production and regulation are critical for pregnancy maintenance 
and fetal growth and neurodevelopment; maternal endocrine disruption during pregnancy may be 
one pathway mediating some of these relationships.10-13 
Limited human health studies have examined the potential thyroid-altering effects of 
phthalates. In a cross-sectional study of men recruited from a U.S. fertility clinic, the urinary 
concentration of mono-(2-ethylhexyl) phthalate (MEHP), a metabolite of di-(2-ethylhexyl) 
phthalate (DEHP), was inversely associated with free thyroxine (3, 3', 5, 5'-tetraiodo-L-
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thyronine, FT4) and total triiodothyronine (3, 3', 5-triiodo-L-thyronine, T3).14 Urinary 
concentrations of DEHP metabolites were also inversely associated with total T3 and T4, and 
positively associated with thyroid-stimulating hormone (thyrotropin, TSH) in a representative 
sample of U.S. adults (non-pregnant women and men) participating in the National Health and 
Nutritional Examination Survey (NHANES).15 Similar inverse relationships between urinary 
DEHP metabolites and total and free T3 (FT3) were reported in a cross-sectional study of Danish 
children.16  While pervasive exposure to phthalates has been documented among pregnant 
women worldwide,17-22 human health studies investigating the effects of phthalate exposure 
during pregnancy on maternal thyroid function are scarce. Huang and colleagues23 reported an 
inverse association between urinary concentrations of monobutyl phthalate (MBP), the 
metabolite of dibutyl phthalate (DBP), and both free and total T4 in the second trimester of 
Taiwanese pregnant women. 
Animal and in vitro studies have also shown that phthalates can interfere with sex 
hormone concentrations, signaling, and/or function,24,25 which may profoundly affect 
implantation, fetal development, and parturition.10,26 However, human data pertaining to the 
relationships between phthalates and sex hormones are limited. In men recruited through a U.S. 
fertility clinic, urinary MEHP was inversely associated with serum estradiol levels.27 A positive 
association between urinary MEHP and sex hormone-binding globulin (SHBG) was also 
reported in separate cohort of fertile U.S. men.28 In a recent study conducted among pregnant 
women in the U.S., an inverse association was found between urinary DEHP metabolite 
concentrations and serum testosterone concentrations, while no statistically significant 
relationship was observed for estradiol.29 Additionally, Hart and coauthors30 reported 
significantly inverse correlations between serum MEHP and SHBG concentrations at both 18 
weeks and 36 weeks of gestation among pregnant women in Australia.  
We are aware of no published investigations that longitudinally evaluate the potential 
thyroid-disrupting effects of environmental phthalate exposure among pregnant women. 
Furthermore, whether alterations in thyroid and sex hormone levels vary by time point of 
exposure during gestation remains largely undetermined and may have important influences on 
downstream hormone-mediated reproductive outcomes. In this preliminary analysis, we 
investigated the relationship between urinary phthalate metabolites and maternal serum thyroid 
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(FT3, FT4, and TSH) and sex (estradiol, progesterone, and SHBG) hormone levels measured in 
samples collected at two time points in pregnancy from women participating in a prospective 
birth cohort in Puerto Rico.  
METHODS 
Study Population 
The Puerto Rico Testsite for Exploring Contamination Threats (PROTECT) project is an 
ongoing prospective birth cohort in the Northern Karst Region of Puerto Rico designed to 
investigate the relationship between phthalates and other environmental contaminants and 
adverse pregnancy outcomes such as preterm birth. A previous study within this project reported 
greater concentrations of some urinary phthalate metabolites measured in Puerto Rican 
participants compared to women of reproductive age in the contiguous U.S.31 The current 
analysis included data collected from the first 106 pregnant women participating in the 
PROTECT project with urinary phthalate metabolites and serum thyroid and sex hormones 
measures completed as of November 2012. Study participants, aged 18 to 40 years, were 
recruited around 14 ± 2 weeks gestation from 7 prenatal clinics and hospitals throughout 
Northern Puerto Rico from 2010 to 2012. Participant recruitment and eligibility criteria as well 
as sample collection and processing are described in detail elsewhere.31 Demographic 
information was obtained from questionnaires administered at the initial study visit. Spot urine 
samples were collected from each participant at three separate study visits (visit 1: 18 ± 2 weeks, 
visit 2: 22 ± 2 weeks, visit 3: 26±2 weeks of gestation). Only urine samples from visits 1 and 3 
were utilized in the present analyses because blood samples were not collected at visit 2. All 
participants in the present analysis provided urine and serum samples for at least one visit (visits 
1 and/or 3). Upon collection and processing (e.g., aliquoting, centrifugation, and separation of 
blood into plasma and serum components), all urine and blood samples were frozen at -80˚C 
until shipped overnight on dry ice to the analytical laboratories where samples were again stored 
at -80˚C until analysis.  
The study protocols were approved by the ethics and research committees of the 
participating institutions. The involvement of the Centers for Disease Control and Prevention 
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(CDC) laboratory was determined not to constitute engagement in human subjects research. The 
study was described in detail to all participating women and all study participants gave informed 
consent.  
Measurement of Phthalate Metabolites 
Available urine samples (N=196 samples, N=106 participants) were analyzed by the 
Centers for Disease Control and Prevention (CDC) laboratories, using protocols developed for 
NHANES, to measure urinary concentrations (free plus glucuronidated) of 11 phthalate 
metabolites: MEHP, MBP, mono-2-ethyl-5-hydroxyhexyl phthalate (MEHHP), mono-2-ethyl-5-
oxohexyl phthalate (MEOHP), mono-2-ethyl-5-carboxypentyl phthalate (MECPP), mono-3-
carboxypropyl phthalate (MCPP), mono-carboxyisooctyl phthalate (MCOP), mono-
carboxyisononyl phthalate (MCNP), mono-benzyl phthalate (MBzP), mono-iso-butyl phthalate 
(MiBP), and mono-ethyl phthalate (MEP). The analytical method involved enzymatic 
deconjugation of the metabolites from their glucuronidated form, solid-phase extraction, 
separation by high-performance liquid chromatography, and detection by isotope-dilution 
tandem mass spectrometry.32 The limits of detection (LOD) were in the low nanogram per 
milliliter range.31 Concentrations below the LOD were assigned a value of LOD divided by the 
square root of 2.33 To account for urine dilution, urinary specific gravity (SG) was measured 
using a digital handheld refractometer (Atago Co., Ltd., Tokyo, Japan). For descriptive analyses, 
metabolite concentrations were standardized using the following formula: PSG=P[(1.019−1)/(SG−
1)], where PSG is the specific gravity-adjusted phthalate metabolite concentration (ng/mL), P is 
the observed phthalate metabolite concentration, 1.019 was the specific gravity population 
median, and SG is the specific gravity of the urine sample. 
Measurement of Thyroid Hormones 
For 106 subjects, serum samples from visits 1 (N= 106) and 3 (N= 89) were available for 
measurement of FT3, FT4, and TSH at the Bioanalytical Core Laboratory of Georgetown 
University (Washington, DC). Limitations in sample volume contributed to differences in the 
number of samples per study visit available for analysis.  Following an ultrafiltration step to 
separate the free hormones, FT3 and FT4 were measured using isotope dilution liquid 
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chromatography tandem mass spectrometry per the methods described in detail previously.34-37 
TSH concentrations were measured using a solid-phase immunochemiluminometric assay (DPC 
Immulite, Diagnostic Products Corporation) according to the manufacturer’s instructions.  
Measurement of Sex Hormones 
For 104 subjects, serum samples were analyzed for estradiol (visit 1: N=103 samples; 
visit 3: N=86 samples) and progesterone (visit 1: N=104; visit 3: N=89) using a 
chemiluminescence immunoassay (DPC Immulite, Diagnostic Products Corporation). Serum 
levels of SHBG from samples collected from 99 subjects (visit 1: N=88; visit 3: N=69) were 
determined using the same procedures. Similar to the thyroid hormone analyses, limitations in 
sample volume contributed to differences in available samples for each sex hormone/study visit.  
These analyses were also performed by the Bioanalytical Core Laboratory at Georgetown 
University (Washington, DC). 
Statistical Analysis 
Serum concentrations of FT4, FT3, estradiol, and SHBG closely approximated normality 
and were untransformed in statistical analyses. TSH, progesterone, and urinary phthalate 
metabolite concentrations were positively skewed and were logarithmically transformed prior to 
analyses. Because MEHP, MEOHP, MEHHP, and MECPP share a single parent compound, the 
sum of concentrations of the DEHP metabolites (ΣDEHP) was calculated from the molar sum 
(nmol/mL) of these four metabolites and log-transformed in statistical analyses. Means and 
standard deviations as well as selected percentiles were used to examine the distributions of the 
urinary phthalate metabolites, thyroid hormones, and sex hormones. Geometric means and 
standard deviations were calculated for non-normally distributed variables.  
Pearson correlations were calculated to assess the relationships between continuous 
variables. To test the differences in the mean concentrations of sex and thyroid hormones by 
visit, we used linear mixed models (LMMs) with serum hormones levels regressed on study visit 
and included a random intercept for subject ID to account for intra-individual correlation of 
repeated measurements over time. Urinary phthalate metabolites and sex and thyroid hormones 
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were tested for associations with demographic variables to examine potential confounding. We 
used LMMs with one phthalate metabolite concentration measure (as exposure) and one outcome 
per model to explore the longitudinal relationships between urinary phthalate metabolites and sex 
and thyroid hormone concentrations. Crude models were adjusted for urinary specific gravity 
and study visit. Full models additionally included maternal prepregnancy body mass index 
(BMI) and age, both measured at the initial study visit. BMI was modeled as a categorical 
variable (≤25 kg/m2, >25 and ≤30 kg/m2, >30 kg/m2) and age was modeled as a continuous 
variable. BMI and age were included as covariates because of their potential influence on urinary 
phthalate metabolite concentrations38 and sex and thyroid hormone levels.39-41 A likelihood ratio 
test for fixed effects was used to identify additional potential covariates in full models. An 
interaction term was added to each full LMM to test whether the effect of urinary phthalate 
metabolites on thyroid and sex hormone serum levels varied by study visit. 
In a secondary analysis, we used linear regression models with one phthalate metabolite 
concentration and one outcome per model to investigate the cross-sectional relationships 
between urinary phthalate metabolites and sex and thyroid hormone serum concentrations at each 
study visit (visits 1 and 3). These models were also adjusted for maternal BMI, age, and urinary 
specific gravity. To enhance interpretability, all regression coefficients and associated 95% 
confidence intervals (CIs) generated from the LMMs and linear regression models were 
expressed as the percent change in hormone serum levels for an interquartile range (IQR) 
increase in urinary phthalate metabolite concentrations. Associations were considered 
statistically significant at the 5% level and marginally significant at the 10% level. All statistical 
analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, NC). 
RESULTS 
Table II.1 shows the distribution of sociodemographic characteristics of the 106 pregnant 
women included in the present analysis. The study participants were generally highly educated 
(79.2% had at least a college education), and did not smoke during pregnancy (94.3%). 
Approximately half (55.7%) of the women had a prepregnancy BMI ≤25 kg/m2. No statistically 
significant differences were observed between the demographic characteristics  of study 
participants with measurable thyroid and sex hormone concentrations at visit 1 vs. those with 
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measurable thyroid and sex hormone concentrations at visit 3 (chi-square test p-values > 0.05). 
Based on the eligibility criteria, no participants used oral contraceptives within three months 
prior to pregnancy or underwent in vitro fertilization as a method of assisted reproductive 
technology, and all participants were free of known medical or obstetric complications. 
The distributions of the 11 urinary phthalate metabolite concentrations across pregnancy 
have been previously investigated in this cohort.31 Greater than 90% of the measured 
concentrations of all 11 urinary phthalate metabolites were detectable.31 Concentrations for a 
majority of the metabolites measured were greater in the Puerto Rican participants when 
compared to women of reproductive age in the contiguous U.S.31 For example, the geometric 
mean concentration of urinary MEHP (unadjusted for urinary dilution) was more than twice as 
high in the Puerto Rican cohort than the corresponding concentration found in women of 
reproductive age participating in the 2009-2010 NHANES study (3.3 vs. 1.6 ng/mL, 
respectively).31  Spearman correlations between the majority of urinary metabolites were modest 
(R= 0.23-0.45), while strong correlations were observed between all urinary metabolites of 
DEHP (MEHP, MEHHP, MEOHP, and MECPP; R>0.83).31 With the exception of MCOP, no 
statistically significant differences were observed in the geometric mean concentrations between 
study visits for any of the other urinary phthalate metabolites (Table II.S1).  
The distributions of the thyroid and sex hormones are presented in Table II.2. All of the 
measured concentrations of the hormones were detectable. We found a significantly positive 
Pearson correlation between estradiol and progesterone (R=0.66, p<0.001). Weak but significant 
positive correlations were observed between FT4 and FT3 (R=0.17, p= 0.02), and between 
SHBG and both progesterone (R= 0.23, p= 0.004) and estradiol (R=0.29, p= 0.0002). Age was 
inversely correlated with thyroid and sex hormone levels (Table II.S2). With the exception of 
TSH, LMMs showed that thyroid hormone levels differed significantly by study visit (Table 
II.3). We found significantly higher mean levels of serum FT3 and FT4 at visit 1 compared to 
corresponding levels at visit 3. Conversely, the mean serum levels of all three sex hormones 




Table II.4 shows the fully adjusted longitudinal associations between urinary phthalate 
metabolite concentrations and serum hormones concentrations from LMMs. Each model 
contained random intercepts only for subject ID to account for intra-individual correlation, as 
addition of random slopes did not improve the model fit. A likelihood ratio test for fixed effects 
indicated that maternal education did not have a significant effect on serum hormone levels. 
Thus, prepregnancy BMI, maternal age, study visit, and urinary specific gravity were the only 
covariates retained in the final models. The crude regression results were similar to the adjusted 
results (not shown). We detected a significant inverse relationship between MCPP and FT3, 
where an IQR increase in MCPP was associated with a 2.89% decrease in FT3 (95% CI= -5.65 
to -0.02, p=0.049). We also observed a significant inverse association between MEP and 
progesterone. An IQR increase in MEP was associated with a 10.6% decrease in progesterone 
(95% CI= -17.6 to -2.84, p=0.01). We detected no significant associations between serum 
hormones levels and ΣDEHP urinary metabolites in longitudinal analyses. Similarly, null results 
were observed for individual DEHP metabolites, with the exception of a marginally significant 
inverse association found between MEHHP and SHBG (percent change in outcome with IQR 
increase [%Δ] =-4.62, 95%CI= -10.0 to 0.75, p=0.09). Most urinary phthalate metabolites were 
positively associated with TSH, although none of these relationships were statistically 
significant. We also found no statistically significant associations for FT4 or estradiol in the 
longitudinal analyses.  
In our examination of the potential interaction between study visit and urinary phthalate 
metabolite concentrations in longitudinal analyses, we observed that study visit significantly 
modified the relationships between FT3 and MBzP (p=0.03) and MCPP (p=0.03), between FT4 
and MiBP (p=0.01) and ΣDEHP metabolites (p=0.048), and between TSH and MBP (p=0.04). 
We found no statistically significant interactions between study visit and urinary phthalate 
metabolites for any of the sex hormones examined (data not shown). 
Table II.5 presents the results from cross-sectional analyses by study visit for 
associations between urinary phthalate metabolites and serum thyroid hormone concentrations. 
At visit 1, we observed a statistically significant positive association between MiBP and FT4 
(%Δ =4.95, 95%CI= 0.27 to 9.28, p=0.04). MBzP and ΣDEHP metabolites were also positively, 
though not significantly, associated with FT4 at visit 1. At visit 3, urinary phthalate metabolites 
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were generally inversely associated with FT4. At this visit, we found a statistically significant 
inverse association between ΣDEHP and FT4 (%Δ =-8.02, 95%CI= -15.3 to -0.80, p=0.03). 
Urinary phthalate metabolites were generally positively associated with TSH at each study visit, 
and suggestive associations were observed with MBzP at visit 1 and MEP at visit 3. While FT3 
was inversely associated with both MCPP and MCOP at visit 1, these effects were greater and 
statistically significant at visit 3.  
The results of cross-sectional analyses for the relationships between urinary phthalate 
metabolites and sex hormone concentrations are presented in Table II.6. We observed a 
marginally significant inverse relationship between MEP and SHBG at visit one (%Δ =-10.1, 
95%CI= -21.8 to 1.65, p=0.09), and a null association at visit 3. The inverse association between 
MEP and progesterone observed in the longitudinal analyses appeared consistent across study 
visits.  
DISCUSSION 
To our knowledge the present study is the first to examine the relationships between 
urinary phthalate metabolites and serum thyroid hormone levels longitudinally across pregnancy. 
Few associations were observed in longitudinal analyses, although we did find statistically 
significant inverse associations between FT3 and MCPP, a non-specific metabolite of several 
high molecular weight phthalate plasticizers, and also between progesterone and MEP, the main 
metabolite of diethyl phthalate commonly used in personal care products. We also found that 
study visit of sample collection significantly modified the relationships between certain urinary 
phthalate metabolites and thyroid hormone levels. Our cross-sectional analyses corroborated our 
findings from the interaction analyses, and showed that associations between certain urinary 
phthalate metabolites and FT3 and FT4 hormone levels differed markedly (in terms of both 
magnitude and significance) based on visit of sample collection. For visit 1, associations with 
FT3 and FT4 were generally inverse, but at visit 3 these inverse relationships were stronger. 
Taken together, these results suggest that phthalate exposure during pregnancy may alter 
maternal thyroid and sex hormone levels. They also suggest that the magnitude of the potential 
endocrine-disrupting effect of phthalates may depend on the timing of exposure during gestation.  
37 
 
 Of the thyroid hormones, we observed that FT4 was inversely associated with certain 
urinary phthalate metabolites at visit 3 (26 ± 2 weeks of gestation). These results are in contrast 
to a previous cross-sectional investigation conducted among 76 Taiwanese pregnant women with 
urinary phthalate metabolites and hormone levels measured in the second trimester (mean time 
of sample collection = 27.9 ± 2.3 weeks of gestation).23 Huang and colleagues reported a 
statistically significant inverse association between urinary MBP and serum FT4 after adjusting 
for similar covariates in their regression model. We did not observe an analogous association at 
visit 3 (a comparable gestational age at sample collection) in the present study. FT3 was not 
measured in this previous investigation and regression results for TSH were not presented by the 
authors, thereby precluding additional comparisons with findings from our analyses. Differences 
between the results of our study and the Taiwanese study may be due to dissimilarities in study 
design, participant demographic characteristics, exclusion/inclusion criteria and/or exposures. 
For example, the median concentration (unadjusted for urinary dilution) of MBP was 
approximately four times higher in the Taiwanese pregnant women (81.8 ng/mL)23 compared to 
the corresponding concentration found in women in the PROTECT cohort (20.1 ng/mL).31 
 Our findings for urinary metabolites of DEHP and serum FT4 and TSH are consistent 
with a previous study of adults (including non-pregnant women and men) participating in 
NHANES that reported significant inverse associations between certain urinary DEHP 
metabolites and FT4, although that larger study also reported positive relationships between 
these metabolites and TSH which were not significant in the present study.15 Our results for FT3 
and FT4 are also in agreement with the limited animal studies in which rats fed DEHP-
contaminated diets, at doses orders of magnitude higher than those experienced by the 
PROTECT participants, had lower plasma T4 levels compared to controls and plasma T3 levels 
remained unchanged.42-45 
Various biological mechanisms have been proposed through which environmental 
chemicals may exert their action on thyroid function. Thyroid-disrupting chemicals may target 
the hypothalamic-pituitary-thyroid axis at multiple levels and may disrupt thyroid hormone 
homeostasis by interfering with the synthesis and regulation by the hypothalamic-pituitary 
thyroid hormones (i.e., thyrotropin-releasing hormone [TRH] and TSH), binding of thyroid 
hormones to distributor proteins, cellular uptake mechanisms of thyroid hormones, metabolism 
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of thyroid hormones by iodothyronine deiodinases, transcriptional activity of thyroid hormone 
receptors and/or receptor activation.46,47 It has been suggested that phthalates may bind to thyroid 
hormone receptors, consequently activating or inhibiting thyroid hormone action,46-48 although 
data overtly demonstrating the binding of phthalates to thyroid receptors are lacking. Available 
experimental studies have provided some evidence for these potential mechanisms of thyroid 
disruption. In vitro studies have shown that phthalates may alter the sodium/iodide symporter-
mediated uptake of iodide by thyroid follicular cells,49,50 exhibit thyroid receptor antagonist 
activities,24,49,50  or displace thyroid hormones (e.g., T3) from distributor proteins.51 Additionally, 
phthalates were found to alter the transcription of genes involved in the hypothalamic-pituitary-
thyroid axis as well as the whole-body content of thyroid hormones in zebrafish.52 
Of the sex hormones, we observed a consistent inverse relationship between urinary MEP 
and serum progesterone across the two time points in pregnancy. In contrast to these findings, 
the previously described study by Huang et al.23 reported no relationship between urinary MEP 
or other phthalate metabolites and progesterone during approximately the same sampling period 
in pregnancy as visit 3 in the current study. At visit 1 (18 ± 2 weeks of gestation), we observed a 
marginally significant inverse relationship between urinary MEP and SHBG, although no 
association was observed at visit 3. These results are in agreement with a previous study 
conducted among 1,377 pregnant Australian women, in which an inverse relationship between 
serum MEP and SHBG concentrations was observed early in pregnancy (18 weeks of 
gestation).30 Animal studies investigating the potential toxicity of phthalates on the female 
reproductive system are scarce, and have primarily examined effects of DEHP and DBP. These 
phthalates have been shown to reduce progesterone production in female rats in vivo and in rat 
granulosa cells in vitro.53-55 However, we did not observe these relationships with metabolites of 
DEHP and DBP in the present analysis.   
Our null findings for estradiol were comparable to those of previous epidemiologic 
studies conducted among pregnant women.23,29 However, available toxicological data have 
shown that the ovary, in particular the granulosa cells of preovulatory follicles, may be the 
primary target site for DEHP.56 Specifically, in vivo and in vitro studies of DEHP-treated female 
cycling rats have demonstrated that suppressed estradiol production may be the principal 
functional modification by DEHP.56-58 These toxicology studies suggest that phthalates have the 
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potential to induce alterations in steroidogenesis in female animals, although further research is 
needed to fully characterize the specific modes of action. Examining this association in a larger 
sample of pregnant women may enable identification of subtler relationships. 
While the timing of exposure to endocrine disrupting chemicals during pregnancy has 
been shown to influence both the severity and onset of adverse developmental and reproductive 
outcomes,59 we are aware of no epidemiologic studies that have attempted to identify periods of 
susceptibility to phthalate-induced alterations in thyroid and sex steroid hormone levels in 
pregnant women. During the first trimester, the fetus relies solely on maternal T3 and T4 until 
the fetal thyroid gland fully develops at approximately 10 weeks of gestation.60 Thus, 
maintaining maternal euthyroidism during the first trimester is critical – even slight alterations in 
maternal thyroid hormones during this period of gestation has been associated with deleterious 
neurodevelopmental and reproductive outcomes.61-63 In later pregnancy, maternal thyroid 
hormones are essential for fetal thyroid homeostasis.64 Although we detected a significant 
inverse relationship between urinary MiBP and serum FT4 in the first trimester (i.e., at visit 1), 
the strongest findings for FT4 were observed in the second half of pregnancy (i.e., at visit 3).  
Despite epidemiological investigations that have shown the potential adverse reproductive 
consequences of overt thyroid disease in early and late gestation,65,66 the impact of trimester-
specific subclinical alterations in maternal thyroid function on pregnancy outcomes remains 
largely understudied. Furthermore, we observed a consistent inverse association between urinary 
MEP and progesterone at each study visit, and this effect was greatest earlier in pregnancy (i.e., 
visit 1). Because progesterone plays an essential physiological role in the establishment and 
maintenance of pregnancy, insufficient concentrations of this hormone throughout gestation may 
lead to pregnancy loss or preterm birth, depending on the timing of hormonal disruption.12,67,68 
 While our findings may have important public health implications, our study has several 
limitations. Characteristic of most preliminary analyses in an ongoing prospective cohort, our 
study was limited by a small sample size. We expected that the availability of multiple 
measurements per subject would increase the power to detect associations, but analysis revealed 
that the effects of phthalates on hormone disruption may be different depending on timing of 
exposure. Furthermore, given the large number of statistical tests performed in the present 
analyses, there is possibility of type-1 error. Another potential limitation is our timing of data 
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collection during mid-pregnancy, which may potentially bias our results since women who 
spontaneously aborted in the first trimester are not captured in our analyses. We do not have 
biological data from these women pertaining to the exposure and outcomes of interest to assess 
the direction of the potential bias. Our study may also have been limited by our evaluation of 
circulating thyroid hormones as a sole indicator of thyroid toxicity.69 Measurements of peripheral 
thyroid hormones may not fully capture the phthalate-induced effects on thyroid homeostasis.64 
That is, blood levels of thyroid hormones may not correspond with actions at the receptor, such 
as regulation of gene expression and the developmental processes in which they are involved.69,70 
However, given the limited amount of data on this subject and the infeasibility of collecting more 
specific markers during pregnancy, levels of circulating thyroid hormone measurements may 
serve as the most appropriate biomarker of thyroid disruption in pregnant women. Additional 
studies are necessary to address potential phthalate-induced alterations in thyroid-hormone 
responsive genes relevant to pregnancy outcomes. It may also be possible that the serum 
measurements included in our analyses represented transient changes in thyroid and sex hormone 
levels that may not have persisted outside of the two measurement time points. However, even 
temporary and/or subclinical alterations in maternal hormone levels may be biologically relevant 
and may induce permanent effects on parturition and/or the developing fetus.64 Our study was 
also limited by the lack of information concerning the iodine and selenium status of our study 
participants, which may be important because deficiencies in these trace elements can impair 
normal thyroid hormone function.71 However, we have no reason to expect that these would be 
associated with phthalate exposure, so any deficiencies in these substances would affect the 
precision of the effect estimates rather than the effect estimates themselves.72 Finally, our study 
was conducted among pregnant women in Northern Puerto Rico, which may have implications 
for the generalizability of results. 
Despite these limitations, our study had several strengths. The collection of biomarker 
measurements at two time points during pregnancy enabled us to utilize mixed modeling 
techniques to more powerfully detect associations among repeated measurements and also 
evaluate potential periods of gestation during which phthalates may have a more profound 
impact on maternal hormone levels. Also, as pregnancy is characterized by a dynamic interplay 
between maternal endocrine hormones, our measurements of hormone concentrations from two 
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disparate endocrine axes is advantageous. Each set of hormones may represent distinct 
mechanisms through which phthalates may influence downstream reproductive health outcomes. 
Furthermore, we used novel and precise analytical techniques to measure serum levels of FT3 
and FT4. Especially pertinent to a population of pregnant women, this method has advantages 
over traditional immunoassays because it is more specific, does not cross-react with other 
analytes, and is not influenced by serum binding proteins.35,73,74 Notably, thyroxine binding 
proteins may increase as much as 50 percent during pregnancy.74 
CONCLUSIONS 
The results of our study provide suggestive evidence for phthalate-induced endocrinal 
disturbances during pregnancy, and may augment mechanistic understanding of the impact of 
phthalates on reproductive health outcomes. Future research on the specific pathways through 
which phthalates may alter thyroid and sex hormone concentrations are required for targeted 
interventions aimed at preventing downstream hormone-mediated adverse reproductive health 
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Table II.1. Sample characteristics of 106 pregnant women 
participating in PROTECT Project (2010-2012) 
Variable mean ± SD or n (%) 
Maternal age at enrollment (years) 27.1 ± 4.8 
Maternal education  
      Missing 3 (2.8) 
      <High school 12 (11.3) 
      High school/equivalent 7 (6.6) 
      College 84 (79.2) 
Annual household income (US$)  
       Missing 17 (16.0) 
      <$20,000 45 (42.4) 
      ≥$20,000 to <$50,000 27 (25.5) 
      ≥$50,000 17 (16.0) 
Race  
      Missing 3 (2.8) 
      White 52 (49.1) 
      Mixed 39 (36.8) 
      Other 12 (11.3) 
Prepregnancy BMI (kg m-2)  
      Missing 4 (3.8) 
      ≤25 59 (55.7) 
      >25 to ≤30 31 (29.2) 
      >30 12 (11.3) 
Smoked during pregnancy  
      Missing 5 (4.7) 
      yes 1 (0.9) 
      no 100 (94.3) 
Alcohol use at first visit during pregnancy  
      Missing 4 (3.8) 
      yes 12 (11.3) 
      no 90 (84.9) 
Abbreviations: PROTECT, Puerto Rico Testsite for Exploring 





























Table II.2. Distributions of serum hormone concentrations  
Biomarker N  Mean (SD) 
Selected Percentiles 
25th 50th 75th 95th Max. 
Thyroid hormones         
TSH (uIU/mL)† 195 1.13 (1.62) 0.81 1.10 1.51 2.83 4.29 
Free T3 (pg/mL) 195 3.94 (0.60) 3.50 3.90 4.40 4.90 5.70 
Free T4 (ng/dL) 195 1.39 (0.32) 1.20 1.40 1.50 1.90 3.10 
Sex hormones*        
Progesterone (ng/mL)† 193 62.8 (1.60) 45.7 57.3 82.0 140 374 
Estradiol (ng/mL) 189 8.16 (4.06) 4.79 7.58 11.8 15.0 15.0 
SHBG (nmol/L) 157 368 (109) 293 352 428 563 736 
SD, standard deviation, TSH, thyroid-stimulating hormone, SHBG, sex hormone-binding globulin. 
† Geometric mean and geometric standard deviation reported.  






















Table II.3. Mean serum hormone concentrations (SD) by visit during gestation  
Biomarker Visit 1 (14-20 weeks)  Visit 3 (24-28 weeks) p-value* 
Thyroid Hormones    
TSH (uIU/mL)† 1.10 (1.60)  1.17 (1.65) 0.25 
Free T3 (pg/mL) 4.01 (0.61) 3.86 (0.59) 0.02 
Free T4 (ng/dL) 1.45 (0.31) 1.32 (0.32) 0.001 
Sex Hormones    
Progesterone (ng/mL)† 46.9 (1.37) 88.4 (1.48) <0.001 
Estradiol (ng/mL) 5.70 (2.48) 11.1 (3.60) <0.001 
SHBG (nmol/L) 349 (108) 391 (106) 0.002 
Abbreviations: SD, standard deviation, TSH, thyroid-stimulating hormone, SHBG, sex hormone-
binding globulin. 
*Test for fixed effects from linear mixed models with random intercepts. 






Table II.4. Longitudinal Analysis: Percent change (95% CIs) in thyroid and sex hormone concentrations in relation to interquartile 
range increase in urinary phthalate metabolite concentration 
Analyte % Change (95% CI)   p-value   % Change (95% CI)   p-value   % Change (95% CI)   p-value 
 
Free T3  
(n=181 observations)  
Free T4  
(n=181 observations)  
ln-TSH  
(n=181 observations) 
MBzP 0.18 (-3.42, 3.77)  0.92  0.58 (-4.45, 5.56)  0.82  5.51 (-4.40, 16.5)  0.28 
MBP 1.33 (-1.90, 4.67)  0.42  0.63 (-4.00, 5.21)  0.79  3.28 (-5.58, 12.8)  0.48 
MiBP 0.19 (-2.86, 3.14)  0.90  1.14 (-3.06, 5.42)  0.59  4.64 (-3.73, 13.0)  0.28 
MEP 1.11 (-2.74, 4.96)  0.57  2.68 (-2.68, 7.83)  0.33  0.05 (-10.1, 11.3)  0.99 
MCPP -2.89 (-5.65, -0.02)  0.049*  -2.01 (-6.12, 2.10)  0.34  1.60 (-6.05, 9.88)  0.68 
MCOP -2.03 (-5.08, 0.98)  0.18  -1.11 (-5.26, 3.13)  0.61  -2.52 (-10.3, 6.13)  0.56 
MCNP 0.48 (-2.03, 2.94)  0.71  -1.64 (-5.28, 1.93)  0.36  3.50 (-2.98, 10.4)  0.30 










MBzP 0.86 (-8.52, 10.3)  0.86  4.89 (-1.52, 11.3)  0.13  3.16 (-4.56, 11.5)  0.67 
MBP 2.65 (-5.90, 11.2)  0.54  -0.65 (-6.29, 4.98)  0.82  3.71 (-3.44, 11.2)  0.31 
MiBP 1.56 (-6.27, 9.39)  0.69  1.19 (-4.25, 6.61)  0.66  2.48 (-3.96, 9.49)  0.46 
MEP 1.60 (-8.49, 11.7)  0.75  -2.24 (-9.43, 4.97)  0.54  -10.6 (-17.6, -2.84)  0.01* 
MCPP -3.86 (-11.5, 3.80)  0.32  -1.27 (-6.40, 3.86)  0.62  -4.31 (-10.2, 1.98)  0.17 
MCOP -3.59 (-11.4, 4.24)  0.36  -0.93 (-6.44, 4.58)  0.74  -4.83 (-11.0, 1.57)  0.13 
MCNP -2.03 (-8.50, 4.41)  0.53  -0.66 (-4.85, 3.46)  0.75  -2.06 (-7.22, 3.28)  0.43 
ΣDEHP -0.56 (-9.17, 8.06)  0.90  -4.11 (-9.83, 1.62)  0.16  1.79 (-5.17, 9.39)  0.62 
CI, confidence interval, TSH, thyroid-stimulating hormone, SHBG, sex hormone-binding globulin. Linear mixed models include a random 








Table II.5. Cross-Sectional Analysis: Percent change (95% CIs) in thyroid hormone concentrations in relation to interquartile 
range increase in urinary phthalate metabolite concentration by visit during gestation 
Visit 1 (16-20 weeks) 
Analyte % Change (95% CI)   p-value   % Change (95% CI)   p-value   % Change (95% CI)   p-value 
 
Free T3  
(n=100 observations)  
Free T4   
(n=100 observations)  
ln-TSH  
(n=100 observations) 
MBzP 1.87 (-2.55, 6.37)  0.40  2.44 (-2.77, 7.65)  0.36  12.9 (-0.93, 28.2)  0.07† 
MBP -0.72 (-4.94, 3.29)  0.73  0.26 (-4.58, 5.04)  0.92  1.29 (-10.2, 13.7)  0.83 
MiBP -1.64 (-5.55, 2.42)  0.43  4.95 (0.27, 9.28)  0.04*  1.09 (-10.3, 13.9)  0.86 
MEP -0.20 (-5.37, 5.02)  0.94  -0.05 (-6.10, 6.10)  0.99  0.77 (-13.6, 17.7)  0.92 
MCPP -1.04 (-4.54, 2.62)  0.57  1.41 (-2.83, 5.80)  0.50  -2.57 (-12.7, 8.69)  0.64 
MCOP -0.50 (-4.11, 2.93)  0.78  -0.44 (-4.58, 3.76)  0.83  -0.39 (-10.3, 10.7)  0.94 
MCNP 1.05 (-2.27, 4.49)  0.53  0.43 (-3.47, 4.37)  0.83  -2.68 (-11.9, 7.35)  0.58 
ΣDEHP -1.62 (-6.05, 2.85)  0.47  3.09 (-2.17, 8.27)  0.25  7.14 (-6.12, 22.3)  0.30 
Visit 3 (24-28 weeks) 
 
Free T3  
(n=81 observations) 
 





MBzP -2.67 (-8.3, 2.86)  0.34  -2.97 (-12.1, 6.07)  0.51  -4.62 (-20.4, 13.5)  0.58 
MBP -0.57 (-5.68, 4.34)  0.82  -1.46 (-9.67, 6.74)  0.72  9.57 (-6.27, 27.3)  0.25 
MiBP -2.51 (-6.81, 1.70)  0.24  -4.70 (-11.8, 2.08)  0.17  2.74 (-9.94, 17.9)  0.68 
MEP 2.76 (-2.68, 8.44)  0.32  4.93 (-3.81, 13.7)  0.27  18.1 (0.00, 37.8)  0.05† 
MCPP -5.93 (-10.2, -1.75)  0.01*  -5.11 (-12.5, 2.22)  0.17  2.41 (-11.1, 17.7)  0.74 
MCOP -5.83 (-10.8, -0.58)  0.03*  -3.02 (-11.5, 5.38)  0.47  -3.35 (-17.1, 13.6)  0.67 
MCNP -1.44 (-5.92, 3.10)  0.54  -6.34 (-14.0, 0.99)  0.09†  5.39 (-8.50, 21.3)  0.46 
ΣDEHP 0.05 (-4.49, 4.49)  0.98  -8.02 (-15.3, -0.80)  0.03*  2.79 (-10.8, 18.6)  0.70 
Abbreviations: CI, confidence interval, TSH, thyroid-stimulating hormone. Linear regression models adjusted for age at enrollment, 








Table II.6. Cross-Sectional Analysis: Percent change (95% CIs) in sex hormone concentrations in relation to interquartile range 
increase in urinary phthalate metabolite concentration by visit during gestation 
Visit 1 (16-20 weeks) 
Analyte % Change (95% CI)   p-value   % Change (95% CI)   p-value   % Change (95% CI)   p-value 
 
Estradiol  
(n=97 observations)  
SHBG  
(n=83 observations)  
ln-Progesterone  
(n=98 observations) 
MBzP -5.65 (-18.9, 7.57)  0.40  4.99 (-4.43, 14.4)  0.29  1.88 (-6.60, 11.3)  0.66 
MBP 0.20 (-10.3, 14.2)  0.75  4.13 (-3.66, 11.9)  0.29  5.68 (-2.41, 13.7)  0.18 
MiBP -0.99 (-13.1, 11.1)  0.87  -0.92 (-9.77, 7.28)  0.77  5.56 (-2.46, 13.9)  0.18 
MEP 0.03 (-15.5, 15.6)  1.00  -10.1 (-21.8, 1.65)  0.09†  -12.15 (-20.5, -2.99)  0.01* 
MCPP -2.93 (-14.4, 8.54)  0.61  -2.66 (-10.6, 5.27)  0.51  -0.42 (-7.61, 7.34)  0.91 
MCOP 0.70 (-9.86, 11.3)  0.90  0.86 (-6.74, 8.48)  0.82  -0.57 (-7.27, 6.62)  0.87 
MCNP 2.43 (-7.42, 12.3)  0.63  -0.65 (-7.75, 6.45)  0.86  -0.58 (-6.85, 6.11)  0.86 
ΣDEHP -7.50 (-20.9, 5.92)  0.27  -5.93 (-15.4, 3.54)  0.22  2.37 (-6.23, 11.9)  0.59 
Visit 3 (24-28 weeks) 
 
Estradiol  
(n=78 observations)  
SHBG  
(n=64 observations)  
ln-Progesterone  
(n=81 observations) 
MBzP 4.38 (-7.12, 15.9)  0.45  6.66 (-4.98, 18.3)  0.26  8.02 (-5.12, 23.4)  0.24 
MBP 6.55 (-3.60, 16.7)  0.20  5.22 (-5.18, 15.7)  0.32  8.19 (-3.61, 21.0)  0.18 
MiBP 2.42 (-5.96, 10.8)  0.57  3.46 (-4.89, 11.8)  0.41  2.86 (-6.81, 13.8)  0.58 
MEP 1.36 (-9.57, 12.3)  0.81  1.00 (-10.4, 12.4)  0.86  -9.43 (-20.1, 2.51)  0.11 
MCPP -0.48 (-9.45, 8.48)  0.91  4.76 (-3.69, 13.2)  0.26  -3.81 (-11.8, 6.87)  0.47 
MCOP -2.17 (-12.4, 8.09)  0.67  3.93 (-5.77, 13.6)  0.42  -5.15 (-15.7, 7.06)  0.39 
MCNP -2.64 (-11.7, 6.45)  0.57  2.70 (-6.31, 11.7)  0.55  -3.99 (-13.9, 6.75)   0.45 
ΣDEHP 2.87 (-6.17, 11.9)  0.53  1.14 (-8.61, 10.9)  0.82  5.85 (-4.81, 17.6)  0.29 
Abbreviations: CI, confidence interval, SHBG, sex hormone-binding globulin. Linear regression models adjusted for age at enrollment, 









Table II.S1. Urinary phthalate metabolite concentrations (ng/mL) in pregnant 
women from Puerto Rico† 
    Percentiles 
 GM (GSD) p-value*  25th 50th 75th 95th Max 
MEHP         
     Visit 1 3.22 (2.90) 
0.98 
 1.61 3.14 6.36 13.5 50.9 
     Visit 3 3.24 (2.79)  1.69 3.08 6.73 19.7 32.8 
MEHHP         
     Visit 1 10.7 (2.61) 
0.98 
 6.14 10.5 19.9 37.9 290 
     Visit 3 10.8 (2.27)  7.28 11.1 16.9 42.0 88.2 
MEOHP         
     Visit 1 9.09 (2.49) 
0.95 
 5.57 8.33 16.5 29.0 259 
     Visit 3 9.41 (2.26)  6.22 9.86 14.8 38.6 64.7 
MECPP         
     Visit 1 20.4 (2.27) 
0.97 
 12.7 20.8 31.4 61.0 712 
     Visit 3 20.2 (1.96)  13.4 20.8 29.3 69.7 121 
MBzP         
     Visit 1 3.62  (3.16) 
0.54 
 1.74 3.73 7.65 27.0 59.0 
     Visit 3 3.60 (3.19)  1.49 3.22 6.99 29.8 108 
MBP         
     Visit 1 19.1 (2.99) 
0.81 
 10.8 19.3 35.3 112 278 
     Visit 3 19.1 (2.48)  10.4 18.6 36 86.6 182 
MiBP         
     Visit 1 10.1 (2.47) 
0.46 
 5.97 10.3 17.9 35.2 157 
     Visit 3 11.5 (2.61)  6.33 10.9 16.9 61.6 654 
MEP         
     Visit 1 96.9 (5.39) 
0.95 
 24.2 97.7 365 1860 6910 
     Visit 3 106.1 (6.36)  24.7 83.6 354 2410 7640 
MCPP         
     Visit 1 1.98 (2.52) 
0.09 
 1.04 2.08 3.02 8.00 82.1 
     Visit 3 2.27 (2.70)  1.24 1.86 3.52 14.8 64.8 
MCOP         
     Visit 1 14.9 (2.93) 
0.02 
 7.96 13.4 24.8 89.8 1060 
     Visit 3 18.5 (3.32)  8.23 15.8 36.0 214 939 
MCNP         
     Visit 1 2.42 (2.56) 
0.13 
 1.33 2.12 3.73 14.9 51.6 
     Visit 3 2.24 (2.24)   1.34 2.06 3.23 11.3 33.6 
Abbreviations: GM, geometric mean, GSD, geometric standard deviation.  
†All concentrations adjusted for specific gravity. 






















Table II.S2. Pearson correlations between serum sex hormones, serum thyroid hormones, and 
maternal age in pregnant women from Puerto Rico 
  Progesterone † Estradiol SHBG TSH † Free T3 Free T4 Age 
Progesterone † 1.00 0.66* 0.23* 0.05 -0.14* -0.17* -0.12 
Estradiol  1.00 0.29* 0.10 -0.08 -0.27* -0.13 
SHBG   1.00 0.06 -0.10 -0.11 -0.09 
TSH †    1.00 0.06 -0.01 -0.17* 
Free T3     1.00 0.17* -0.11 
Free T4      1.00 -0.10 
Age       1.00 
Abbreviations: TSH, thyroid-stimulating hormone, SHBG, sex hormone-binding globulin. 





CHAPTER III. Associations between Repeated Measures of Maternal 
Urinary Phthalate Metabolites and Thyroid Hormone Parameters during 
Pregnancy (LifeCodes Cohort) 
 
ABSTRACT  
Background: Maintaining thyroid homeostasis during pregnancy is essential for normal fetal 
growth and development. Growing evidence suggests that phthalates interfere with normal 
thyroid function. Few human studies have investigated the degree to which phthalates may affect 
thyroid hormone levels in particularly susceptible populations such as pregnant women.  
Objectives: We examined the associations between repeated measures of urinary phthalate 
metabolites and plasma thyroid hormone levels in samples collected at up to four time points per 
subject in pregnancy. Additionally, we investigated the potential windows of susceptibility to 
thyroid hormone disturbances related to study visit of sample collection. 
Methods: Data were obtained from pregnant women (N=439) participating in a nested case-
control study of preterm birth with 116 cases and 323 controls. We measured 9 phthalate 
metabolite concentrations in urine samples collected at up to four study visits per subject during 
pregnancy (median= 10, 18, 26, and 35 weeks of gestation, respectively). We also measured a 
panel of thyroid function markers in plasma collected at the same four time points per subject 
during pregnancy. 
Results: While our results were generally null, in repeated measures analyses we observed that 
phthalate metabolites were largely inversely associated with thyrotropin (TSH) and positively 




that the magnitude and/or direction of these relationships varied by timing of exposure during 
gestation. 
Conclusions: These results support previous reports showing the potential for environmental 
phthalate exposure to alter circulating levels of thyroid hormones in pregnant women.  
INTRODUCTION 
Maintaining thyroid homeostasis during pregnancy is essential for normal fetal growth 
and development, and especially for early fetal neurodevelopment.1-3 Human health studies have 
shown that both overt and subclinical maternal thyroid disease (hyper- and hypothyroidism) may 
be associated with adverse birth outcomes such as preterm birth,4-6 low birth weight4,7-9 and 
impaired fetal growth,4,7,10 although similar associations have not been observed for maternal 
subclinical hyperthyroidism.10 Notably, these birth outcomes are associated with lasting physical 
and neurodevelopmental complications among surviving infants.11  
Phthalate diesters have been commonly used as plasticizers and solvents in a variety of 
consumer and industrial products.12,13 Due to their extensive use, phthalate metabolites have been 
consistently detected in humans, and more specifically in pregnant women worldwide.14-17 
Growing scientific evidence suggests that this group of environmental chemicals may interfere 
with normal thyroid function.18,19 
Animal and in vitro studies suggest that phthalates may be capable of disrupting 
circulating thyroid hormone levels, although the exact biological mechanism(s) of action remain 
unclear.20-22 Additionally, a limited number of epidemiological studies have shown that 
phthalates may alter thyroid hormone levels in adult men and non-pregnant women as well as 
children.23-25 Less is known about the degree to which phthalates may affect thyroid function in 
other vulnerable populations such as pregnant women.  
To date, three epidemiological investigations have assessed the relationships between 
phthalate exposure and thyroid hormone levels in pregnant women.26-28 While the findings 
reported in these investigations provide suggestive evidence for the potential thyroid-disrupting 
effects of phthalates during pregnancy, these studies are limited by study design and/or sample 




disturbing thyroid hormone levels in pregnant women by investigating similar associations in a 
large nested case-control study. Here, we examined the associations between repeated measures 
of urinary phthalate metabolites and plasma thyroid hormone levels in samples collected at up to 
four time points per subject in pregnancy. Additionally, we investigated the potential windows of 
susceptibility to phthalate exposure related to study visit of sample collection. 
METHODS 
Study Population  
This was a secondary analysis of data from a nested case-control study with the primary 
aim of investigating the effects of environmental phthalate exposure on the risk of preterm 
birth.29 The study population includes a subset of pregnant women participating in the ongoing 
LifeCodes prospective birth cohort. All pregnant women who planned to deliver at the Brigham 
and Women’s Hospital in Boston, who were older than 18 years old, and whose initial visit was 
before 15 weeks of gestation were eligible to participate and were recruited between 2006 and 
2008. The only exclusion criterion was higher-order multiple gestations (e.g., triplets or 
greater).30 Additional information regarding recruitment as well as sample collection and 
processing are described in detail elsewhere.29-31 Briefly, at the initial study visit (median: 9.71 
weeks of gestation; range: 4.71 to 19.1 weeks), participants completed a questionnaire to collect 
sociodemographic information (e.g., race/ethnicity, income, health insurance provider, etc.) and 
relevant health information (e.g., tobacco and alcohol use, family health history, etc.), and 
provided urine and blood samples for biomarker analysis. Participants were followed until 
delivery, and provided relevant health information (e.g., body mass index [BMI] and blood 
pressure) as well as urine and blood samples at three additional study visits: visit 2 (median: 17.9 
weeks of gestation; range: 14.9 to 32.1 weeks), visit 3 (median: 26.0 weeks of gestation; range: 
22.9 to 36.3 weeks), and visit 4 (median: 35.1 weeks of gestation; range: 33.1 to 38.3 weeks).  
Approximately 1,600 women were enrolled in the original cohort at the Brigham and 
Women’s Hospital, and 1,181 were followed until delivery and had a singleton live birth. In 
2011, 130 women who delivered a preterm singleton infant (<37 completed weeks of gestation) 
and 352 randomly selected women who delivered singletons at or after 37 weeks of gestation 




women diagnosed with thyroid disease based on medical records (e.g., diagnosed hyper- or 
hypothyroidism, Grave’s disease, or thyroid cancer) (N=41) and those who did not provide blood 
samples at any study visit during follow-up (N=2). The final study population (N=439) included 
116 preterm birth cases and 323 controls. The study protocols were approved by the ethics and 
research committees of the participating institutions and all study participants gave written 
informed consent.  
Thyroid Hormone Measurements  
 We assayed plasma samples (N=439 participants; N=1,445 total samples) collected up to 
four time points in pregnancy at the Clinical Ligand Assay Service Satellite (CLASS) Lab at the 
University of Michigan (Ann Arbor, MI). Samples were analyzed for thyrotropin (TSH) as well 
as total triiodothyronine (T3) and thyroxine (T4) using an automated chemiluminescence 
immunoassay according to manufacturer’s instructions (Bayer ADVIA Centaur, Siemens Health 
Care Diagnostics, Inc.). We measured free T4 using direct equilibrium dialysis followed by 
radioimmunoassay (IVD Technologies). The manufacturer did not provide trimester-specific 
reference ranges for TSH. In their absence, the American Thyroid Association recommends the 
following for TSH: first trimester, 0.1-2.5 µIU/mL; second trimester, 0.2-3.0 µIU/mL; third 
trimester, 0.3-3.0 µIU/mL.32 The free T4 pregnancy reference ranges provided by the laboratory 
were: first trimester, 0.7-2.0 ng/dL; second trimester, 0.5-1.6 ng/dL; third trimester, 0.5-1.6 
ng/dL. The limits of detection (LOD) were 0.01 µIU/mL for TSH, 10 ng/dL for total T3, 0.3 
µg/dL for total T4, and 0.1 ng/dL for free T4. Thyroid hormone concentrations less than the 
LOD were assigned a value of LOD divided by the square root of 2.33 
In addition to exploring individual thyroid hormone parameters, we calculated the ratio of 
T3 to T4 (T3/T4) from the respective total hormone concentrations. The T3/T4 ratio is an index 
of thyroid homeostasis and reflects the action of thyroid hormones on peripheral tissues.34,35  
Phthalate Metabolite Measurements  
NSF International (Ann Arbor, MI) analyzed available urine samples (N=439 




metabolites using a method developed by the Center for Disease Control (CDC) described 
elsewhere.36,37 Briefly, the analytical technique involved enzymatic deconjugation of metabolites 
from their glucuronidated form, solid-phase extraction, separation by high-performance liquid 
chromatography, and detection by tandem mass spectrometry. The following nine metabolites 
were measured in urine samples: MEHP, MBP, mono-2-ethyl-5-hydroxyhexyl phthalate 
(MEHHP), mono-2-ethyl-5-oxohexyl phthalate (MEOHP), mono-2-ethyl-5-carboxypentyl 
phthalate (MECPP), mono-benzyl phthalate (MBzP), mono-iso-butyl phthalate (MiBP), and 
mono-ethyl phthalate (MEP), and mono-3-carboxypropyl phthalate (MCPP). LOD for individual 
metabolites were in the low microgram per liter range.31 As with the hormones, phthalate 
metabolite concentrations below the LOD were assigned a value of LOD divided by the square 
root of 2 33. In addition to examining individual phthalate metabolites, we created a variable for 
the molar sum (µmol/L) of the four measured DEHP metabolites (MEHP, MEHHP, MEOHP, 
and MECPP; ΣDEHP).17 
To correct for urinary dilution in univariate analyses, we standardized phthalate 
metabolite concentrations using specific gravity (SG) according to the following equation: 
PSG=P[(1.015-1)/(SG-1)], where PSG is the specific gravity-adjusted phthalate metabolite 
concentration (µg/L), P is the observed phthalate metabolite concentration, 1.015 is the specific 
gravity population median, and SG is the specific gravity of the urine sample 17. Unadjusted 
phthalate metabolite concentrations were used in multivariate analyses with SG added as a 
separate covariate since modeling corrected metabolite levels may introduce bias.38 
Statistical Analyses   
To make our study population more representative of the original cohort from which the 
case-control sample arose, we applied inverse probability weighting to all analyses considering 
association between secondary variables measured under case-control sampling. Specifically, we 
corrected for over-representation of preterm birth cases by applying study-specific weights 
related to the inverse probability of inclusion of controls so that the relative weights of cases and 





The empirical histogram of total T3 as well as free and total T4 approximately resembled 
a normal distribution. The distributions of TSH as well as all 9 phthalate metabolites and ΣDEHP 
were right-skewed; thus, we used the natural log transformation of these variables for statistical 
analyses. We tabulated means and percentiles for all urinary phthalate metabolites and plasma 
thyroid hormones. We calculated geometric means and geometric standard deviations for log-
normally distributed variables. We examined the distribution of thyroid hormone parameters by 
study visit of sample collection and demographic characteristics. We calculated Spearman 
correlations between phthalate metabolites using SG-corrected values. We used linear mixed 
models (LMMs) with subject-specific random intercepts and slopes for gestational age at sample 
collection to test the differences in repeated measures of thyroid hormone levels by each 
categorical covariate that were introduced as predictors in the mixed model regression. 
In repeated measures analyses, we explored the associations between urinary phthalate 
metabolites and plasma thyroid hormone concentrations across pregnancy using LMMs with one 
hormone regressed on one phthalate metabolite per model, with each model including a subject-
specific random intercept and slope for gestational age at sample collection. Crude models 
included fixed effects terms for gestational age at sample collection and urinary SG. Full models 
were additionally adjusted for maternal age at enrollment, body mass index (BMI) at time of 
sample collection, and health insurance provider. We chose maternal age and BMI a priori as 
covariates in full models because of their known associations with thyroid hormone 
concentrations and urinary phthalate metabolite levels.40-42 We identified additional covariates 
based on ≥ 10% change in the main effect estimates when added to the models.  
In our secondary analyses, we investigated the cross-sectional relationships between 
urinary phthalate metabolites and plasma thyroid hormone concentrations at each study visit 
(visits 1 through 4) using linear regression models with one phthalate metabolite and one 
outcome variable per model. We adjusted these models for maternal age at enrollment, BMI at 
time of sample collection, health insurance provider, and urinary specific gravity. To enhance the 
interpretation of statistical models containing log-transformed exposure and/or outcome 
variables, we expressed all regression coefficients and associated 95% confidence intervals (CIs) 
as the percent change in thyroid hormone levels for an interquartile range (IQR) increase in 




at the 5% level. We performed all data analyses using SAS version 9.3 (SAS Institute Inc., Cary, 
North Carolina). 
RESULTS 
Population characteristics of the case-control study population as well as the distributions 
of the phthalate metabolites by study visit have been previously reported.29,43 Bivariate analyses 
showed that thyroid hormone concentrations significantly varied by certain demographic 
characteristics (Table III.1). Specifically, TSH concentrations were significantly lower among 
pregnant women who identified as African-American or Other race/ethnicity compared to White, 
and who had public health insurance compared to private. Women who reported no alcohol use 
during pregnancy had higher concentrations of TSH compared to those who reported drinking 
alcohol. For free T4, concentrations were significantly lower among women who graduated from 
technical school compared to those with a high school diploma or the equivalent, and among 
women who were obese (>30 kg/m2) compared to those with a BMI <25 kg/m2.  
All thyroid hormone parameters were detected in most samples in this study population 
(% detected for total T4 and T3=100%, TSH=99.5%, and free T4=98%), and measurable 
concentrations of the 9 urinary phthalate metabolites were detected in at least 95% of urine 
samples.29,43 Correlations between phthalate metabolites were strongest for DEHP metabolites 
(Spearman r= 0.74-0.93), were moderate between MBzP, MBP, and MiBP (r= 0.43-0.61) and 
between DEHP metabolites and MCPP (r= 0.35-0.44), and were weak between all other 
metabolites (r=-0.03-0.29). Weighted geometric mean concentrations of urinary and plasma 
biomarkers varied by study visit of sample collection (Table III.2). Compared to visit 1, we 
observed significantly decreased levels of all DEHP metabolites and MCPP at visit 3. We 
detected significantly increased concentrations of MBzP, MBP, MiBP, and MEP at visit 4. For 
the hormones, compared to visit 1, we found significantly increased levels of TSH at visits 2-4 
whereas free T4 levels were significantly lower at these three subsequent study visits. 
Associations from repeated measures analyses using fully adjusted LMMs were similar to 
those observed in crude unadjusted models (data not shown). We detected a significant inverse 




5.31% (95% CI: -10.1, -0.23) decrease in TSH (Table III.3). We also observed significant 
inverse associations between MiBP (percent change in outcome for an IQR increase in exposure 
[%Δ] = -9.51; 95% CI: -16.4, -2.01) and MCPP (%Δ= -6.63; 95% CI: -11.6, -1.41). We detected 
generally positive associations between each metabolite and free T4, with a significant 
relationship observed for MCPP (%Δ=6.91; 95% CI: 1.70, 12.1). Finally, we observed 
significant positive associations between MEP and both total T3 (%Δ=2.24; 95% CI: 0.32, 4.17) 
and the T3/T4 ratio (%Δ=2.87; 95% CI: 1.27, 4.47) as well as between MEHP and total T4 
(%Δ=1.29; 95% CI: 0.26, 2.32).  
To explore potential windows of susceptibility, we stratified linear regression analyses by 
time of sample collection in pregnancy (see Table III.S1). Similar to repeated measures 
analyses, phthalate metabolites were generally inversely associated with TSH at each of the four 
study visits, although statistically significant associations were observed only in visits 1 and 2 
(Figure III.1). We detected significant positive associations between several urinary phthalate 
metabolites and free T4 at visits 1 and 4. In contrast to repeated measures analyses, phthalate 
metabolites were inversely related to free T4 at visit 3, although these associations were not 
statistically significant (Figure III.2). For total hormones, ΣDEHP was significantly positively 
associated with T3 and T4 at visit 1, and with T4 at visit 4. We observed null associations 
between metabolites and the T3/T4 ratio at visits 1-3, with inverse associations for ΣDEHP, 
including several individual DEHP metabolites, at visit 4.  
DISCUSSION 
In the largest cohort study conducted on this topic to date, we report significant 
associations between several phthalate metabolites and thyroid hormone parameters in samples 
collected at up to four time points in pregnancy. In repeated measures analyses, we observed that 
phthalate metabolites were largely inversely associated with TSH and positively associated with 
free and total thyroid hormones. Cross-sectional analyses by study visit revealed that the 
magnitude and/or direction of these relationships varied by time point of exposure during 
gestation. We detected inverse relationships between several metabolites (particularly DEHP 
metabolites) and TSH at visits 1 and 2, while no significant associations were observed in the 




visits with the exception of visit 3 (median 26 weeks of gestation), where these associations 
became inverse in direction. These results suggest that environmental phthalate exposure may 
alter thyroid hormone parameters in pregnant women. Moreover, our findings indicate that the 
timing of phthalate exposure during gestation may be important for a pregnant woman’s 
susceptibility to thyroidal disruption. 
Three epidemiological studies have previously investigated the potential phthalate-
associated alterations in thyroid hormone parameters among pregnant women.26-28 Notably, only 
one of these investigations, which we conducted using pilot data, assessed the relationships using 
biomarker measurements collected at multiple time points in pregnancy (Johns et al. 2015). In 
that population of pregnant women in Puerto Rico, no statistically significant associations were 
observed between urinary phthalate metabolites and serum concentrations of TSH or free T4 in 
repeated measures analyses using data from two study visits in pregnancy. However, in cross-
sectional analyses, we previously observed a significant positive association between MiBP and 
free T4 at median 18 weeks of gestation as well as inverse associations between several phthalate 
metabolites, including ΣDEHP, and free T4 at median 26 weeks of gestation.27 While these 
associations were similar in direction to the corresponding results reported at visit 2 (median 18 
weeks of gestation) and visit 3 (median 26 weeks of gestation) in the current study, here we did 
not report statistically significant associations for free T4 at either visit. The discrepant results 
observed between these two studies may be due to differences in: population size, number of 
serial biological samples available as well as the timing of sample collection in pregnancy, 
phthalate exposure levels, laboratory methods used to measure free hormones, and/or population 
demographic characteristics. 
Our results for free and total T4 also differ from those reported in a prior cross-sectional 
study conducted among a cohort of Taiwanese pregnant women undergoing amniocentesis 
(N=76).26 Huang and colleagues26 observed significant inverse associations between urinary 
MBP and both plasma free and total T4 at mean 27.9 weeks of gestation. In contrast, we 
observed largely null and in some cases positive associations between phthalate metabolites, 
including MBP, and free or total T4 in both repeated measures and cross-sectional analyses. In a 
more recent cross-sectional analysis conducted among a separate cohort of Taiwanese pregnant 




between several urinary phthalate metabolites (MEOHP, MEHHP, and MBzP) and serum TSH 
in the third trimester. Likewise, we generally found inverse relationships between phthalate 
metabolites and TSH in both repeated measures and cross-sectional analyses, although these 
were specific to visits early in gestation. 
The pattern of results reported in the current study, specifically those observed for urinary 
DEHP metabolites, conflict with findings from previous human health studies conducted among 
adult men and non-pregnant women. In a cross-sectional study of men recruited from a fertility 
clinic, urinary concentrations of MEHP were inversely associated with free T4 and total T3.24 
Urinary concentrations of DEHP metabolites were also inversely associated with total T3 and 
total and free T4 in a representative sample of U.S. adults.25 No significant associations were 
observed for TSH in either study. It is possible that differences in exposure levels and/or in the 
physiological state of participants (i.e., pregnancy) may have contributed to discrepancies in the 
results between these studies and the present study.   
Various biological mechanisms have been proposed through which phthalates may act to 
alter thyroid function. Phthalates may exert thyroid-disrupting action at multiple points along the 
hypothalamic-pituitary-thyroid axis. It has been suggested that phthalates may bind to thyroid 
hormone receptors and alter their signaling, although evidence for overt binding is lacking.18,44,45 
Additionally, limited in vitro studies have shown that phthalates may have thyroid hormone 
receptor antagonist activity.46,47 Several studies have also demonstrated potential phthalate 
actions on thyroid hormone biosynthesis and biotransport.21,22,48-50  
Phthalates may also impact the peripheral metabolism of thyroid hormones. To our 
knowledge, this is the first study to investigate the effects of phthalates on thyroid homeostasis 
using the T3/T4 ratio. This ratio has been used as an index of the peripheral conversion of T4 to 
T3 (the more biologically active hormone) by deiodinase enzymes, and can be high or low in 
certain thyroid disease states.34,35 Here, we observed a statistically significant positive 
association between urinary MEP and the T3/T4 ratio in repeated measures analyses. Cross-
sectional analyses by study visit revealed significant inverse associations with several phthalate 
metabolites, including DEHP metabolites, at visit 4. While we did not directly measure 
deiodinase activity in tissues, these results suggest that phthalates may influence circulating 




hormones. Indeed, limited animal studies have shown that certain phthalates and/or their 
metabolites may influence the gene expression of deiodinase enzymes.21,22 However, additional 
research is required to examine the influences of phthalates on extrathyroidal regulation of 
thyroid hormone production in humans, particularly in tissues relevant to pregnancy (e.g., the 
placenta).  
Since each organ system develops at different time points in pregnancy and because any 
disturbances in the normal growth and maturation of these systems may have lasting 
consequences on the developing fetus, the health effects of in utero exposures depend not only 
on the structure and dose of the chemical but also on the timing of exposure in gestation.51 In 
humans, the fetus relies exclusively on maternal thyroid hormones in the first trimester until the 
fetal thyroid gland becomes fully functional after 18 weeks of gestation.52,53 In later pregnancy, 
maternal thyroid hormones are essential for fetal thyroid homeostasis.1 Even mild alterations in 
circulating thyroid hormones in pregnancy may have important implications for fetal health. In 
pregnant women with normal range free T4 and TSH levels, increases in free T4 in the first 
trimester were associated with lower birth weight and an increased risk of small for gestational 
age.54 Notably, we observed significant phthalate-associated increases in free T4 levels at study 
visit 1 (first trimester) in the current study. 
Our study was limited by the lack of iodine status of our study participants, which is a 
trace element essential for normal thyroid function.55 While recent population-based studies have 
shown that the pregnant women in the U.S. may have less than adequate median urinary iodine 
levels,56 it is unlikely that this would be a confounder in the phthalate-thyroid hormone 
associations. Although some studies have observed correlations between urinary iodine and 
phthalate concentrations, it is unclear whether an individual’s phthalate exposure directly 
influences iodine status or whether both are simply found in the same dietary source. Moreover, 
in a study conducted among a representative sample of U.S. adult men and women, iodine 
excretion had a negligible impact on the significant relationships observed between phthalate 
metabolites and thyroid hormone levels.57 An additional limitation is that we did not assess the 
thyroid autoimmunity of the study participants. It is possible that the associations observed in our 
study may differ by level of anti-thyroid antibodies, which may be present in approximately 10-




potential that some of the observed associations may have been due to chance. We did not 
correct for multiple comparisons because available methods (e.g., Bonferroni adjustments) are 
often too conservative due to underlying assumptions of independence and increase the 
probability of type II errors, thereby potentially masking truly important differences.60 Despite 
these limitations, our study has many strengths. We have investigated the effects of 
environmental phthalate exposure on maternal thyroid hormone levels in the largest longitudinal 
study to date. The collection of biomarker measurements at multiple time points in pregnancy 
allows for the use of statistical modeling techniques to more powerfully detect associations 
among repeated measurements. Furthermore, our analytical method for measuring free T4 is 
advantageous over traditional immunoassays since it is specific and not influenced by serum 
binding proteins, which change dramatically over normal pregnancy.61,62  
CONCLUSIONS 
Overall, the results from our analyses support previous reports showing the potential for 
environmental phthalate exposure to disturb circulating levels of thyroid hormones in pregnant 
women. Additional human health and animal studies are required to resolve the direction of the 
specific relationships, to further elucidate periods of vulnerability in pregnancy to phthalate 
exposure, and to reveal the specific biological mechanisms involved at phthalate levels 
comparable to those to which humans (and more specifically, pregnant women) are 
environmentally exposed. Furthermore, the implications of these findings to maternal and fetal 




1. Hartoft-Nielsen ML, Boas M, Bliddal S, Rasmussen AK, Main K, Feldt-Rasmussen U. 
Do Thyroid Disrupting Chemicals Influence Foetal Development during Pregnancy? J 
Thyroid Res. 2011;2011:342189. 
2. Preau L, Fini JB, Morvan-Dubois G, Demeneix B. Thyroid hormone signaling during 
early neurogenesis and its significance as a vulnerable window for endocrine disruption. 
Biochim. Biophys. Acta. Feb 2015;1849(2):112-121. 
3. Williams GR. Neurodevelopmental and neurophysiological actions of thyroid hormone. 
J. Neuroendocrinol. Jun 2008;20(6):784-794. 
4. Aggarawal N, Suri V, Singla R, et al. Pregnancy outcome in hyperthyroidism: a case 
control study. Gynecol. Obstet. Invest. 2014;77(2):94-99. 
5. Casey BM, Dashe JS, Wells CE, et al. Subclinical hypothyroidism and pregnancy 
outcomes. Obstet. Gynecol. Feb 2005;105(2):239-245. 
6. Su PY, Huang K, Hao JH, et al. Maternal thyroid function in the first twenty weeks of 
pregnancy and subsequent fetal and infant development: a prospective population-based 
cohort study in China. J. Clin. Endocrinol. Metab. Oct 2011;96(10):3234-3241. 
7. Chen LM, Du WJ, Dai J, et al. Effects of subclinical hypothyroidism on maternal and 
perinatal outcomes during pregnancy: a single-center cohort study of a Chinese 
population. PLoS One. 2014;9(10):e109364. 
8. Millar LK, Wing DA, Leung AS, Koonings PP, Montoro MN, Mestman JH. Low birth 
weight and preeclampsia in pregnancies complicated by hyperthyroidism. Obstet. 
Gynecol. Dec 1994;84(6):946-949. 
9. Phoojaroenchanachai M, Sriussadaporn S, Peerapatdit T, et al. Effect of maternal 
hyperthyroidism during late pregnancy on the risk of neonatal low birth weight. Clin. 
Endocrinol. (Oxf.). Mar 2001;54(3):365-370. 
10. Casey BM, Dashe JS, Wells CE, McIntire DD, Leveno KJ, Cunningham FG. Subclinical 
hyperthyroidism and pregnancy outcomes. Obstet. Gynecol. Feb 2006;107(2 Pt 1):337-
341. 
11. Institute of Medicine. The National Academies Collection: Reports funded by National 
Institutes of Health. In: Behrman RE, Butler AS, eds. Preterm Birth: Causes, 
Consequences, and Prevention. Washington (DC): National Academies Press 
(US)National Academy of Sciences; 2007. 
12. Agency for Toxic Substances and Disease Registry. Toxicological profile for di-n-butyl 
phthalate. Atlanta, Georgia: U.S. Department of Health and Human Services Public 
Health Service; 2001. 
13. Agency for Toxic Substances and Disease Registry. Toxicological profile for di(2-
ethylhexyl) phthalate (DEHP). Atlanta, Georgia: U.S. Department of Health and Human 




14. Adibi JJ, Perera FP, Jedrychowski W, et al. Prenatal exposures to phthalates among 
women in New York City and Krakow, Poland. Environ. Health Perspect. Nov 
2003;111(14):1719-1722. 
15. Cantonwine DE, Cordero JF, Rivera-Gonzalez LO, et al. Urinary phthalate metabolite 
concentrations among pregnant women in Northern Puerto Rico: distribution, temporal 
variability, and predictors. Environ. Int. Jan 2014;62:1-11. 
16. Casas L, Fernandez MF, Llop S, et al. Urinary concentrations of phthalates and phenols 
in a population of Spanish pregnant women and children. Environ. Int. Jul 
2011;37(5):858-866. 
17. Meeker JD, Hu H, Cantonwine DE, et al. Urinary phthalate metabolites in relation to 
preterm birth in Mexico city. Environ. Health Perspect. Oct 2009;117(10):1587-1592. 
18. Kashiwagi K, Furuno N, Kitamura S, et al. Disruption of Thyroid Hormone Function by 
Environmental Pollutants. J. Health Sci. Apr 2009;55(2):147-160. 
19. Boas M, Main KM, Feldt-Rasmussen U. Environmental chemicals and thyroid function: 
an update. Curr. Opin. Endocrinol. Diabetes Obes. Oct 2009;16(5):385-391. 
20. Boas M, Feldt-Rasmussen U, Main KM. Thyroid effects of endocrine disrupting 
chemicals. Mol. Cell. Endocrinol. May 22 2012;355(2):240-248. 
21. Liu C, Zhao L, Wei L, Li L. DEHP reduces thyroid hormones via interacting with 
hormone synthesis-related proteins, deiodinases, transthyretin, receptors, and hepatic 
enzymes in rats. Environ. Sci. Pollut. Res. Int. Aug 2015;22(16):12711-12719. 
22. Zhai W, Huang Z, Chen L, Feng C, Li B, Li T. Thyroid endocrine disruption in zebrafish 
larvae after exposure to mono-(2-ethylhexyl) phthalate (MEHP). PLoS One. 
2014;9(3):e92465. 
23. Boas M, Frederiksen H, Feldt-Rasmussen U, et al. Childhood exposure to phthalates: 
associations with thyroid function, insulin-like growth factor I, and growth. Environ. 
Health Perspect. Oct 2010;118(10):1458-1464. 
24. Meeker JD, Calafat AM, Hauser R. Di(2-ethylhexyl) phthalate metabolites may alter 
thyroid hormone levels in men. Environ. Health Perspect. Jul 2007;115(7):1029-1034. 
25. Meeker JD, Ferguson KK. Relationship between urinary phthalate and bisphenol A 
concentrations and serum thyroid measures in U.S. adults and adolescents from the 
National Health and Nutrition Examination Survey (NHANES) 2007-2008. Environ. 
Health Perspect. Oct 2011;119(10):1396-1402. 
26. Huang PC, Kuo PL, Guo YL, Liao PC, Lee CC. Associations between urinary phthalate 
monoesters and thyroid hormones in pregnant women. Hum. Reprod. Oct 
2007;22(10):2715-2722. 
27. Johns LE, Ferguson KK, Soldin OP, et al. Urinary phthalate metabolites in relation to 
maternal serum thyroid and sex hormone levels during pregnancy: a longitudinal 




28. Kuo FC, Su SW, Wu CF, et al. Relationship of urinary phthalate metabolites with serum 
thyroid hormones in pregnant women and their newborns: a prospective birth cohort in 
Taiwan. PLoS One. 2015;10(6):e0123884. 
29. Ferguson KK, McElrath TF, Ko YA, Mukherjee B, Meeker JD. Variability in urinary 
phthalate metabolite levels across pregnancy and sensitive windows of exposure for the 
risk of preterm birth. Environ. Int. Sep 2014;70:118-124. 
30. McElrath TF, Lim KH, Pare E, et al. Longitudinal evaluation of predictive value for 
preeclampsia of circulating angiogenic factors through pregnancy. Am. J. Obstet. 
Gynecol. Nov 2012;207(5):407 e401-407. 
31. Ferguson KK, McElrath TF, Meeker JD. Environmental phthalate exposure and preterm 
birth. JAMA Pediatr. Jan 2014;168(1):61-67. 
32. Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid 
Association for the diagnosis and management of thyroid disease during pregnancy and 
postpartum. Thyroid. Oct 2011;21(10):1081-1125. 
33. Hornung RWR, L. D.  . Estimation of average concentration in the presence of 
nondetectable values Appl. Occup. Environ. Hyg. 1990;5(1):46-51. 
34. Dietrich JW, Landgrafe G, Fotiadou EH. TSH and Thyrotropic Agonists: Key Actors in 
Thyroid Homeostasis. J Thyroid Res. 2012;2012:351864. 
35. Mortoglou A, Candiloros H. The serum triiodothyronine to thyroxine (T3/T4) ratio in 
various thyroid disorders and after Levothyroxine replacement therapy. Hormones 
(Athens). Apr-Jun 2004;3(2):120-126. 
36. Lewis RC, Meeker JD, Peterson KE, et al. Predictors of urinary bisphenol A and 
phthalate metabolite concentrations in Mexican children. Chemosphere. Nov 
2013;93(10):2390-2398. 
37. Silva MJ, Samandar E, Preau JL, Jr., Reidy JA, Needham LL, Calafat AM. 
Quantification of 22 phthalate metabolites in human urine. J. Chromatogr. B Analyt. 
Technol. Biomed. Life Sci. Dec 1 2007;860(1):106-112. 
38. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL. Urinary 
creatinine concentrations in the U.S. population: implications for urinary biologic 
monitoring measurements. Environ. Health Perspect. Feb 2005;113(2):192-200. 
39. Richardson DB, Rzehak P, Klenk J, Weiland SK. Analyses of case-control data for 
additional outcomes. Epidemiology. Jul 2007;18(4):441-445. 
40. Hatch EE, Nelson JW, Qureshi MM, et al. Association of urinary phthalate metabolite 
concentrations with body mass index and waist circumference: a cross-sectional study of 
NHANES data, 1999-2002. Environ. Health. 2008;7:27. 
41. Iacobellis G, Ribaudo MC, Zappaterreno A, Iannucci CV, Leonetti F. Relationship of 
thyroid function with body mass index, leptin, insulin sensitivity and adiponectin in 
euthyroid obese women. Clin. Endocrinol. (Oxf.). Apr 2005;62(4):487-491. 




43. Ferguson KK, McElrath TF, Chen YH, Mukherjee B, Meeker JD. Urinary phthalate 
metabolites and biomarkers of oxidative stress in pregnant women: a repeated measures 
analysis. Environ. Health Perspect. Mar 2015;123(3):210-216. 
44. Zoeller RT. Environmental chemicals as thyroid hormone analogues: new studies 
indicate that thyroid hormone receptors are targets of industrial chemicals? Mol. Cell. 
Endocrinol. Oct 20 2005;242(1-2):10-15. 
45. Zoeller RT. Environmental chemicals impacting the thyroid: targets and consequences. 
Thyroid. Sep 2007;17(9):811-817. 
46. Shen O, Du G, Sun H, et al. Comparison of in vitro hormone activities of selected 
phthalates using reporter gene assays. Toxicol. Lett. Dec 1 2009;191(1):9-14. 
47. Sugiyama S, Shimada N, Miyoshi H, Yamauchi K. Detection of thyroid system-
disrupting chemicals using in vitro and in vivo screening assays in Xenopus laevis. 
Toxicol. Sci. Dec 2005;88(2):367-374. 
48. Breous E, Wenzel A, Loos U. The promoter of the human sodium/iodide symporter 
responds to certain phthalate plasticisers. Mol. Cell. Endocrinol. Dec 1 2005;244(1-2):75-
78. 
49. Wenzel A, Franz C, Breous E, Loos U. Modulation of iodide uptake by dialkyl phthalate 
plasticisers in FRTL-5 rat thyroid follicular cells. Mol. Cell. Endocrinol. Dec 1 
2005;244(1-2):63-71. 
50. Ishihara A, Sawatsubashi S, Yamauchi K. Endocrine disrupting chemicals: interference 
of thyroid hormone binding to transthyretins and to thyroid hormone receptors. Mol. Cell. 
Endocrinol. Jan 31 2003;199(1-2):105-117. 
51. Schug TT, Janesick A, Blumberg B, Heindel JJ. Endocrine disrupting chemicals and 
disease susceptibility. J. Steroid Biochem. Mol. Biol. Nov 2011;127(3-5):204-215. 
52. Glinoer D, de Nayer P, Bourdoux P, et al. Regulation of maternal thyroid during 
pregnancy. J. Clin. Endocrinol. Metab. Aug 1990;71(2):276-287. 
53. Obregon MJ, Calvo RM, Del Rey FE, de Escobar GM. Ontogenesis of thyroid function 
and interactions with maternal function. Endocr. Dev. 2007;10:86-98. 
54. Medici M, Timmermans S, Visser W, et al. Maternal thyroid hormone parameters during 
early pregnancy and birth weight: the Generation R Study. J. Clin. Endocrinol. Metab. 
Jan 2013;98(1):59-66. 
55. Zimmermann MB, Kohrle J. The impact of iron and selenium deficiencies on iodine and 
thyroid metabolism: biochemistry and relevance to public health. Thyroid. Oct 
2002;12(10):867-878. 
56. Caldwell KL, Pan Y, Mortensen ME, Makhmudov A, Merrill L, Moye J. Iodine status in 
pregnant women in the National Children's Study and in U.S. women (15-44 years), 





57. Mendez W, Jr., Eftim SE. Biomarkers of perchlorate exposure are correlated with 
circulating thyroid hormone levels in the 2007-2008 NHANES. Environ. Res. Oct 
2012;118:137-144. 
58. Wang W, Teng W, Shan Z, et al. The prevalence of thyroid disorders during early 
pregnancy in China: the benefits of universal screening in the first trimester of pregnancy. 
Eur. J. Endocrinol. Feb 2011;164(2):263-268. 
59. Stagnaro-Green A, Roman SH, Cobin RH, el-Harazy E, Alvarez-Marfany M, Davies TF. 
Detection of at-risk pregnancy by means of highly sensitive assays for thyroid 
autoantibodies. JAMA. Sep 19 1990;264(11):1422-1425. 
60. Perneger TV. What's wrong with Bonferroni adjustments. BMJ. Apr 18 
1998;316(7139):1236-1238. 
61. Lee RH, Spencer CA, Mestman JH, et al. Free T4 immunoassays are flawed during 
pregnancy. Am. J. Obstet. Gynecol. Mar 2009;200(3):260 e261-266. 
62. Nelson JC, Weiss RM, Wilcox RB. Underestimates of serum free thyroxine (T4) 




TABLES AND FIGURES 
 
Table III.1. Thyroid hormone measurements (weighted median [25th, 75th percentiles]) by demographic characteristics in all samples measured (N=439 




TSH (uIU/mL) Free T4 (ng/dL) Total T3 (ng/dL) Total T4 (ug/dL) T3/T4 Ratiob 
Age 18-24 years old [ref] 13 1.04 (0.70, 1.60) 1.12 (0.91, 1.36) 179 (155, 209) 11.2 (10.1, 12.3) 16.2 (13.6, 18.8) 
 25-29 years old  21 1.20 (0.79, 1.64) 1.13 (0.87, 1.35) 157 (130, 186)* 10.4 (9.30, 11.6) 15.1 (13.2, 17.4)* 
 30-34 years old  40 1.25 (0.81, 1.75) 1.09 (0.86, 1.35) 149 (127, 182)* 10.0 (8.90, 11.3)* 14.8 (12.7, 17.6)* 
 35+ years old  26 1.33 (0.96, 1.83) 1.11 (0.87, 1.37) 149 (124, 184)* 10.0 (8.90, 11.2)* 14.8 (12.5, 17.7)* 
        
Race/Ethnicity White [ref] 56 1.36 (0.97, 1.88) 1.09 (0.86, 1.34) 148 (127, 182) 10.0 (8.90, 11.1) 14.8 (12.6, 17.6) 
 African-American 17 0.96 (0.70, 1.35)* 1.11 (0.90, 1.32) 169 (145, 198)* 10.9 (9.60, 12.4)* 15.5 (13.6, 17.9)* 
 Other  27 1.12 (0.70, 1.66)* 1.16 (0.88, 1.41) 162 (130, 192)* 10.4 (9.20, 11.9) * 15.4 (12.8, 18.2) 
        
Education High School [ref] 15 1.13 (0.69, 1.60) 1.14 (0.93, 1.43) 171 (147, 200) 11.1 (9.90, 12.3) 15.6 (13.3, 18.4) 
 Technical School  17 1.09 (0.76, 1.64) 1.09 (0.86, 1.31)* 164 (136, 195) 10.3 (9.00, 11.6)* 16.2 (13.6, 18.6) 
 Junior College or some college 29 1.30 (0.90, 1.82) 1.10 (0.84, 1.35) 152 (132, 183)* 10.0 (8.80, 11.3)* 14.9 (13.0, 17.6)* 
 College graduate  39 1.30 (0.89, 1.83) 1.09 (0.87, 1.37) 147 (124, 178)* 10.1 (9.10, 11.2) * 14.6 (12.5, 17.0)* 
        
Health Insurance  Private/HMO/Self-pay [ref] 80 1.27 (0.85, 1.79) 1.10 (0.87, 1.35) 150 (127, 182) 10.0 (8.90, 11.3) 14.8 (12.7, 17.6) 
 Medicaid/SSI/MassHealth 20 1.06 (0.72, 1.60)* 1.13 (0.90, 1.36) 182 (153, 214)* 11.1 (10.0, 12.4)* 16.2 (13.8, 18.6)* 
        
BMI at Initial Visit <25 kg/m2 [ref] 53 1.25 (0.82, 1.79) 1.15 (0.89, 1.42) 144 (122, 169) 10.1 (9.00, 11.4) 14.0 (12.0, 16.5) 
 25-30 kg/m
2  26 1.28 (0.84, 1.78) 1.11 (0.87, 1.35) 168 (142, 194)* 10.4 (9.30, 11.6) 16.1 (13.8, 18.7)* 
 >30 kg/m
2  21 1.17 (0.78, 1.66) 1.05 (0.83, 1.25)* 181 (142, 208)* 10.3 (8.90, 11.6) 17.1 (14.3, 19.6)* 
        
Tobacco Use Smoked during pregnancy [ref] 7 1.23 (0.85, 1.60) 1.13 (0.85, 1.35) 171 (145, 209) 10.2 (9.10, 11.1) 16.8 (13.9, 20.7) 
 No smoking during pregnancy 93 1.25 (0.81, 1.76) 1.10 (0.87, 1.35) 154 (129, 185)* 10.3 (9.10, 11.6) 15.0 (12.8, 17.6)* 
        
Alcohol Use 
Alcohol use during pregnancy 
[ref] 
5 0.93 (0.66, 1.34) 1.10 (0.96, 1.34) 154 (118, 182) 9.60 (8.10, 10.8) 16.5 (14.0, 19.4) 
 No alcohol use during pregnancy 95 1.25 (0.82, 1.76)* 1.11 (0.87, 1.35) 156 (130, 186) 10.3 (9.10, 11.6)* 15.0 (12.9, 17.7) 
        
Fetal sex Male [ref] 46 1.28 (0.85, 1.73) 1.09 (0.88, 1.33) 157 (130, 187) 10.3 (9.00, 11.6) 15.4 (13.3, 18.0) 
 Female 54 1.22 (0.80, 1.77) 1.12 (0.89, 1.38) 154 (129, 185) 10.2 (9.10, 11.5) 14.7 (12.5, 17.6) 
Abbreviations: Pop., Population BMI, Body Mass Index; HMO, Health Maintenance Organization; SSI, Supplemental Security Income.  
a Weighted by case-control sampling probabilities to represent the general sampling population. 
b Total T3 expressed in ng/dL and Total T4 in µg/dL. 
*Significant difference (p<0.05) in thyroid hormone concentration in the category compared to reference (first category listed) using linear mixed models with a random intercept and 










Table III.2: Weighted distributions of urinary and plasma biomarkers by study visit of sample collection in pregnancy 
Biomarker # Samplesc 
Geometric Mean (Geometric Standard Deviation)  
Visit 1 
(median 10 weeks gestation) 
Visit 2 
(median 18 weeks 
gestation) 
Visit 3 
(median 26 weeks 
gestation) 
Visit 4 
(median 35 weeks 
gestation) 
Phthalate Metabolitesa 
MEHP (µg/L) 1,541 10.6 (3.52) 10.9 (3.39) 9.46 (3.28)* 9.83 (3.52)* 
MEHHP (µg/L) 1,541 34.7 (3.37) 34.8 (3.10) 27.2 (3.21)* 36.6 (3.33) 
MEOHP (µg/L) 1,541 18.6 (3.28) 18.3 (3.03) 15.6 (3.19)* 20.9 (3.22) 
MECPP (µg/L) 1,541 44.4 (3.35) 42.6 (3.25)* 36.8 (3.31)* 49.3 (3.35) 
ΣDEHP (µmol/L) 1,541 0.39 (3.16) 0.38 (3.01) 0.32 (3.04)* 0.42 (3.18) 
MBzP (µg/L) 1,541 7.36 (3.07) 7.34 (3.15) 7.05 (2.93) 8.03 (2.94)* 
MBP (µg/L) 1,541 18.3 (2.39) 18.4 (2.53) 17.3 (2.50) 19.7 (2.11)* 
MiBP (µg/L) 1,541 7.66 (2.29) 7.14 (2.38) 7.45 (2.32) 9.05 (2.17)* 
MEP (µg/L) 1,541 145 (4.66) 144 (4.84) 141 (4.48) 156 (4.99)* 
MCPP (µg/L) 1,541 2.11 (3.09) 2.25 (3.26)* 1.94 (2.89)* 2.04 (2.77) 
Thyroid Hormones 
TSH (µIU/mL) 1,210 1.13 (2.11) 1.30 (1.90)* 1.26 (1.67)* 1.31 (1.71)* 
Free T4 (ng/dL)b 1,435 1.49 (0.87) 1.16 (0.63)* 1.08 (0.81)* 0.99 (0.49)* 
Total T3 (ng/dL) b 1,130 140 (39.9) 166 (38.9)* 170 (39.8)* 171 (41.6)* 
Total T4 (µg/dL) b 1,391 10.2 (2.03) 10.7 (1.73)* 10.5 (1.97)* 10.2 (2.04) 
T3/T4 Ratio b 1,120 13.8 (2.67) 15.5 (3.43)* 16.5 (4.00)* 17.1 (4.46)* 
a Urinary phthalate concentrations corrected for specific gravity. 
b Arithmetic mean and standard deviation reported. 
c Number of plasma samples per hormone varied due to limitations in sample volume. 
*Significant difference (p<0.05) in urinary phthalate metabolite concentration or thyroid hormone compared to Visit 1 (reference) using linear mixed models with a  












Table III.3. Repeated measures analysis: percent change (95% CIs) in thyroid hormone concentrations in relation to interquartile range increase in urinary 
phthalate metabolite concentrations 
Analyte 








value  %Δ (95%CI) 
p-
value  %Δ (95%CI) 
p-































































































































































0.01*   
6.91  
(1.70, 12.1) 
0.01*   
1.55  
(-0.11, 3.21) 








Linear mixed models include random intercept and slope for each subject and were adjusted for urinary specific gravity, gestational age at time of sample collection, maternal 








Figure III.1. Cross-sectional analysis: percent change in TSH concentrations in relation to an interquartile range increase in urinary 






























Figure III.2. Cross-sectional analysis: percent change in free T4 concentrations in relation to an interquartile range increase in urinary 




























Table III.S1. Cross-sectional analysis: percent change (95% CIs) in thyroid hormone concentrations in relation to interquartile range increase in urinary 
phthalate metabolite concentrations by study visit during gestation 
Visit 1 : median 10 weeks of gestation 
Analyte %Δ (95%CI) p-value %Δ (95%CI) p-value %Δ (95%CI) p-value %Δ (95%CI) p-value %Δ (95%CI) p-value 
 ln-TSH Free T4 Total T3 Total T4 T3/T4 Ratio 
MEHP -16.0 (-27.6, -2.55) 0.02* 8.24 (-1.06, 17.5) 0.08 -0.11 (-III.98, 3.77) 0.96 0.20 (-2.45, 2.85) 0.88 -0.26 (-2.89, 2.36) 0.84 
MEHHP -14.9 (-26.1, -1.90) 0.03* 3.22 (-6.00, 12.4) 0.49 0.76 (-3.22, 4.74) 0.71 0.04 (-2.72, 2.80) 0.98 1.00 (-1.70, 3.71) 0.46 
MEOHP -15.7 (-27.5, -2.01) 0.03* 5.84 (-2.94, 14.6) 0.19 1.19 (-2.62, 4.99) 0.54 0.42 (-2.21, 3.06) 0.75 0.87 (-1.72, 3.46) 0.51 
MECPP -17.8 (-30.6, -2.52) 0.02* 10.5 (0.86, 20.1) 0.03* 0.57 (-3.55, 4.70) 0.78 0.67 (-2.12, 3.45) 0.64 0.13 (-2.66, 2.91) 0.93 
ΣDEHP -17.7 (-29.8, -3.46) 0.02* 9.30 (-1.42, 20.0) 0.09 0.68 (-3.87, 5.23) 0.77 0.51 (-2.61, 3.62) 0.75 0.44 (-2.64, 3.52) 0.78 
MBzP -13.6 (-29.2, 5.57) 0.15 2.60 (-8.56, 13.8) 0.65 -0.14 (-4.94, 4.66) 0.95 0.62 (-2.59, 3.82) 0.71 -1.64 (-4.87, 1.59) 0.32 
MBP -8.99 (-24.0, 8.93) 0.30 -0.99 (-15.4, 13.4) 0.89 1.66 (-4.34, 7.66) 0.59 0.96 (-3.24, 5.17) 0.65 -0.06 (-4.17, 4.05) 0.98 
MiBP -11.0 (-27.9, 9.79) 0.27 -1.67 (-13.8, 10.5) 0.79 3.00 (-2.28, 8.27) 0.26 2.43 (-1.17, 6.04) 0.18 0.04 (-3.55, 3.64) 0.98 
MEP 3.82 (-11.8, 22.1) 0.65 -3.68 (-10.9, 3.54) 0.32 2.36 (-0.76, 5.49) 0.14 0.51 (-1.59, 2.61) 0.63 1.18 (-0.94, 3.29) 0.27 
MCPP -22.0 (-31.9, -10.6) 0.00* 14.7 (3.41, 26.0) 0.01* 2.14 (-2.78, 7.05) 0.39 -0.24 (-3.57, 3.08) 0.89 2.14 (-1.16, 5.45) 0.20 
Visit 2 : median 18 weeks of gestation 
 ln-TSH Free T4 Total T3 Total T4 T3/T4 Ratio 
MEHP 3.77 (-6.10, 14.7) 0.47 4.42 (-2.7, 11.5) 0.22 1.79 (-1.56, 5.15) 0.29 1.81 (-0.52, 4.14) 0.13 -0.43 (-3.56, 2.69) 0.79 
MEHHP 6.44 (-4.38, 18.5) 0.26 1.36 (-6.23, 8.94) 0.73 4.45 (0.90, 7.99) 0.01* 1.31 (-1.16, 3.77) 0.30 3.25 (-0.05, 6.55) 0.05 
MEOHP 8.55 (-2.69, 21.1) 0.14 1.53 (-6.30, 9.37) 0.70 4.31 (0.65, 7.97) 0.02* 2.39 (-0.16, 4.93) 0.07 1.75 (-1.68, 5.18) 0.32 
MECPP 11.3 (-0.03, 24.0) 0.05 0.89 (-6.50, 8.28) 0.81 3.41 (-0.05, 6.87) 0.05 3.27 (0.87, 5.67) 0.01* 0.01 (-3.24, 3.26) 0.99 
ΣDEHP 9.93 (-1.62, 22.8) 0.09 1.79 (-6.54, 10.1) 0.67 4.11 (0.20, 8.02) 0.04* 2.89 (0.18, 5.60) 0.04* 1.04 (-2.63, 4.70) 0.58 
MBzP -12.6 (-23.5, -0.05) 0.049* 1.63 (-6.94, 10.2) 0.71 3.91 (-0.08, 7.90) 0.06 5.18 (2.42, 7.94) 0.00* -0.6 (-4.32, 3.12) 0.75 
MBP -12.6 (-23.3, -0.37) 0.04* 9.62 (-1.61, 20.9) 0.09 3.42 (-1.60, 8.44) 0.18 2.49 (-1.37, 6.35) 0.21 1.65 (-3.27, 6.58) 0.51 
MiBP -15.1 (-26.9, -1.51) 0.03* 1.77 (-8.43, 12.0) 0.73 3.05 (-1.57, 7.68) 0.19 4.18 (0.68, 7.68) 0.02* 1.29 (-3.26, 5.85) 0.58 
MEP -4.99 (-18.0, 5.90) 0.28 0.95 (-5.32, 7.22) 0.77 1.44 (-1.46, 4.34) 0.33 0.89 (-1.17, 2.95) 0.40 1.54 (-1.16, 4.25) 0.26 







Table III.S1. Continued 
Visit 3 : median 26 weeks of gestation 
 ln-TSH Free T4 Total T3 Total T4 T3/T4 Ratio 
MEHP -6.31 (-13.9, 1.93) 0.13 -2.48 (-16.6, 11.7) 0.73 -0.13 (-4.02, 3.75) 0.95 0.22 (-2.83, 3.28) 0.89 0.65 (-3.37, 4.67) 0.75 
MEHHP -1.14 (-9.30, 7.74) 0.79 -7.35 (-20.8, 6.14) 0.28 -0.07 (-3.73, 3.59) 0.97 -0.17 (-3.04, 2.70) 0.91 0.82 (-2.97, 4.61) 0.67 
MEOHP -2.58 (-10.5, 6.08) 0.55 -4.18 (-18.8, 10.4) 0.57 0.65 (-3.28, 4.58) 0.75 1.46 (-1.64, 4.57) 0.35 0.46 (-3.62, 4.53) 0.83 
MECPP -2.92 (-11.1, 5.97) 0.51 -3.27 (-17.4, 10.9) 0.65 1.27 (-2.58, 5.13) 0.52 2.67 (-0.30, 5.63) 0.08 0.59 (-3.41, 4.58) 0.77 
ΣDEHP -2.91 (-10.8, 5.73) 0.50 -5.44 (-21.6, 10.7) 0.51 0.92 (-3.48, 5.33) 0.68 2.08 (-1.35, 5.51) 0.23 0.74 (-3.82, 5.30) 0.75 
MBzP -8.68 (-18.2, 1.88) 0.10 -2.26 (-18.3, 13.8) 0.78 1.08 (-3.31, 5.47) 0.63 3.75 (0.36, 7.14) 0.03* -2.69 (-7.23, 1.85) 0.24 
MBP -6.71 (-15.4, 2.81) 0.16 -0.02 (-21.1, 21.1) 1.00 1.42 (-4.07, 6.90) 0.61 0.50 (-3.81, 4.80) 0.82 0.76 (-4.93, 6.45) 0.79 
MiBP -8.29 (-17.5, 1.91) 0.11 -2.98 (-21.0, 15.0) 0.74 -1.53 (-6.41, 3.36) 0.54 0.86 (-2.89, 4.60) 0.65 -0.27 (-5.35, 4.82) 0.92 
MEP -4.11 (-12.3, 4.85) 0.36 -2.07 (-12.5, 8.33) 0.70 2.12 (-0.56, 4.81) 0.12 0.74 (-1.38, 2.86) 0.49 1.83 (-0.96, 4.62) 0.20 
MCPP -6.92 (-14.5, 1.31) 0.10 -9.80 (-31.8, 12.2) 0.38 0.74 (-5.19, 6.67) 0.81 1.24 (-3.31, 5.78) 0.59 0.46 (-5.70, 6.62) 0.88 
Visit 4 : median 35 weeks of gestation 
 ln-TSH Free T4 Total T3 Total T4 T3/T4 Ratio 
MEHP -6.31 (-14.7, 2.86) 0.17 2.98 (-2.84, 8.80) 0.31 0.31 (-4.31, 4.93) 0.90 4.03 (1.19, 6.88) 0.01* -6.18 (-10.9, -1.47) 0.01* 
MEHHP 0.17 (-9.36, 10.7) 0.97 2.95 (-3.32, 9.21) 0.36 1.20 (-3.74, 6.13) 0.63 1.90 (-1.20, 4.99) 0.23 -4.30 (-9.39, 0.78) 0.10 
MEOHP -1.12 (-10.9, 9.78) 0.83 3.59 (3.00, 10.17) 0.28 1.34 (-3.81, 6.49) 0.61 3.01 (-0.23, 6.25) 0.07 -5.76 (-11.0, -0.48) 0.03* 
MECPP -0.74 (-11.5, 11.4) 0.90 4.32 (-2.94, 11.6) 0.24 1.68 (-3.86, 7.23) 0.55 4.23 (0.65, 7.80) 0.02* -5.37 (-11.1, 0.33) 0.06 
ΣDEHP -2.03 (-12.3, 9.49) 0.72 4.43 (-2.55, 11.4) 0.21 1.71 (-3.75, 7.17) 0.54 3.99 (0.56, 7.42) 0.02* -5.88 (-11.5, -0.28) 0.04* 
MBzP 5.29 (-5.63, 17.5) 0.35 8.26 (1.34, 15.2) 0.02* -2.84 (-8.03, 2.35) 0.28 0.42 (-3.03, 3.87) 0.81 -6.09 (-11.4, -0.77) 0.03* 
MBP -1.29 (-12.3, 11.1) 0.83 3.42 (-4.07, 10.9) 0.37 -0.51 (-6.00, 4.98) 0.85 0.02 (-3.67, 3.71) 0.99 -3.60 (-9.26, 2.06) 0.21 
MiBP -2.44 (-13.4, 9.96) 0.68 3.45 (-4.35, 11.2) 0.39 -1.23 (-6.94, 4.48) 0.67 0.37 (-3.56, 4.29) 0.85 -1.58 (-7.74, 4.58) 0.61 
MEP -2.04 (-11.8, 8.79) 0.70 2.97 (-3.82, 9.77) 0.39 3.34 (-1.59, 8.27) 0.18 0.61 (-2.78, 3.99) 0.73 3.01 (-2.19, 8.22) 0.26 
MCPP -5.15 (-14.3, 5.01) 0.31 8.55 (2.05, 15.1) 0.01* 1.64 (-3.11, 6.38) 0.50 0.51 (-2.74, 3.75) 0.76 -1.26 (-6.18, 3.66) 0.61 
Linear regression models adjusted for urinary specific gravity, gestational age at time of sample collection, maternal age at enrollment, body mass index (BMI) at time of sample 





CHAPTER IV. Longitudinal Profiles of Thyroid Hormone Parameters in 
Pregnancy and Associations with Preterm Birth 
 
ABSTRACT 
Background: Overt thyroid disease in pregnancy is associated with numerous maternal and 
neonatal complications including preterm birth. Less is known about the contribution of 
trimester-specific subclinical alterations in individual thyroid hormones, especially in late 
gestation, on the risk of preterm birth. Herein, we examined the associations between subclinical 
changes in maternal thyroid hormone concentrations (TSH, total T3, free and total T4), measured 
at multiple time points in pregnancy, and the odds of preterm birth in pregnant women without 
clinical thyroid disease.  
Methods: Data were obtained from pregnant women participating in a nested case-control study 
of preterm birth within on ongoing birth cohort study at Brigham and Women’s Hospital in 
Boston, MA (N=439; 116 cases and 323 controls). We measured thyroid hormones in plasma 
collected at up to four time points in pregnancy (median= 10, 18, 26, and 35 weeks). We used 
multivariate logistic regression models stratified by study visit of sample collection to examine 
associations. To reveal potential biological pathways, we also explored these relationships by 
obstetric presentation of preterm birth (e.g., spontaneous preterm delivery) that have been 
previously hypothesized to share common underlying mechanisms.  
Results: In samples collected at median 10 and 26 weeks of gestation, we found inverse 
associations between FT4 and the odds of overall preterm birth (odds ratio [OR] = 0.57, 95% 




associations were detected for total T3 at these same time points (OR=2.52, 95% CI=1.20, 5.31; 
and OR=3.40, 95% CI=1.56, 7.40, respectively). These effect estimates were stronger for 
spontaneous preterm birth.  
Conclusions: Our results suggest that subclinical alterations in individual maternal thyroid 
hormones may influence the risk of preterm birth, and the strength of these associations vary by 
gestational age. 
INTRODUCTION 
Preterm birth is among the most frequent causes of global infant and neonatal mortality.1 
While recent medical advances have improved survival among preterm infants, the long-term 
health and economic consequences associated with prematurity are substantial.1,2 Prevention of 
preterm birth is a challenge owing to the complexity of its causes, many of which are poorly 
understood.3  
Maternal thyroid hormones are crucial for normal fetal growth and development, 
especially neurodevelopment.4 This is particularly true in the first trimester when the fetus is 
entirely dependent on the transplacental passage of maternal thyroid hormones.5,6 Maternal 
thyroid hormones also play a physiological role in early placental development by regulating 
human trophoblast proliferation and invasion.6-10 Inadequate trophoblast cell invasion may result 
in abnormal placentation, which notably is a risk factor for preterm delivery.9,11  
Research has shown that overt hyper- and hypothyroidism in pregnancy are associated 
with poor maternal and neonatal outcomes.12-16 However, data on the consequences of milder 
forms of maternal thyroid dysfunction on the risk of preterm birth in particular have been less 
conclusive. Subclinical hypothyroidism or elevated thyrotropin (TSH) has been associated with 
preterm delivery in some studies17-20 but not in others.13,21 There has also been suggestive 
evidence that hypothyroxinemia (normal TSH concentrations with low free thyroxine [FT4]) in 
early pregnancy may increase the risk of prematurity.19 Notably, these studies are limited by 




Currently, there are a lack of data on the effects of trimester-specific subclinical 
alterations in individual parameters of thyroid function, especially in late gestation, on the risk of 
preterm birth. The purpose of this study was to examine the associations between subclinical 
fluctuations in biochemical markers of thyroid function, measured at up to four time points in 
pregnancy, and the risk of preterm birth in a nested case-control study of pregnant women 
without clinical thyroid disease. 
METHODS 
Study Population  
Participants were part of a nested case-control study of preterm birth drawn from a 
prospective birth cohort (the LIFECODES cohort) of pregnant women recruited early in 
gestation (<15 weeks) at Brigham and Women’s Hospital in Boston, MA. Additional 
information regarding recruitment and eligibility criteria are described in detail elsewhere.22,23 
The nested case-control study includes 130 women who delivered preterm (<37 weeks) and 352 
randomly selected controls. We additionally excluded from the study, women who reported pre-
existing or gestational thyroid disease/conditions based on answers to medical questionnaires 
administered at each of the study visits (N=41; e.g., hyper- or hypothyroidism, Graves’ disease, 
or thyroid cancer) and those who did not provide plasma samples at any study visit (N=2). The 
final study population for the current analyses included 116 cases of preterm birth and 323 
controls. The proportion of women delivering preterm did not significantly differ between 
women included vs. excluded from the current study (χ2=0.75, p=0.39). The study protocols 
were approved by the ethics review board at Brigham and Women’s Hospital (Partners Health 
Research Committee) and all study participants gave written informed consent. 
Gestational age at individual study visits and at delivery were calculated based on last 
menstrual period and confirmed by first trimester ultrasound.22 Overall preterm birth was defined 
as delivery before 37 weeks postmenstrual gestation.24 To create more homogenous 
subpopulations, outcome measures were additionally stratified by clinical presentation of 
preterm birth that were found to share common placental features.25 Based on the findings by 




cohort22,24, preterm birth was additionally classified as: (1) spontaneous preterm birth (defined by 
preterm labor or preterm premature rupture of the membranes [PPROM]; N=49); and (2) preterm 
birth resulting from aberrant placentation or placental preterm birth (defined by preeclampsia or 
intrauterine growth restriction [IUGR]; N=33).  Deliveries for non-medical indications (i.e. prior 
intrauterine fetal death or prior classical cesarean section) were not analyzed separately in this 
study as these cases have not been found to share common underlying biological processes.25  
Thyroid Hormone Measurements 
Plasma samples were collected at up to four study visits: visit 1 (median 10.0 weeks; 
range: 4.7 to 19.1 weeks), visit 2 (median 17.9 weeks; range: 14.9 to 32.1 weeks), visit 3 (median 
26.0 weeks; range: 22.9 to 36.3 weeks), and visit 4 (median 35.2 weeks; range: 33.1 to 38.3 
weeks). A total of 1,443 plasma samples were assayed at the Clinical Ligand Assay Service 
Satellite (CLASS) Lab at University of Michigan (Ann Arbor) for TSH, total and free thyroxine 
(T4 and FT4, respectively), and total triiodothyronine (T3). TSH and total hormones (T3 and T4) 
were assayed via automated chemiluminescence immunoassay (Bayer ADVIA Centaur, Siemens 
Health Care Diagnostics, Inc.). FT4 was measured using direct equilibrium dialysis followed by 
radioimmunoassay (IVD Technologies).  
The manufacturer did not provide trimester-specific reference ranges for TSH only a non-
pregnant normal range of 0.35-5.50 uIU/mL. In their absence, the American Thyroid Association 
(ATA) recommended in 2011 the following TSH reference ranges: first trimester, 0.1-
2.5 µIU/mL; second trimester, 0.2-3.0 µIU/mL; and third trimester, 0.3-3.0 µIU/mL.26 However, 
the ATA has recently proposed changing the upper limit of these intervals to the non-pregnancy 
upper limit (~ 4.0 mU/l).27,28 The FT4 pregnancy reference ranges provided by the laboratory 
were: first trimester, 0.7-2.0 ng/dL; second trimester, 0.5-1.6 ng/dL; and third trimester, 0.5-1.6 
ng/dL. The limits of detection (LOD) were 0.01 µIU/mL for TSH, 0.1 ng/mL for T3, 0.3 µg/dL 
for T4, and 0.1 ng/dL for FT4. The inter-assay coefficients of variation (CV) for all hormones 
ranged from 2.3% (for total T3) to 10.4% (for FT4) and the intra-assay CVs ranged from 1.2% 
(for total T3) to 12.3% (for FT4). Thyroid hormone concentrations less than the LOD were 




Free T3 (FT3) was not measured in this study due to sample volume constraints. Since 
unbound T3 is the principal bioactive hormone and potentially relevant to the mechanisms 
involved in preterm birth 30, we estimated its concentration using total T3 and the ratio of free vs. 
bound T4 concentrations assayed for each individual at visits 1-3. We determined the fraction of 
T4 that was unbound by dividing the concentration of FT4 by the concentration of T4 (both in 
µg/dL). Since approximately 10 times more T3 is unbound compared to T4 (~0.05% of T4 is in 
free form vs. ~0.5% of T3),31 we multiplied each FT4/T4 fraction by 10 to obtain the 
approximate proportion of unbound T3 per sample. We then applied this proportion to the 
measured total T3 concentrations to estimate the fractional concentration of FT3 (in pg/mL) per 
sample collected from each individual at visits 1-3. While our estimations are potentially limited 
by differences between T3 and T4 in binding ratios of free to total hormones and in intracellular 
versus extracellular concentrations of unbound hormones, we used the estimated concentrations 
of FT3 to explore our hypothesis about its potential association with preterm birth and included 
this estimation in only the regression models assessing the odds of overall preterm birth. 
Statistical Methods 
Analyses were performed using SAS version 9.3 (SAS Institute Inc.) and R version 3.1.1 
(R Foundation for Statistical Computing). The empirical histograms of total T3 and T4 
approximated a normal distribution. The distributions of TSH and FT4 were right-skewed so we 
used the natural log transformation (ln) of these variables in statistical analyses. We used a chi-
square statistic to test the differences in demographic characteristics between cases and controls.  
We assessed the variability of the assayed thyroid hormones (TSH, free and total T4, and 
total T3) across pregnancy for the overall population as well as separately for cases and controls 
using several methods. First, we tabulated the median and interquartile range (25th and 75th 
percentiles) for each hormone, and evaluated differences in visits 2-4 compared to visit 1 using 
linear mixed models (LMMs) with a subject-specific random intercept. We also calculated the 
intraclass correlation coefficient (ICC) and associated 95% confidence intervals to examine the 
temporal variability in hormones for each subject. ICC measures the reproducibility of repeated 




(between- plus within-subject variance).32 ICC ranges from 0 to 1, with the latter indicating no 
within-subject variability.32  
In our third variability analysis, we examined the patterns of each hormone across 
pregnancy by fitting generalized additive mixed effects models (GAMM) using the R mgcv 
package. For each model, we used repeated measures of individual thyroid hormones and 
regressed them on a penalized spline of gestational age to assess potential nonlinear associations. 
We accounted for the correlation of repeated measures taken from the same subject by including 
subject-specific random intercepts and slopes. Predicted thyroid hormone concentrations were 
plotted in relation to gestational age at time of sample collection to examine patterns across 
pregnancy. To test whether the observed patterns varied by case-control status, we included an 
interaction term between preterm birth and gestational age.  
We used logistic regression to explore associations between increases in individual 
thyroid hormones and the odds of preterm birth. Crude models included gestational age at time 
of sample collection. Full models were additionally adjusted for maternal age at enrollment, 
body mass index (BMI) at time of sample collection, parity, health insurance provider, and 
educational attainment. We chose age, BMI, and parity as covariates a priori based on their 
biological relevance to maternal thyroid hormone concentrations and preterm birth.33-37 We 
identified the additional covariates based on ≥ 10% change in the main effect estimates when 
added to the models in a forward stepwise procedure. 
We stratified logistic regression models by study visit of sample collection. We excluded 
data collected at visit 4 from all regression analyses in order to avoid potential bias resulting 
from a disproportionate number of controls compared to cases providing plasma samples at this 
study visit. To reveal potential biological pathways, we explored these relationships by obstetric 
presentation of preterm birth that have been previously hypothesized to share common 
underlying mechanisms.25 Specifically, we repeated these stratified analyses for each subtype of 
preterm birth (spontaneous and placental preterm birth), adjusting logistic regression analyses for 
gestational age at time of sample collection, maternal age at enrollment, and maternal race. Since 
the gestational age ranges varied considerably for each study visit of sample collection, we also 




regression models for overall preterm birth by five-week intervals of gestational age (e.g., 5-10 
weeks, 10-15 weeks, etc.).  
RESULTS 
The demographic characteristics of the study population by preterm birth status are 
presented in Table IV.1 and are consistent with our prior publications.24 Overall, the study 
population was predominately white, highly educated, and non-smokers. The majority of women 
were giving birth for the first time and a greater proportion of women delivering preterm were 
obese (>30 kg/m2) compared to controls (31% of cases vs. 20% of controls).  
Variability in hormones across pregnancy 
The distributions of thyroid hormones by study visit of sample collection are reported in 
Table IV.2 for the overall population and by preterm birth status. Results from linear mixed 
models (LMMs) indicated that thyroid hormone concentrations varied by study visit of sample 
collection for both cases and controls. Intraclass correlation coefficients (ICCs) showed the 
lowest temporal reliability for FT4 and the highest reliability for total hormones (T3 and T4).  
Smoothed plots of predicted thyroid hormone concentrations in association with 
gestational age at sample collection in cases and controls are presented in Figure IV.1. The 
observed trajectories of each hormone across gestation were similar to the pattern of results 
reported in Table IV.2. Interaction terms from generalized additive mixed effects models 
(GAMMs) indicated that trends in hormone concentrations across pregnancy were significantly 
different between cases and controls (p<0.001 for all hormones). The smoothed plot for TSH 
showed that concentrations were greater in controls in early pregnancy and subsequently 
decreased to lower concentrations than those observed in cases in the latter half of the first 
trimester. Predicted values of FT4 in controls were also higher in samples taken in early 
pregnancy, but converged to similar concentrations as those observed in cases as pregnancy 
progressed. Total thyroid hormone concentrations (T4 and T3) increased across gestation in both 
cases and controls, with a greater increase observed between approximately 5 and 15 weeks of 




Gestational age-stratified analyses 
 Adjusted odds ratios (OR) of overall preterm birth in relation to a unit increase in thyroid 
hormone concentrations are presented in Table IV.3 by study visit of sample collection. ORs 
from fully adjusted logistic regression models were similar to those observed in crude models. At 
visits 1 and 3, a one ng/dL decrease in ln-transformed FT4 was associated with approximately 
two times the odds of preterm birth.  Similar to results detected for FT4, ORs for overall preterm 
birth were reduced for estimated FT3 at visits 1 and 3, although these associations were not 
statistically significant (data not shown).  
For total hormones, total T4 concentrations were suggestively associated with an increase 
in odds of overall preterm birth (p=0.07-0.16). A unit increase of total T3 was associated with a 
two- to threefold increase in odds of overall preterm birth at all study visits with the exception of 
visit 2. Associations for TSH were null at all time points.   
Narrower windows of gestational age were explored by stratifying ORs by five-week 
intervals of gestational age at time of sample collection (Table IV.S1). Results from this 
sensitivity analysis were similar to those reported in Table IV.3 by study visit of sample 
collection. Significant elevated ORs were observed for total T3 measured in samples taken in 
early (5-10 weeks) and mid- to late pregnancy (20-25 weeks and 25-30 weeks). At these same 
time points, reduced albeit nonsignificant, ORs were detected for FT4. 
Figures IV.2 and IV.3 show visit-specific associations between measured thyroid 
hormone concentrations and odds of spontaneous and placental preterm birth, respectively (data 
reported in Tables IV.S2 and IV.S3). For spontaneous preterm birth, reduced ORs for FT4 and 
estimated FT3 at visits 1 and 3 were similar in direction to those observed for overall preterm 
birth but were stronger and statistically significant for this subtype. The results for total T3 were 
in the opposite directions as those observed for FT4, and were significantly elevated at study 
visits 1 and 2. For placental preterm birth, no significant associations were observed for any of 






In this nested case-control study drawn from a large prospective birth cohort, we 
characterized the temporal patterns of thyroid function parameters across gestation. We explored 
windows of vulnerability for the risk of preterm birth using plasma samples collected at up to 
four time points in pregnancy. Additionally, we evaluated whether the effects of these subclinical 
hormonal deviations on the risk of preterm birth varied by clinical presentation.   
Profiles of hormones across pregnancy 
This is the first study to evaluate the differences in the variability and trajectories of 
maternal thyroid hormone concentrations across pregnancy between women delivering preterm 
and at term.  Various physiological changes that accompany the normal pregnancy state increase 
the demands of the maternal thyroid gland.4,38 In response to the estrogen-stimulated rise in the 
transport protein, thyroxine-binding globulin (TBG), there is a concomitant rise in total T3 and 
T4 in the first half of pregnancy until a new steady state is reached.4 Also in the first trimester, 
there is a transient lowering of circulating TSH that coincides with peak human chorionic 
gonadotropin (hCG) concentrations.4 Due to the structural homology between hCG and TSH 
molecules, hCG binds to the TSH receptor and exerts a stimulatory effect – the increased 
hormonal output of FT4 results in the lowering of TSH levels via the negative feedback 
system.4,39 Following the initial increase in FT4 between approximately 6 and 10 weeks of 
gestation as a result of the high placental production of hCG during this time period,40 FT4 
subsequently decreases over pregnancy.4 In the present study, the trajectories of thyroid hormone 
parameters in women delivering at term were consistent with what has been reported in the 
medical literature.  Differences in the temporal hormonal patterns between cases and controls 
were most evident in the first trimester of pregnancy.  
We found that total T3 and T4 concentrations were lower in controls in early pregnancy, 
and rose to similar or slightly greater concentrations as cases by the end of the first trimester 
(Figure IV.1). An upward trend in total hormones was observed in both groups until 
approximately 20 to 25 weeks of gestation, when a more stable concentration was reached. For 




In controls, we observed the characteristic sharp decrease in TSH in the first trimester followed 
by an increase in concentrations until approximately 20 to 25 weeks of gestation (Figure IV.1). 
Whereas TSH concentrations fluctuated across gestation in controls and exhibited patterns 
similar to those reported in the literature, there was a constant upward slope in concentrations 
across pregnancy in women delivering preterm. However, it is uncertain whether this somewhat 
linear trend is a consequence of a smaller sample size in cases or if this pattern represents the 
true trajectory of TSH in women delivering preterm.  Finally, we detected downward trends in 
FT4 across gestation in both cases and controls, with greater concentrations of FT4 observed in 
controls in early pregnancy (Figure IV.1).  In response to peak hCG production in normal 
pregnancy, TSH decreases to its lowest concentration and FT4 to its highest concentration 
between approximately 9 and 12 weeks of gestation.40 The temporal differences in the trends of 
TSH and FT4 between cases and controls that we observed in early pregnancy – specifically, the 
higher concentrations of TSH and lower concentrations of FT4 in cases compared to controls 
around approximately 10 weeks of gestation – may indicate a lack of thyroidal response to hCG 
in women delivering preterm 41. In their recent study, Korevaar et al. observed an impaired 
thyroidal response to hCG in thyroperoxidase antibody (TPOAb)-positive pregnant women.41 
While TPOAb positivity is a risk factor for premature delivery,19 we did not assess thyroid 
autoimmunity in our study participants and therefore cannot examine the extent to which thyroid 
autoimmunity modifies the relationships between subclinical changes in thyroid function 
parameters and the risk of preterm birth in this study. 
Associations by gestational age 
In the present study, we found that a unit decrease in FT4 was associated with an 
approximate twofold increase in the odds of overall preterm birth at median 10 weeks of 
gestation. These findings are in agreement with a previous study showing associations between 
low FT4 concentrations (<2.5th percentile) at median 13 weeks of pregnancy and an increased 
risk of preterm delivery.19 However, null associations have been reported by other studies for 
low FT4 in early pregnancy42-45 and for continuous measures of FT4 sampled in the first half of 
gestation.46,47 Currently, there are no published data on the relationship of total T3 concentrations 




and overall preterm birth are compatible with an earlier birth cohort study in which a lack of 
association was observed in early pregnancy.46  
Our null findings for TSH contrast with the results reported in studies showing 
associations between preterm birth and elevated TSH concentrations in early pregnancy20,48 and 
maternal subclinical hypothyroidism (defined as elevated TSH with normal FT4). 42,49,50 
However, these results were not confirmed by other studies.13,17,45,46,51  
The observed dissimilarities between our analyses and findings reported previously may 
be due to differences in assay methods used to measure FT4 (electrochemiluminescence 
immunoassay vs. direct equilibrium dialysis followed be radioimmunoassay), variability in the 
classification of subclinical thyroid dysfunction (e.g., differing statistical cutoff points to define 
elevated TSH or low FT4), inconsistent ascertainment of preterm birth (e.g., gestational age 
based on self-reported last menstrual period vs. first trimester ultrasound-validated 
measurements), and/or the proportion of spontaneous versus iatrogenic preterm birth cases. 
Furthermore, no other studies assessed additional time points outside of the first or second 
trimester.  
One of the strengths of our study was our analyses by subtype of preterm birth. Only one 
previous study has examined associations between thyroid hormone concentrations and preterm 
birth with attention to presentation at delivery.52 In that study, women with spontaneous preterm 
delivery (delivery <34 weeks) had significantly reduced concentrations of FT4 (within the 
normal range) measured in the first trimester compared to women delivering at term, although no 
differences were observed for TSH between the two groups. In our analysis we observed odds 
ratios that were greater in magnitude and more precise in models of spontaneous preterm birth 
alone, specifically for FT4 and total T3. While these findings may be due to differences in 
sample size between the two stratified analyses, our results for spontaneous preterm birth 
suggests that changes in these hormone concentrations during gestation may have particular 
consequences for spontaneous preterm labor and/or PPROM. For placental preterm birth, we did 
not observe any significant associations. Specifically, our generally null results for TSH are in 
contrast to studies showing associations between abnormally elevated TSH concentrations and 




birth.25 Additional studies with larger sample sizes are required to disentangle the relationships 
between subclinical maternal thyroid dysfunction and subtype of preterm birth, and to identify 
the underlying biological mechanisms potentially driving these associations. 
It is possible that the observed fluctuations in thyroid function parameters are a result of 
other underlying physiological processes that ultimately lead to preterm birth.  Spontaneous 
preterm birth is strongly associated with inflammation at the maternal-fetal interface.55,56 We 
previously demonstrated that the pro-inflammatory cytokine, interleukin-6 (IL-6), is a strong 
predictor of spontaneous preterm delivery in the current study population.57 Mild thyroid 
hormone dysfunction at various time points in pregnancy may contribute to the inflammatory 
processes involved in the pathogenesis of spontaneous preterm birth, or vice versa. Indeed, 
human health studies have shown increased pro-inflammatory markers, including IL-6, in overt 
and subclinical hypothyroid patients.58,59 Consistent with this hypothesis, we found strong and 
highly significant inverse relationships between free hormones and spontaneous preterm birth in 
early and/or late pregnancy.  
Strengths and Limitations 
The primary strengths of our study was our repeated measures of thyroid function 
parameters collected in each trimester of pregnancy and our accurately defined clinical 
outcomes. Our longitudinal study design permitted an assessment of the variability in individual 
parameters across gestation in cases and controls as well as time points in pregnancy during 
which subclinical thyroidal disturbances may have a more profound effect on the risk of preterm 
birth. Additionally, our assay method for measuring FT4 using equilibrium dialysis is considered 
analytically accurate and is preferred over traditional immunoassays since measurements are not 
affected by thyroid hormone binding protein concentrations, which increase in pregnancy.60,61 
Despite these strengths, our study was limited by the lack of assessment of the thyroid 
autoimmunity of our study participants due to biological sample volume constraints. As 
mentioned previously, the presence of thyroid anti-thyroid antibodies have been found to modify 






 In conclusion, our results support previous studies showing the potential for subclinical 
changes in thyroid hormone concentrations in pregnancy to influence the risk of preterm birth. 
Our stratified analyses showed that these effects may vary by gestational age and clinical 
presentation of preterm birth. Additional human health and animal studies should take these 
findings into account when trying to elucidate the mechanism(s) of subclinical thyroid 
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Table IV.1. Population demographic characteristics by cases (N=116) and controls (N=323) 
Population Characteristics 
Cases Controls 
N (%) N (%) 
    
Age 18-24 years old 10 (9) 44 (14) 
 25-29 years old 25 (22) 67 (21) 
 30-34 years old 49 (42) 127 (39) 
 
35+ years old 32 (28) 85 (26) 
Race White 65 (56) 182 (56) 
 African-American 21 (18) 54 (17) 
 Other 30 (26) 87 (27) 
Education High School 21 (18) 46 (15) 
 Technical School 25 (22) 51 (16) 
 Junior College or some college 34 (30) 93 (30) 
 College graduate 35 (30) 124 (39) 
Health Insurance Provider Private 94 (82) 250 (80) 
 Public 20 (18) 63 (20) 
BMI at Initial Visit <25 kg/m2 51 (44) 176 (54)* 
 25-30 kg/m2 29 (25) 84 (26) 
 
>30 kg/m2 36 (31) 63 (20) 
Tobacco Use Smoked during pregnancy 11 (9) 20 (6) 
 
No smoking during pregnancy 105 (91) 297 (94) 
Alcohol Use Alcohol use during pregnancy 1 (1) 12 (4) 
 No alcohol use during pregnancy 113 (99) 299 (96) 
Fetal sex Male 50 (43) 148 (46) 
 Female 66 (57) 175 (54) 
Parity Nulliparous 50 (43) 147 (45) 
 Primiparous 32 (28) 112 (35) 
 Multiparous 34 (29) 64 (20) 
Abbreviations: BMI, Body Mass Index 


















Table IV.2. Median (25th-75th) concentrations and intraclass correlation coefficient (ICCs) of 
thyroid hormone parameters by case-control status and study visit of sample collection. 
   Study Visit TSH (µIU/mL) FT4 (ng/dL) T4 (µg/dL) T3 (ng/mL) 
All Samples (N=1756 observations) 
 visit 1 [ref] 0.92 (0.54, 1.50) 1.37 (1.15, 1.62) 10.1 (8.78, 11.4) 1.32 (1.13, 1.62) 
 visit 2 1.34 (0.97, 1.90)
* 1.13 (0.90, 1.30)* 10.6 (9.60, 11.9)* 1.61 (1.35, 1.92)* 
 visit 3 1.28 (0.93, 1.70)
* 1.00 (0.81, 1.18)* 10.4 (9.20, 11.5)* 1.66 (1.38, 1.96)* 
 visit 4 1.39 (0.97, 1.93)
* 0.96 (0.77, 1.17)* 10.0 (9.00, 11.5) 1.66 (1.41, 2.02)* 
 ICC (95%CI) 0.51 (0.46, 0.57)
† 0.18 (0.13, 0.24)† 0.67 (0.63, 0.71) 0.62 (0.57, 0.67) 
Cases (N=116; 464 observations) 
 visit 1 [ref] 0.94 (0.51, 1.40) 1.35 (1.08, 1.55) 10.4 (8.93, 11.6) 1.38 (1.25, 1.68) 
 visit 2 1.24 (0.89, 1.83)
* 1.13 (0.83, 1.30)* 10.6 (9.85, 12.1)* 1.70 (1.32, 2.09)* 
 visit 3 1.24 (0.96, 1.73)
* 0.95 (0.79, 1.15)* 10.5 (9.45, 11.8)* 1.83 (1.55, 2.19)* 
 visit 4 1.54 (1.00, 2.02)
* 0.96 (0.75, 1.24)* 10.7 (9.18, 11.9) 1.92 (1.45, 2.13)* 
 ICC (95%CI) 0.47 (0.35, 0.58)
† 0.32 (0.20, 0.43)† 0.59 (0.49, 0.68) 0.62 (0.51, 0.71) 
Controls (N= 323; 1292 observations) 
 visit 1 [ref] 0.91 (0.55, 1.52) 1.39 (1.17, 1.65) 10.0 (8.70, 11.2) 1.30 (1.11, 1.60) 
 visit 2 1.39 (0.99, 1.91)
* 1.14 (0.94, 1.30)* 10.6 (9.43, 11.8)* 1.60 (1.37, 1.87)* 
 visit 3 1.30 (0.90, 1.70)
* 1.00 (0.82, 1.20)* 10.3 (9.10, 11.3)* 1.60 (1.35, 1.87)* 
 visit 4 1.34 (0.97, 1.92)
* 0.96 (0.77, 1.17)* 10.0 (8.90, 11.4) 1.65 (1.39, 1.99)* 
  ICC (95%CI) 0.53 (0.46, 0.59)
† 0.15 (0.09, 0.22)† 0.69 (0.65, 0.74) 0.61 (0.55, 0.67) 
Abbreviations: CI, confidence interval; ICC, intraclass correlation coefficient. 
* Indicates significant difference (p<0.05) in thyroid hormone concentration at the study visit compared 
to the reference (visit=1) using linear mixed models with a subject-specific random intercept.  




















Table IV.3 Adjusted odds ratios (95% CI) of overall preterm birth (N=116 cases) associated with a unit increase in thyroid hormone parameters. 




OR (95%CI) p-value 
 N 
OR (95%CI) p-value 
 N 






ln-TSH 81, 220 0.91 (0.71, 1.16) 0.43  86, 221 0.88 (0.61, 1.28) 0.52  75, 219 1.43 (0.85, 2.46) 0.19 
ln-FT4 98, 257 0.57 (0.33, 1.00) 0.05  96, 260 0.97 (0.60, 1.54) 0.89  88, 247 0.53 (0.34, 0.84) <0.01
* 
T4 100, 246 1.12 (0.99, 1.27) 0.07  92, 253 1.11 (0.96, 1.28) 0.16  85, 235 1.13 (0.99, 1.29) 0.08 
T3 76, 212 2.52 (1.20, 5.31) 0.01*  82, 209 1.71 (0.81, 3.60) 0.16  70, 204 3.40 (1.56, 7.40) <0.01
* 
Adjusted models include gestational age at time of sample collection, maternal age at enrollment, body mass index (BMI) at time of sample collection, parity, health 































Figure IV.2. Adjusted odds ratios of spontaneous preterm birth (N=49 cases) associated with a 
















Figure IV.3. Adjusted odds ratios of placental preterm birth (N=33 cases) associated with a unit 
















Table IV.S1. Adjusted odds ratios (95% CI) of overall preterm birth (N=116 cases) associated unit increase in thyroid hormone concentrations: results 
stratified by gestational age. 
Gestational Age  
(weeks) 
 
















OR (95%CI) p-value 
5-10 44, 122 
0.74 
(0.52, 1.07) 
0.11 53, 143 
0.44 
(0.18, 1.11) 
0.08 54, 137 
1.12 
(0.93, 1.35) 




10-15 36, 98 
1.18 
(0.77, 1.81) 
0.46 44, 114 
0.63 
(0.29, 1.34) 
0.23 45, 109 
1.11 
(0.93, 1.34) 




15-20 84, 211 
0.83 
(0.58, 1.17) 
0.29 94, 249 
0.98 
(0.60, 1.62) 
0.95 90, 243 
1.14 
(0.98, 1.31) 




20-25 31, 48 
1.46 
(0.49, 4.34) 
0.49 33, 58 
0.44 
(0.18, 1.05) 
0.06 32, 52 
1.11 
(0.82, 1.50) 




25-30 47, 178 
1.49 
(0.77, 2.89) 
0.23 58, 197 
0.61 
(0.36, 1.01) 
0.06 56, 190 
1.07 
(0.92, 1.25) 




Adjusted models include gestational age at time of sample collection, maternal age at enrollment, body mass index (BMI) at enrollment, parity, health insurance 



















Table IV. S2. Adjusted odds ratios (95% CI) of spontaneous preterm birth associated with a unit increase in thyroid hormone parameters. 
Thyroid  
Hormone 
Visit 1  
(median 10 weeks of gestation)  
Visit 2  
(median 18 weeks of gestation)  
Visit 3  
(median 26 weeks of gestation) 
N 
OR (95% CI) p-value 
 N 
OR (95% CI) p-value 
 N 






ln-TSH 36, 233 1.11 (0.75, 1.65) 0.60  38, 229 1.05 (0.59, 1.88) 0.86  32, 228 0.88 (0.42, 1.85) 0.73 
ln-FT4 42, 272 0.48 (0.25, 0.91) 0.02  45, 269 0.94 (0.51, 1.74) 0.84  38, 257 0.42 (0.24, 0.75) <0.01 
T4 43, 260 1.14 (0.97, 1.34) 0.12  42, 262 1.16 (0.96, 1.40) 0.14  36, 235 1.14 (0.96, 1.35) 0.15 
T3 34, 225 3.40 (1.25, 9.25) 0.02  36, 217 2.48 (0.96, 6.42) 0.06  29, 213 4.20 (1.49, 11.8) <0.01 




















Table IV.S3. Adjusted odds ratios (95% CI) of placental preterm birth associated with a unit increase in thyroid hormone parameters. 
Thyroid  
Hormone 
Visit 1  
(median 10 weeks of gestation)  
Visit 2  
(median 18 weeks of gestation)  
Visit 3  
(median 26 weeks of gestation) 
N 
OR (95%CI) p-value 
 N 
OR (95%CI) p-value 
 N 






ln-TSH 21, 233 0.78 (0.53, 1.14) 0.20  27, 229 0.99 (0.51, 1.91) 0.98  24, 228 1.26 (0.54, 2.93) 0.59 
ln-FT4 29, 272 0.80 (0.37, 1.72) 0.57  29, 269 0.75 (0.39, 1.45) 0.39  29, 257 0.58 (0.31, 1.10) 0.10 
T4 29, 260 0.98 (0.79, 1.20) 0.82  28, 262 1.00 (0.80, 1.26) 1.00  26, 244 1.04 (0.85, 1.26) 0.73 
T3 18, 225 1.50 (0.32, 7.03) 0.60  25, 217 0.63 (0.16, 2.44) 0.50  23, 213 2.48 (0.62, 9.90) 0.20 




CHAPTER V. Subclinical Changes in Maternal Thyroid Function 
Parameters in Pregnancy are Associated with Fetal Growth 
 
ABSTRACT  
Introduction: Thyroid hormones play a crucial role in placental development and intrauterine 
growth. While overt thyroid disease in pregnancy is a known risk factor for abnormal fetal 
growth and development, data on the effects of milder forms of variation in maternal thyroid 
function on intrauterine growth are less well examined.  
Methods: Data were obtained from 439 pregnant women without diagnosed thyroid disease who 
were participants in a nested case-control study of preterm birth within an ongoing prospective 
birth cohort in Boston, MA. Thyroid function parameters were measured and ultrasound scans 
were performed at up to four time points in pregnancy. Birth weight was recorded at delivery. 
All fetal growth indicators were standardized to those measured in a larger population. 
Results: At median 10, 18, and 26 weeks of gestation, we observed significant inverse 
associations between FT4 and birth weight z-scores, with the greatest association detected at 
median 10 weeks. At this time point, a unit increase in ln-transformed FT4 was associated with 
almost a half of a z-score decrease (approximately 175 grams) in birth weight (β = -0.41; 95% 
confidence interval [CI] = -0.64, -0.18). FT4 was also inversely associated with repeated fetal 
growth measurements, with significant estimates found for estimated fetal weight, head 
circumference, and abdominal circumference. Birth weight did not significantly differ between 
women with subclinical hypothyroidism (N=10) and those without (N=426), although the lack of 




between total T4 and fetal growth indices, and a positive relationship between total T3 at median 
26 weeks of gestation and birth weight. We did not observe any associations for TSH. 
Conclusions: In pregnant women without overt thyroid disease, subclinical changes in thyroid 
function parameters may influence fetal growth. 
INTRODUCTION  
Impaired fetal growth is a major predictor of neonatal mortality and morbidity, and may 
increase the risk of long-term health complications such as diabetes and cardiovascular disease in 
adulthood.1,2 Thyroid hormones play a crucial physiological role in early placental development 
as well as intrauterine growth and fetal tissue accretion and differentiation.3,4 Overt thyroid 
dysfunction in pregnancy (hyper- and hypothyroidism) has been consistently linked to abnormal 
fetal growth and development, including neurodevelopment.5-8  
Investigations of the effects of milder forms of thyroid dysfunction on fetal growth are 
less conclusive. Subclinical hypothyroidism (high thyroid-stimulating hormone [TSH] with 
normal free thyroxine [FT4]) and hypothyroxinemia (normal TSH with low FT4) have been 
associated with a smaller head circumference and birth length,8 intrauterine growth restriction 
(IUGR),9 low birth weight9,10 and/or an increased risk for small for gestational age (SGA) 
neonates.8,11 However, similar studies on these relationships have reported conflicting results12-14 
or null associations.15-18 The more consistent findings have been in generally euthyroid pregnant 
women in whom increases in FT4 have been associated with lower birth weight14,19-21 and an 
increased risk for SGA newborns.20 
Few longitudinal studies have been performed with repeated measures of maternal 
thyroid hormones in pregnant women.22-25 To our knowledge, only one study has utilized serial 
measurements of thyroid function parameters to explore potential associations with fetal 
growth.26 Specifically, Nishioka et al.26 reported that an increase in maternal TSH concentrations 
between the first and third trimesters was associated with low birth weight (< 2500 g). This 




precluded trimester-specific analyses and likely contributed to the lack of variation in free 
hormones between women who delivered low birth weight babies and controls.  
Given the heterogeneous results in the available literature as well as the lack of 
longitudinally collected data across pregnancy, we investigated the extent to which thyroid 
function parameters, collected at up to four times points in pregnancy, were associated with birth 




The present study is a secondary analysis of data from a nested case-control study of 
preterm birth drawn from the LIFECODES cohort – a prospective birth cohort of pregnant 
women in Boston, MA. Women ages ≥ 18 years old were recruited early in pregnancy (< 15 
weeks of gestation) between 2006 and 2008 and were eligible for participation if they were 
carrying a singleton, non-anomalous fetus and planned to deliver at Brigham and Women’s 
Hospital. Details regarding recruitment and eligibility criteria are described in detail 
elsewhere.27,28 At the initial study visit (median = 10 weeks of gestation), women completed a 
medical questionnaire that collected sociodemographic and health-related information (e.g., 
personal and family health history). Participants were followed until delivery, and provided 
relevant health information as well as blood samples at three additional study visits: visit 2 
(median = 18 weeks of gestation), visit 3 (median = 26 weeks of gestation), and visit 4 (median = 
35 weeks of gestation). Gestational age at individual study visits and at delivery were calculated 
based on last menstrual period and confirmed by first trimester ultrasound or based entirely upon 
first trimester ultrasound. Birth weight was recorded at delivery. 
From the prospective birth cohort, we selected 130 women who delivered preterm (< 37 
weeks) and 352 randomly selected controls for inclusion in the nested case-control study. For the 
current analysis, we additionally excluded 41 women with self-reported pre-existing or 




thyroid cancer) based on answers to medical questionnaires administered at each of the study 
visits. Two women who did not provide plasma samples at any study visit were also excluded. 
Our final study population included 116 cases of preterm birth and 323 controls. The study 
protocols were approved by the ethics review board at Brigham and Women’s Hospital (Partners 
Health Research Committee) and all study participants gave written informed consent. 
Ultrasound Measurements 
The American College of Obstetricians and Gynecologists’ (ACOG) guidelines for 
perinatal care recommend that all women undergo evaluations for aneuploidy in the first 
trimester and again in the second trimester to examine fetal anatomy.29 Thus, in our study 
population all women had ultrasound scans that provide crown rump length at visit 1 and fetal 
morphology at visit 2. Ultrasound scans at visits 3 and 4 were not routine, but were obtained 
frequently for a variety of indications including  maternal gestational diabetes or suspected 
restricted fetal growth).30 All ultrasound measurements were conducted by experienced faculty 
sonologists with active Society of Maternal-Fetal Medicine certification. 
In the current analysis, we used the following ultrasound measurements from visits 2 
through 4: head circumference (HC), abdominal circumference (AC), and femur length (FL). We 
calculated estimated fetal weight (EFW) at each of the study visits using the Hadlock formula 
that combines biparietal diameter, abdominal circumference, and femur length.31 In order to 
combine and compare fetal growth measurements across different time points, we standardized 
raw ultrasound measurements using z-scores based on the mean and standard deviation of 
ultrasound measurements available for 18,904 non-anomalous singleton pregnancies delivered 
between 2006 and 2012 at Brigham and Women’s Hospital.30,32 
Thyroid Hormone Measurements 
A total of 1,443 plasma samples from 439 pregnant women were assayed for thyroid 
function parameters at the University of Michigan Clinical Ligand Assay Service Satellite 
(CLASS) Lab (Ann Arbor, MI). These samples were collected at up to four study visits. We 




chemiluminescence immunoassay (Bayer ADVIA Centaur; Siemens Health Care Diagnostics, 
Inc.). FT4 was measured using direct equilibrium dialysis followed by radioimmunoassay (IVD 
Technologies).  
The manufacturer only provided a non-pregnant normal range of 0.35-5.50 uIU/mL for 
TSH. In the absence of trimester-specific reference ranges, the American Thyroid Association 
(ATA) recommended in 2011 the following TSH reference ranges: first trimester, 0.1-2.5 
μIU/mL; second trimester, 0.2-3.0 μIU/mL; and third trimester, 0.3-3.0 μIU/mL.33 However, the 
ATA recently recommended an upper limit of ~ 4.0 μIU/mL when TSH pregnancy references are 
not available.34 The laboratory pregnancy reference ranges for FT4 were: first trimester, 0.7-2.0 
ng/dL; second trimester, 0.5-1.6 ng/dL; and third trimester, 0.5-1.6 ng/dL. In an exploratory 
analysis, we defined subclinical hypothyroidism as TSH exceeding the ATA recommended 
upper limit of 4 μIU/mL in any trimester in combination with a normal FT4 concentration within 
trimester-specific reference ranges.34 The limits of detection (LOD) were 0.01 μIU/mL for TSH, 
0.1 ng/mL for T3, 0.3 μg/dL for T4, and 0.1 ng/dL for FT4. The inter-assay coefficients of 
variation (CV) for all hormones ranged from 2.3% (for total T3) to 10.4% (for FT4) and the 
intra-assay CVs ranged from 1.2% (for total T3) to 12.3% (for FT4).25  
Statistical Analyses 
All analyses were performed using R version 3.3.2. Fetal growth indicators included in 
our study are secondary outcomes in the original nested case-control study of preterm birth. 
Thus, to correct for potential over-representation of preterm birth cases and to make the present 
study more representative of the base LIFECODES cohort, we applied to all analyses inverse 
probability weights representing the inverse sampling fraction for selection of cases (90.1%) and 
controls (33.9%) from the base population.35,36 
To assess the bivariate associations between population characteristics and birth weight 
z-scores, we used linear regression models adjusted for gestational age at delivery. We examined 
the distributions of raw ultrasound measurements and thyroid hormone parameters by calculating 
selected percentiles at each study visit of sample collection as well as at delivery (for birth 




distributions of TSH and FT4 were positively skewed and were natural log transformed (ln) for 
all statistical analyses. We calculated percentiles and tested the differences in mean thyroid 
hormone concentrations between women who underwent ultrasound scans at visit 3 and/or visit 4 
vs. those who did not undergo scans at either visit using linear mixed models (LMMs) with 
subject-specific random intercepts. 
In cross-sectional analysis, we explored the relationships between continuous thyroid 
hormone concentrations measured at each of the four study visits and birth weight z-scores using 
stratified (by study visit) multivariable linear regression models. We included maternal age, 
race/ethnicity, body mass index (BMI) at initial study visit, and fetal sex a priori. Additional 
covariates –such as health insurance provider, educational attainment, parity, and smoking and 
alcohol use in pregnancy– were retained in models if their inclusion resulted in ≥10% change in 
the main beta estimates using a forward step-wise selection procedure. Crude models were 
adjusted for gestational age at time of sample collection. Final models were adjusted for maternal 
age (continuous), race/ethnicity (White/Black/Other regardless of Hispanic origin), BMI at initial 
study visit (continuous), fetal sex (male/female), health insurance provider (private/public), and 
parity (no previous pregnancy/one previous pregnancy/more than one previous pregnancy). 
Given previously published data showing the potential for fetal sex to modify the associations 
between maternal thyroid function and fetal growth,14 we investigated differences in these 
relationships by fetal sex by including an interaction term in each cross-sectional model.  
Our second analysis explored the relationships between repeated measures of thyroid 
hormones and fetal growth z-scores using linear mixed models (LMMs) with one growth 
indicator regressed on one thyroid hormone per model. Given that ultrasound measurements at 
visit 2 tended to be more homogeneous with regard to estimated fetal weight and to remain 
consistent with previous analyses of fetal growth indicators within this cohort,30 we presented 
results from repeated measures models using thyroid hormone and ultrasound measurements 
from visits 3-4. For models with fetal weight as the outcome, we created vectors for each subject 
with repeated measures of estimated fetal weight at visits 3 and 4 and birth weight at delivery. 
Since maternal blood samples were not collected at delivery, we imputed these concentrations by 
using the last observation carried forward method. That is, hormone concentrations from visit 4 




intercept and slope for gestational age – chosen based on Akaike Information Criterion (AIC) – 
and were adjusted for the same covariates as those in our cross-sectional analysis. All LMMs 
were repeated with the addition of an interaction term for fetal sex to investigate potential sex 
differences in these relationships. We also reported results from LMMs that included visit 2 
through delivery for comparison. 
Since thyroid hormones directly influence fetal tissue metabolism4 and are regulated to 
remain within a narrow range,37 we hypothesized that the degree of hormonal variability within 
individual pregnant women may influence fetal growth. To explore this hypothesis, we 
calculated the ratios of intra-individual variation to inter-individual variation (= within-person 
variance/between-person variance) for samples collected at visits 1 through 4. We regressed 
natural log-transformed variability ratios for each hormone on repeated measures of fetal growth 
z-scores using fully adjusted LMMs with the same random effects and covariates as those used 
in the main repeated measures analysis. Results from models utilizing repeated measurements 
from visits 2 through delivery as well as visits 3 for delivery were presented. All associations 
were considered statistically significant at the 5% level. 
RESULTS 
As previously reported, our study participants were predominately white (56%), of a 
healthy BMI (<25 kg/m2; 53%), held private health insurance (80%), and many were college 
educated (38%) (Table V.1). In our bivariate analyses presented in Table V.1, we observed 
significantly lower birth weight z-scores among babies born to Black women compared to White 
women and to women who reported smoking in pregnancy versus those who reported no 
smoking. Significantly greater birth weight z-scores were detected among babies born to 
overweight (25-30 kg/m2) and obese (>30 kg/m2) women compared to women with a healthy 
BMI, to women with at least one previous pregnancy compared to women with no previous 
pregnancies, and in female versus male babies. We did not find a significant difference in birth 
weight between women with subclinical hypothyroidism in gestation (N=10) and those without 
(N=426). Due to the limited number of women with subclinical hypothyroidism, we did not 




We reported distributions of raw fetal growth indicators (not z-scored) as well as thyroid 
hormone concentrations by study visit of sample collection in Table V.2. The weighted median 
(25th-75th percentile) gestational age at delivery was 38.9 weeks (37.9-40.0 weeks) and for birth 
weight, 3345 g (2945-3660 g). Thyroid function parameters were highly detected in this study 
population (percent detected for total T4 and T3 = 100%, TSH = 99.5%, and FT4 = 98%). The 
weighted median (25th-75th percentile) concentrations of the four parameters in the overall study 
population were: TSH, 1.26 µIU/mL (0.85-1.79 µIU/mL); FT4, 1.08 ng/dL (0.85-1.32 ng/dL); 
T4, 10.2 µg/dL (9.1-11.5 µg/dL); and T3, 1.56 ng/mL (1.31-1.89 ng/mL). More women had 
ultrasound scans at visit 2 (N = 389 for HC and AC; N=390 for FL; N = 324 for EFW) compared 
to visit 3 (N = 201 for all growth indicators) and visit 4 (N = 221 for HC; N = 223 for AC, FL, 
and EFW). All women had birth weight measurements (N=439). Thyroid hormone 
concentrations did not significantly differ between women without ultrasound scans at visits 3 
and 4 (N = 146) compared to women with scans during at least one of these visits (N = 293) 
(Table V.S1). Thus, the potential for differential bias resulting from the inclusion of ultrasound 
metrics obtained after visit 2 (i.e., those obtained for clinical indications and not uniformly 
measured for all subjects) is limited. 
Table V.3 presents results from our fully adjusted cross-sectional analysis in which we 
explored the associations between thyroid hormone parameters sampled at each study visit and 
birth weight z-scores. In measurements collected at visits 1-3, we observed significant inverse 
associations between FT4 and birth weight, with the greatest association detected at visit 1. At 
this visit, a unit increase in ln-transformed FT4 was associated with almost a half a z-score 
decrease in birth weight (β = -0.41; 95% confidence interval [CI] = -0.64, -0.18), or 
approximately 175 grams (g) based on the birth weight standard deviation at 40 weeks estimated 
for the reference population.32 The inverse associations for total T4 were weaker than those 
observed for FT4, although a significant association observed at visit 3 (β = -0.08; 95% CI = -
0.13, -0.02). In contrast to the inverse associations observed for free and total T4, total T3 was 
generally positively associated with birth weight z-scores. We detected a significant association 
for T3 at visit 3, at which point a unit increase in T3 was associated with a 0.35 z-score (95% CI 




were detected for TSH at any of the four study visits of sample collection. There were no 
significant interactions with fetal sex (data not shown). 
In Table V.4, we reported our results from repeated measures analysis of thyroid 
function parameters and z-scored fetal growth indicators (HC, AC, and EFW) from visits 3-4 and 
delivery (birth weight). Similar to cross-sectional associations, FT4 was inversely associated 
with fetal growth indicators, with significant estimates found for EFW (β = -0.14; 95% CI = -
0.26, -0.02), HC (β = -0.17; 95% CI = -0.31, -0.02), and AC (β = -0.16; 95% CI = -0.29, -0.02). 
We also observed significant inverse associations between T4 and HC (β = -0.05; 95% CI = -
0.09, 0.00) and AC (β = -0.05; 95% CI = -0.10, 0.00). While repeated measures associations 
were generally inverse for TSH and positive for total T3, the beta estimates for these hormones 
were not significant. We also found no significant associations between thyroid function 
parameters and FL in our study population. Finally, we did not observe any significant 
interactions with fetal sex (data not shown). For comparison, we presented results from our 
repeated measures analysis utilizing samples and ultrasound measurements from visits 2 through 
4 and delivery in Table V.S2. The only significant association in that analysis was observed 
between FT4 and HC (β = -0.12; 95% CI = -0.23, -0.01). 
In our variability analysis, we found higher inter-individual variation compared to intra-
individual variation for all hormones, with total T4 displaying the greatest variability overall 
(Table V.S3). Upon regressing the variability ratio (an index of an individual’s hormone 
variation) on repeated measures of fetal growth z-scores, we observed that a unit increase in the 
variability ratio for total T4 was significantly associated with reduced EFW (β = -0.29; 95% CI = 
-0.58, -0.01), HC (β = -0.41; 95% CI = -0.74, -0.08), and FL (β = -0.43; 95% CI = -0.77, -0.08) 
in models utilizing repeated measurements from visits 3 through delivery (Table V.S4). Similar 
results were observed for models additionally including visit 2 ultrasound measurements (Table 






In this prospective study of pregnant women without overt thyroid disease, we observed 
consistent inverse associations between FT4 and fetal growth indicators. Specifically, FT4 was 
inversely associated with birth weight in cross-sectional models stratified by study visit as well 
as with estimated fetal weight in repeated measures models. Not surprisingly, given that head 
and abdominal circumference are the major constituents of estimated fetal weight, the models 
also found these metrics to be similarly inversely associated. . We observed weaker inverse 
associations for total T4, and a positive relationship between total T3 at median 26 weeks of 
gestation and birth weight. No significant associations were observed for TSH. Finally, we did 
not detect any different effects by fetal sex, although the lack of an interaction may be due to 
sample size limitations. 
Studies investigating the effects of subclinical thyroid dysfunction in pregnancy on fetal 
growth have produced variable results. Subclinical hypothyroidism (elevated TSH and euthyroid 
FT4) in early pregnancy (< 20 weeks of gestation) has been associated with smaller head 
circumference and birth length in 1,107 mother-child pairs,8 and in the third trimester has been 
linked to higher rates of intrauterine growth restriction (IUGR; estimated fetal weight < 10th 
percentile for gestational age) and low birth weight (LBW; < 2500 g) in another large study.9 
High maternal TSH, defined by study-specific cutoffs (i.e., exceeding reference ranges or 90th 
percentile), in the first trimester has also been associated with LBW10 and small for gestational 
age (SGA; birth weight < 10th percentile for gestational age) infants.11 In contrast to these 
findings, a recent study found that subclinical hypothyroidism in early pregnancy was associated 
with a greater risk for large for gestational age (LGA; birth weight > 90th percentile for 
gestational age) in male newborns.14  
Results have also been conflicting for maternal hypothyroxinemia (normal TSH with low 
FT4). One study reported a higher risk for SGA,8 while others have found larger birth weights 
among these babies compared to those born to euthyroid mothers.12,13 Despite these results, 
studies conducted within other large birth cohorts have reported no associations between 
maternal subclinical hypothyroidism or hypothyroxinemia and similar growth metrics at delivery 
(e.g., birth length, head circumference, LBW, or SGA).15-18 In the current study, we did not 
observe an association between subclinical hypothyroidism and birth weight, which may be in 




analysis as only two women had FT4 levels below the trimester-specific reference ranges. 
Moreover, while estimates were generally inverse, we did not detect any associations between 
TSH in pregnancy and birth weight or repeated growth measurements. These dissimilar results 
may be due in part to differences in study sample size, laboratory assays utilized to measure free 
hormones (e.g., chemiluminescence immunoassay vs. radioimmunoassay), timing of sample 
collection in pregnancy, regional iodine status, or varying cutoff points used to define subclinical 
thyroid disease (e.g., different percentile and/or concentrations thresholds). 
The more consistent findings from these studies, however, have been among generally 
euthyroid women in whom increases in FT4 have been associated with smaller birth weight.14,19-
21 In pregnant women without overt thyroid disease, Shields et al.21 observed that maternal FT4 
at 28 weeks of gestation was inversely associated with birth weight in a dose-dependent manner. 
Maternal FT4 within the normal range in early pregnancy (median ~13 weeks) was also 
inversely associated with birth weight in the Generation R cohort20 and in a recent study among a 
community-based cohort of pregnant women living in Amsterdam14. Additionally, Haddow et 
al.19 found that babies born to euthyroid pregnant women with second-trimester FT4 
concentrations in the highest quintile had the lowest birth weight. Our results from the present 
study support these findings. In pregnant women without overt thyroid disease, we detected 
inverse associations between maternal FT4 and birth weight z-scores at three time points in 
pregnancy (median at median 10, 18, and 26 weeks of gestation).We also found consistent 
inverse associations between FT4 and estimated fetal growth as well as head and abdominal 
circumferences in repeated measures analysis. 
Maternal thyroid hormones can indirectly and/or directly influence fetal growth and 
development. The placenta is a thyroid hormone-responsive organ, evident by its high binding 
capacity for T3 and concentration of deiodinase enzymes needed to regulate the transplacental 
passage of maternal thyroid hormones to the developing fetus. 38,39 Prior to the formation of the 
fetal thyroid gland in the second trimester, the fetus relies solely on the trans-placental supply of 
maternal thyroid hormones,39 which are integral in the maintenance and function of the human 
placenta in early pregnancy.3 In vitro studies have shown that maternal T3 may play a 




and decidual remodeling.38,40 Inadequate trophoblast invasion leads to restricted perfusion which  
would be a risk factor for IUGR among other gestational abnormalities.38,41  
During the second half of gestation, thyroid hormones influence intrauterine growth by 
stimulating fetal metabolism (i.e., consumption of oxygen and glucose), affecting fetal 
bioavailability of growth-related hormones (e.g., growth hormones and prostaglandins) and 
growth factors (e.g., insulin-like growth factors), and by indirectly regulating fetal tissue 
accretion and differentiation near term.4 The direct effects of thyroid hormones on skeletal 
growth and tissue differentiation have been shown in animal studies in which the lack of thyroid 
hormones (specifically, T3) in mice resulted in skeletal abnormalities42 and in fetal sheep, 
thyroidectomy showed delayed bone maturation and altered bone strength and density.4,43 While 
free T3 (FT3) is the biologically active thyroid hormone,44 plasma sample volume constraints 
precluded its measurement in our study population. Furthermore, FT3 is generally not routinely 
assessed due to its low sensitivity and specificity for diagnosing hypothyroidism.45,46 For total 
T3, we observed a positive association with birth weight in samples collected at 26 weeks. 
Currently, we are not aware of published data on the relationship between total T3 and fetal 
growth. However, our findings contrast with the null associations reported between unbound T3 
and the risk for LBW and SGA neonates in a population-based cohort of pregnant women.10 
The underlying physiology behind our observed inverse associations between free and 
total T4 and the fetal growth indicators is unclear. In our cross-sectional analyses, we observed 
that associations between FT4 and birth weight z-scores were strongest in the first trimester (in 
terms of both magnitude and significance) – a unit increase in ln-transformed FT4 measured at 
median 10 weeks of gestation was associated with an approximate 175-gram decrease in birth 
weight. While the majority of fetal weight gain occurs after approximately 24 weeks of 
gestation,32,47 our results suggest that maternal FT4 concentrations in early pregnancy may have 
a lasting impact on fetal growth across gestation. These effects may be explained by altered 
placental function, which has an indirect impact on fetal growth by modifying nutritional 
transport and metabolism.48 A crude marker of placental function is placental weight, which 
through surface area influences the capacity of nutrient transfer to the fetus 48 and correlates 
closely with birth weight.49,50 In a cohort of 321 euthyroid pregnant women, Bassols et al. 




potential role of maternal thyroid hormones in regulating placental growth and more indirectly, 
fetal growth.51 Higher maternal FT4 in early pregnancy has also been found to influence 
placental function later in pregnancy.3 Specifically, among pregnant women without thyroid 
disease, a higher maternal FT4 at median 13 weeks of gestation was associated with increased 
vascular resistance in the latter half of pregnancy, and thus, may be a potential risk factor for 
impaired placentation and/or vascularization.3 Maternal FT4 may also influence fetal growth via 
the effects of deiodinase activity in tissues, including the placenta, on maternal metabolism. The 
FT3 to FT4 ratio is an index of thyroid hormone metabolism and the peripheral conversion of T4 
to T3 by deiodinase enzymes.52,53 Previous studies have suggested that higher FT4 and a lower 
FT3 to FT4 ratio in normal pregnancy are associated with reduced maternal BMI and metabolic 
parameters (e.g., hemoglobin A1c and triglycerides).51 In turn, these metabolic markers, 
including maternal BMI, have been found to positively influence placental weight and fetal 
growth.54 Thus, it is possible that within our cohort higher FT4, coupled with potentially lower 
deiodinase activity, may indirectly influence fetal growth via altered maternal metabolism.19 Our 
findings for FT4 may be also explained by other factors determining thyroid hormone 
bioavailability in utero (e.g., transporter or receptor proteins) or additional thyroid hormone-
dependent processes involved in fetal growth that are not captured by the biochemical markers of 
thyroid function available in our study. Further research is required to characterize the 
underlying mechanisms by which FT4 may influence fetal growth in additional cohorts of 
generally euthyroid pregnant women. 
Finally, results from our variability analysis support the findings from a previous 
longitudinal investigation among 132 pregnant women showing markedly higher inter-individual 
variation compared to corresponding intra-individual variation for all hormones assayed.22 
Similar to our study, Boas et al.22 observed the greatest overall variability (both within- and 
between) for total T4 and the largest variability ratio for FT4. Our repeated measures analysis 
revealed that a unit increase in within-subject variance in total T4 was associated with decreased 
head circumference, femur length, and estimated fetal weight z-scores. These results suggest that 
increased variability of total T4 within the normal range may have an impact on fetal bone 
maturation especially since similar associations were not observed for fetal abdominal 




secondary analysis have implications for trimester-specific reference intervals. That is, current 
reference ranges based on population data may not be sensitive markers of thyroid dysfunction at 
the individual-level since they markedly exceed the ranges of intra-individual variation.22,56 
Additionally, the smaller intra-individual variations of thyroid hormones relative to inter-
individual variations suggest that a woman’s thyroid hormone levels remain within a narrow 
range in pregnancy. While additional plasma measurements per woman may reduce exposure 
misclassification, our variability findings suggest that these effects may be marginal and that 
study funds may be better utilized by recruiting more study participants rather than collecting 
additional measurements per subject. Additional studies are required to determine the public 
health and clinical impact of these findings, and to explore whether accounting for the hormonal 
trajectories within each woman in reference intervals (i.e., via creating individual-level reference 
intervals) may help mitigate the potential adverse birth outcomes associated with subclinical 
thyroid dysfunction.  
Our study was limited by sample size for the evaluation of subclinical thyroid disease 
(e.g., subclinical hypothyroidism and hypothyroxinemia) as well as by the fewer ultrasound 
measurements available at later time points in pregnancy. As previously reported, ultrasound 
scans at visits 3 (median 26 weeks) and 4 (median 35 weeks) were not routine and were 
requested if pregnancy complications were suspected. However, receiving an ultrasound scan 
later in pregnancy was not associated with thyroid hormone concentrations in our study 
population, thereby reducing the possibility of differential bias in our results. Additionally, we 
did not measure maternal anti-thyroid antibodies, the presence of which may increase the risk of 
adverse maternal and birth outcomes independent of thyroid function.34 Strengths of our study 
include the availability of up to four repeated measures of thyroid hormone concentrations, 
which allowed us to investigate potential windows of susceptibility in pregnancy to thyroid 
hormone disruption. Repeated ultrasound measurements, standardized to those from a large 
population of pregnant women in Boston, allowed us to explore the influence of subclinical 
changes in thyroid function in gestation on intrauterine growth. Finally, our assay method of 
measuring FT4 using direct equilibrium dialysis followed by radioimmunoassay is preferred over 
traditional immunoassays as it is not influenced by serum binding proteins, which increase 





 Among pregnant women without clinical thyroid disease, we observed consistent inverse 
associations between FT4 and fetal growth indicators, including birth weight. Future animal and 
human health studies are needed to elucidate the biological mechanisms underlying the 





1. Cosmi E, Fanelli T, Visentin S, Trevisanuto D, Zanardo V. Consequences in infants that 
were intrauterine growth restricted. J Pregnancy. 2011;2011:364381. 
2. Risnes KR, Vatten LJ, Baker JL, et al. Birthweight and mortality in adulthood: a 
systematic review and meta-analysis. Int J Epidemiol. Jun 2011;40(3):647-661. 
3. Barjaktarovic M, Korevaar TI, Chaker L, et al. The association of maternal thyroid 
function with placental hemodynamics. Hum Reprod. Mar 01 2017;32(3):653-661. 
4. Forhead AJ, Fowden AL. Thyroid hormones in fetal growth and prepartum maturation. J 
Endocrinol. Jun 2014;221(3):R87-R103. 
5. Blazer S, Moreh-Waterman Y, Miller-Lotan R, Tamir A, Hochberg Z. Maternal 
hypothyroidism may affect fetal growth and neonatal thyroid function. Obstet Gynecol. 
Aug 2003;102(2):232-241. 
6. Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid deficiency during 
pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 
Aug 19 1999;341(8):549-555. 
7. Luewan S, Chakkabut P, Tongsong T. Outcomes of pregnancy complicated with 
hyperthyroidism: a cohort study. Arch Gynecol Obstet. Feb 2011;283(2):243-247. 
8. Su PY, Huang K, Hao JH, et al. Maternal thyroid function in the first twenty weeks of 
pregnancy and subsequent fetal and infant development: a prospective population-based 
cohort study in China. J Clin Endocrinol Metab. Oct 2011;96(10):3234-3241. 
9. Chen LM, Du WJ, Dai J, et al. Effects of subclinical hypothyroidism on maternal and 
perinatal outcomes during pregnancy: a single-center cohort study of a Chinese 
population. PLoS One. 2014;9(10):e109364. 
10. Karakosta P, Alegakis D, Georgiou V, et al. Thyroid dysfunction and autoantibodies in 
early pregnancy are associated with increased risk of gestational diabetes and adverse 
birth outcomes. J Clin Endocrinol Metab. Dec 2012;97(12):4464-4472. 
11. Alvarez-Pedrerol M, Guxens M, Mendez M, et al. Iodine levels and thyroid hormones in 
healthy pregnant women and birth weight of their offspring. Eur J Endocrinol. Mar 
2009;160(3):423-429. 
12. Cleary-Goldman J, Malone FD, Lambert-Messerlian G, et al. Maternal thyroid 
hypofunction and pregnancy outcome. Obstet Gynecol. Jul 2008;112(1):85-92. 
13. Leon G, Murcia M, Rebagliato M, et al. Maternal thyroid dysfunction during gestation, 
preterm delivery, and birthweight. The Infancia y Medio Ambiente Cohort, Spain. 
Paediatr Perinat Epidemiol. Mar 2015;29(2):113-122. 
14. Vrijkotte TG, Hrudey EJ, Twickler MB. Early Maternal Thyroid Function During 
Gestation Is Associated With Fetal Growth, Particularly in Male Newborns. J Clin 




15. Casey BM, Dashe JS, Spong CY, McIntire DD, Leveno KJ, Cunningham GF. Perinatal 
significance of isolated maternal hypothyroxinemia identified in the first half of 
pregnancy. Obstet Gynecol. May 2007;109(5):1129-1135. 
16. Casey BM, Dashe JS, Wells CE, et al. Subclinical hypothyroidism and pregnancy 
outcomes. Obstet Gynecol. Feb 2005;105(2):239-245. 
17. Mannisto T, Vaarasmaki M, Pouta A, et al. Perinatal outcome of children born to mothers 
with thyroid dysfunction or antibodies: a prospective population-based cohort study. J 
Clin Endocrinol Metab. Mar 2009;94(3):772-779. 
18. Sahu MT, Das V, Mittal S, Agarwal A, Sahu M. Overt and subclinical thyroid 
dysfunction among Indian pregnant women and its effect on maternal and fetal outcome. 
Arch Gynecol Obstet. Feb 2010;281(2):215-220. 
19. Haddow JE, Craig WY, Neveux LM, et al. Implications of High Free Thyroxine (FT4) 
concentrations in euthyroid pregnancies: the FaSTER trial. J Clin Endocrinol Metab. Jun 
2014;99(6):2038-2044. 
20. Medici M, Timmermans S, Visser W, et al. Maternal thyroid hormone parameters during 
early pregnancy and birth weight: the Generation R Study. J Clin Endocrinol Metab. Jan 
2013;98(1):59-66. 
21. Shields BM, Knight BA, Hill A, Hattersley AT, Vaidya B. Fetal thyroid hormone level at 
birth is associated with fetal growth. J Clin Endocrinol Metab. Jun 2011;96(6):E934-938. 
22. Boas M, Forman JL, Juul A, et al. Narrow intra-individual variation of maternal thyroid 
function in pregnancy based on a longitudinal study on 132 women. Eur J Endocrinol. 
Dec 2009;161(6):903-910. 
23. Ekinci EI, Lu ZX, Sikaris K, et al. Longitudinal assessment of thyroid function in 
pregnancy. Ann Clin Biochem. Nov 2013;50(Pt 6):595-602. 
24. Haddow JE, Knight GJ, Palomaki GE, McClain MR, Pulkkinen AJ. The reference range 
and within-person variability of thyroid stimulating hormone during the first and second 
trimesters of pregnancy. J Med Screen. 2004;11(4):170-174. 
25. Johns LE, Ferguson KK, McElrath TF, Mukherjee B, Seely EW, Meeker JD. 
Longitudinal Profiles of Thyroid Hormone Parameters in Pregnancy and Associations 
with Preterm Birth. PLoS One. 2017;12(1):e0169542. 
26. Nishioka E, Hirayama S, Ueno T, et al. Relationship between maternal thyroid-
stimulating hormone (TSH) elevation during pregnancy and low birth weight: a 
longitudinal study of apparently healthy urban Japanese women at very low risk. Early 
Hum Dev. Mar 2015;91(3):181-185. 
27. Ferguson KK, McElrath TF, Ko YA, Mukherjee B, Meeker JD. Variability in urinary 
phthalate metabolite levels across pregnancy and sensitive windows of exposure for the 
risk of preterm birth. Environ Int. Sep 2014;70:118-124. 
28. McElrath TF, Lim KH, Pare E, et al. Longitudinal evaluation of predictive value for 
preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol. 




29. American Academy of Pediatrics; American College of Obstetricians and Gynecologists. 
Guidelines for Perinatal Care. 7th ed. Elk Grove Village, IL2012. 
30. Ferguson KK, Meeker JD, Cantonwine DE, Chen YH, Mukherjee B, McElrath TF. 
Urinary phthalate metabolite and bisphenol A associations with ultrasound and delivery 
indices of fetal growth. Environ Int. Sep 2016;94:531-537. 
31. Hadlock FP, Harrist RB, Martinez-Poyer J. In utero analysis of fetal growth: a 
sonographic weight standard. Radiology. Oct 1991;181(1):129-133. 
32. Cantonwine DE, Ferguson KK, Mukherjee B, et al. Utilizing Longitudinal Measures of 
Fetal Growth to Create a Standard Method to Assess the Impacts of Maternal Disease and 
Environmental Exposure. PLoS One. 2016;11(1):e0146532. 
33. Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid 
Association for the diagnosis and management of thyroid disease during pregnancy and 
postpartum. Thyroid. Oct 2011;21(10):1081-1125. 
34. Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid 
Association for the Diagnosis and Management of Thyroid Disease During Pregnancy 
and the Postpartum. Thyroid. Mar 2017;27(3):315-389. 
35. Jiang Y, Scott AJ, Wild CJ. Secondary analysis of case-control data. Stat Med. Apr 30 
2006;25(8):1323-1339. 
36. Richardson DB, Rzehak P, Klenk J, Weiland SK. Analyses of case-control data for 
additional outcomes. Epidemiology. Jul 2007;18(4):441-445. 
37. Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev. 
Apr 2014;94(2):355-382. 
38. Barber KJ, Franklyn JA, McCabe CJ, et al. The in vitro effects of triiodothyronine on 
epidermal growth factor-induced trophoblast function. J Clin Endocrinol Metab. Mar 
2005;90(3):1655-1661. 
39. Chan SY, Vasilopoulou E, Kilby MD. The role of the placenta in thyroid hormone 
delivery to the fetus. Nat Clin Pract Endocrinol Metab. Jan 2009;5(1):45-54. 
40. Oki N, Matsuo H, Nakago S, Murakoshi H, Laoag-Fernandez JB, Maruo T. Effects of 
3,5,3'-triiodothyronine on the invasive potential and the expression of integrins and 
matrix metalloproteinases in cultured early placental extravillous trophoblasts. J Clin 
Endocrinol Metab. Oct 2004;89(10):5213-5221. 
41. Sheppard BL, Bonnar J. Uteroplacental hemostasis in intrauterine fetal growth 
retardation. Semin Thromb Hemost. 1999;25(5):443-446. 
42. Bassett JH, Williams AJ, Murphy E, et al. A lack of thyroid hormones rather than excess 
thyrotropin causes abnormal skeletal development in hypothyroidism. Mol Endocrinol. 
Feb 2008;22(2):501-512. 
43. Lanham SA, Fowden AL, Roberts C, Cooper C, Oreffo RO, Forhead AJ. Effects of 
hypothyroidism on the structure and mechanical properties of bone in the ovine fetus. J 




44. Peeters RP, Visser TJ. Metabolism of Thyroid Hormone. In: De Groot LJ, Chrousos G, 
Dungan K, et al., eds. Endotext. South Dartmouth (MA)2000. 
45. Carvalho GA, Perez CL, Ward LS. The clinical use of thyroid function tests. Arq Bras 
Endocrinol Metabol. Apr 2013;57(3):193-204. 
46. Li H, Yuan X, Liu L, et al. Clinical evaluation of various thyroid hormones on thyroid 
function. Int J Endocrinol. 2014;2014:618572. 
47. Williams RL, Creasy RK, Cunningham GC, Hawes WE, Norris FD, Tashiro M. Fetal 
growth and perinatal viability in California. Obstet Gynecol. May 1982;59(5):624-632. 
48. Roland MC, Friis CM, Voldner N, et al. Fetal growth versus birthweight: the role of 
placenta versus other determinants. PLoS One. 2012;7(6):e39324. 
49. Salafia CM, Zhang J, Charles AK, et al. Placental characteristics and birthweight. 
Paediatr Perinat Epidemiol. May 2008;22(3):229-239. 
50. Sanin LH, Lopez SR, Olivares ET, Terrazas MC, Silva MA, Carrillo ML. Relation 
between birth weight and placenta weight. Biol Neonate. Aug 2001;80(2):113-117. 
51. Bassols J, Prats-Puig A, Soriano-Rodriguez P, et al. Lower free thyroxin associates with a 
less favorable metabolic phenotype in healthy pregnant women. J Clin Endocrinol 
Metab. Dec 2011;96(12):3717-3723. 
52. Dietrich JW, Landgrafe G, Fotiadou EH. TSH and Thyrotropic Agonists: Key Actors in 
Thyroid Homeostasis. J Thyroid Res. 2012;2012:351864. 
53. Mortoglou A, Candiloros H. The serum triiodothyronine to thyroxine (T3/T4) ratio in 
various thyroid disorders and after Levothyroxine replacement therapy. Hormones 
(Athens). Apr-Jun 2004;3(2):120-126. 
54. Roland MC, Friis CM, Godang K, Bollerslev J, Haugen G, Henriksen T. Maternal factors 
associated with fetal growth and birthweight are independent determinants of placental 
weight and exhibit differential effects by fetal sex. PLoS One. 2014;9(2):e87303. 
55. Peleg D, Kennedy CM, Hunter SK. Intrauterine growth restriction: identification and 
management. Am Fam Physician. Aug 1998;58(2):453-460, 466-457. 
56. Hoermann R, Midgley JE. TSH Measurement and Its Implications for Personalised 
Clinical Decision-Making. J Thyroid Res. 2012;2012:438037. 
57. Lee RH, Spencer CA, Mestman JH, et al. Free T4 immunoassays are flawed during 
pregnancy. Am J Obstet Gynecol. Mar 2009;200(3):260 e261-266. 
58. Nelson JC, Weiss RM, Wilcox RB. Underestimates of serum free thyroxine (T4) 





TABLES AND FIGURES 
 
 
Table V.1. Associations between population characteristics (N=439 pregnant women) and birth weight z-scores 
Population Characteristics N (%)b 
 Association with birth weight z-score 
  β (95% CI) p-valuec 
Age 18-24 years old 54 (13)  reference 
 25-29 years old 92 (21)  0.26 (-0.07, 0.60) 0.12 
 30-34 years old 176 (40)  0.32 (0.02, 0.62) 0.04  
35+ years old 117 (27) 
 
0.30 (-0.03, 0.62) 0.07 
Race/Ethnicity White  247 (56)  reference 
 Black 75 (17)  -0.38 (-0.64, -0.12) <0.01  
Other 117 (27) 
 
-0.05 (-0.27, 0.17) 0.67 
Education Levela High School 67 (15)  reference 
 Technical School 76 (17)  -0.13 (-0.47, 0.21) 0.45 
 Junior College or Some College 127 (30)  0.21 (-0.09, 0.51) 0.18  
College Graduate 159 (38) 
 
0.21 (-0.08, 0.50) 0.16 
Health Insurance Providera Private 344 (80)  reference  
Public 83 (20) 
 
-0.24 (-0.48, 0.00) 0.05 
BMI at Initial Visita <25 kg/m2  223 (53)  reference 
 25-30 kg/m2 113 (26)  0.31 (0.08, 0.54) <0.01  
>30 kg/m2 99 (21) 
 
0.34 (0.10, 0.59) <0.01 
IVF No 414 (95)  reference  
Yes 25 (6) 
 
-0.01 (-0.43, 0.41) 0.97 
Fetal Sex Male  198 (46)  reference  
Female 241 (54) 
 
0.27 (0.08, 0.46) <0.01 
Parity No previous pregnancies 197 (45)  reference 
 One previous pregnancy 144 (34)  0.37 (0.16, 0.58) <0.001  
More than one previous pregnancy 98 (21) 
 
0.41 (0.16, 0.66) <0.01 
Tobacco Usea No smoking in pregnancy 402 (93)  reference  
Smoked in pregnancy 31 (7) 
 
-0.42 (-0.8, -0.03) 0.03 
Alcohol Usea No alcohol use in pregnancy 412 (95)  reference  
Alcohol use in pregnancy 18 (5) 
 
0.13 (-0.32, 0.57) 0.58 
Subclinical Hypothyroidisma,d No 426 (98)  reference 
  Yes 10 (2)   0.01 (-0.67, 0.69) 0.98 
Abbreviations: BMI, Body Mass Index 
aMissing observations: N=10 for education level, N=12 for insurance provider, N=4 for BMI, N=9 for alcohol use, N= 6 for 
tobacco use, and N=3 for subclinical hypothyroidism. 
bProportions weighted by preterm birth case-control sampling probabilities to represent the general sampling population. 
cp-value for the difference in mean birth weight z-score in each category compared to the reference using linear regression models 
adjusted for gestational age at delivery. 






Table V.2. Weighted distributions of thyroid hormone and ultrasound measurements by study 
visit of sample collection. 
 N 
Selected Percentiles 
25th  50th  75th  90th 95th Max 
Visit 2 (median 18 weeks) 
Ultrasound Measurements         
Head Circumference (mm) 389 141 148 159 166 173 202 
Abdominal Circumference 
(mm) 
389 119 127 137 148 154 177 
Femur Length (mm) 390 25 27 29 31 32 40 
Estimated Fetal Weight (g) 324 221 253 290 334 361 528 
Thyroid Hormonesa   
      
TSH (µIU/mL) 317 0.98 1.36 1.91 2.52 3.15 6.08 
FT4 (ng/dL) 368 0.92 1.13 1.30 1.54 1.77 8.96 
T4 (µg/dL) 357 9.50 10.6 11.8 12.7 13.6 16.4 
T3 (ng/mL) 301 1.36 1.60 1.90 2.16 2.28 2.86 
Visit 3 (median 26 weeks) 
Ultrasound Measurements         
Head Circumference (mm) 201 231 248 263 280 288 307 
Abdominal Circumference 
(mm) 
201 207 221 239 255 263 280 
Femur Length (mm) 201 46 50 54 57 60 68 
Estimated Fetal Weight (g) 201 810 978 1200 1442 1619 2032 
Thyroid Hormonesa   
      
TSH (µIU/mL) 306 0.90 1.29 1.70 2.31 2.86 8.73 
FT4 (ng/dL) 349 0.81 1.00 1.18 1.44 1.97 12.5 
T4 (µg/dL) 333 9.20 10.3 11.4 12.7 13.5 21.7 
T3 (ng/mL) 286 1.36 1.62 1.90 2.15 2.37 2.79 
Visit 4 (median 35 weeks) 
Ultrasound Measurements         
Head Circumference (mm) 221 308 317 326 333 340 366 
Abdominal Circumference 
(mm) 
223 302 317 333 349 361 393 
Femur Length (mm) 223 65 68 71 74 75 77 
Estimated Fetal Weight (g) 223 2323 2671 3034 3478 3643 4384 
Thyroid Hormonesa   
      
TSH (µIU/mL) 270 0.97 1.35 1.92 2.44 2.71 6.22 
FT4 (ng/dL) 344 0.77 0.96 1.17 1.43 1.58 6.19 
T4 (µg/dL) 337 8.90 10.0 11.4 12.7 13.6 20.2 
T3 (ng/mL) 239 1.40 1.66 2.00 2.21 2.4 3.22 
Birth (median 38 weeks) 
Birth Weight (g) 439 2946 3345 3660 3909 4139 4720 
Analyses weighted by preterm birth case-control sampling 
probabilities.     



















Table V.3. Weighted multivariate cross-sectional associations between thyroid function parameters and birth weight z-scores by study visit of sample 
collection (N=439 pregnant women) 
Hormones 
















(-0.13, 0.10) 0.79 308 
0.02  
(-0.17, 0.20) 0.86 297 
-0.14  
(-0.36, 0.09) 0.23 259 
-0.16  
(-0.38, 0.05) 0.13 
FT4a 359 
-0.41  
(-0.64, -0.18) <0.001 357 
-0.26  
(-0.46, -0.05) 0.01 339 
-0.24  
(-0.44, -0.05) 0.02 330 
-0.10  
(-0.27, 0.07) 0.25 
T4 349 
-0.01  
(-0.06, 0.05) 0.79 346 
-0.06  
(-0.12, 0.00) 0.06 324 
-0.08  
(-0.13, -0.02) 0.01 323 
-0.05  
(-0.11, 0.00) 0.06 
T3 290 
0.25  
(-0.09, 0.59) 0.15 292 
0.25  
(-0.09, 0.59) 0.16 277 
0.35  
(0.01, 0.69) 0.04 228 
0.18  
(-0.13, 0.50) 0.26 
All models adjusted weighted by preterm birth case-control sampling probabilities and adjusted for gestational age at time of sample collection, maternal age, 
race/ethnicity, BMI at initial study visit, insurance provider, parity, and fetal sex. 
















Table V.4. Weighted multivariate repeated measures associations between thyroid function parameters and fetal growth z-scores (N=439 pregnant women; 
measurements from visits 3 through delivery) 
Hormones 
Estimated Fetal Weight  
(V3-delivery) 























(-0.30, 0.05) 0.17 294 
-0.06  
(-0.26, 0.14) 0.55 296 
-0.17  
(-0.38, 0.05) 0.13 296 
-0.06  




(-0.26, -0.02) 0.02 361 
-0.17  
(-0.31, -0.02) 0.02 363 
-0.16  
(-0.29, -0.02) 0.03 363 
-0.10  
(-0.26, 0.05) 0.18 
T4 671 
-0.04  
(-0.08, 0.01) 0.09 346 
-0.05  
(-0.09, 0.00) 0.048 348 
-0.05  
(-0.10, 0.00) 0.04 348 
-0.03  
(-0.08, 0.02) 0.23 
T3 493 
0.21  
(-0.05, 0.48) 0.11 263 
0.15  
(-0.13, 0.42) 0.29 265 
0.16  
(-0.15, 0.47) 0.31 265 
0.06  
(-0.27, 0.39) 0.71 
All analyses weighted by preterm birth sampling probabilities. Linear mixed models include random subject specific random intercept and slope, and were 
adjusted for gestational age at time of sample collection/delivery, maternal age, race/ethnicity, body mass index (BMI) at initial study visit, insurance provider, 
parity, and fetal sex. 




































Table V.S1. Differences in thyroid hormone distributions by availability of 
ultrasound scans at visit 3 and/or visit 4  
Thyroid Hormone 
Median (IQR) 
No ultrasound scans at 
V3 and V4 
(N = 146 women) 
Ultrasound scans at 
V3 and/or V4 
(N = 293 women) 
TSH 1.25 (0.83, 1.84) 1.27 (0.87, 1.73) 
FT4 1.09 (0.85, 1.32) 1.08 (0.85, 1.32) 
T4 10.3 (9.30, 11.3) 10.1 (8.90, 11.6) 
T3 1.55 (1.30, 1.88) 1.57 (1.31, 1.89) 
* p<0.05 for a significant difference in thyroid hormone concentrations between the two groups 
















Table V.S2. Weighted multivariate repeated measures associations between thyroid function parameters and fetal growth z-scores 
(measurements from visits 2 through delivery) 
Hormones 
Estimated Fetal Weight 
(V2-delivery) 










































































All analyses weighted by preterm birth sampling probabilities. Linear mixed models include random subject specific random intercept and slope, and were 
adjusted for gestational age at time of sample collection, maternal age, race/ethnicity, body mass index (BMI) at initial study visit, insurance provider, parity, 
and fetal sex. 











































TSH 0.11 0.65 0.17 
FT4 0.07 0.22 0.31 
T4 0.69 3.03 0.23 
T3 0.03 0.14 0.24 















Table V.S4. Weighted multivariate repeated measures associations between variability ratio of thyroid function parameters and fetal growth z-scores (measurements from 
visits 3 through delivery) 
Variability 
Ratioc 
Estimated Fetal Weight  
(V3-delivery) 






Nd β (95% CI) 
p-
value 
Nd β (95% CI) 
p-
value 
Nd β (95% CI) 
p-
value 
Nd β (95% CI) 
p-
value 
TSHa 717 0.03 (-0.31, 0.36) 0.88 348 -0.12 (-0.54, 0.31) 0.59 350 -0.06 (-0.54, 0.41) 0.80 350 0.21 (-0.26, 0.69) 0.38 
FT4b 817 -0.01 (-0.06, 0.04) 0.78 403 -0.01 (-0.07, 0.05) 0.85 405 0.01 (-0.05, 0.08) 0.66 405 -0.02 (-0.08, 0.05) 0.60 
T4a 795 -0.29 (-0.58, -0.01) 0.04 391 -0.41 (-0.74, -0.08) 0.02 393 -0.09 (-0.43, 0.26) 0.62 393 -0.43 (-0.77, -0.08) 0.02 
T3a 672 0.31 (-0.02, 0.63) 0.07 323 0.25 (-0.12, 0.62) 0.19 325 0.22 (-0.2, 0.63) 0.30 325 0.41 (0.00, 0.82) 0.05 
Linear mixed models include random subject specific random intercept and slope, and were adjusted for gestational age at time of sample collection/delivery, maternal age, race/ethnicity, 
body mass index (BMI) at initial study visit, insurance provider, parity, and fetal sex. 
aln(ratio + 1)             
bln(ratio) 
cVariability ratio = within-woman variance/between-women variance 




















Table V.S5. Weighted multivariate repeated measures associations between variability ratio of thyroid function parameters and fetal growth z-scores 
(measurements from visits 2 through delivery) 
Variability 
Ratioc 
Estimated Fetal Weight  
(V2-delivery) 






Nd β (95% CI) p-value Nd β (95% CI) p-value Nd β (95% CI) p-value Nd β (95% CI) p-value 
TSHa 1021 -0.05 (-0.34, 0.24) 0.74 652 -0.20 (-0.49, 0.10) 0.19 654 -0.21 (-0.55, 0.13) 0.22 655 0.09 (-0.24, 0.42) 0.58 
FT4b 1160 -0.02 (-0.06, 0.03) 0.41 746 -0.03 (-0.08, 0.02) 0.22 748 0.00 (-0.06, 0.05) 0.88 749 -0.04 (-0.09, 0.01) 0.12 
T4a 1129 -0.25 (-0.50, 0.00) 0.05 725 -0.23 (-0.49, 0.03) 0.08 727 -0.08 (-0.35, 0.20) 0.57 728 -0.36 (-0.63, -0.09) 0.01 
T3a 958 0.15 (-0.13, 0.44) 0.3 609 0.00 (-0.28, 0.29) 0.99 611 0.09 (-0.24, 0.42) 0.61 612 -0.12 (-0.45, 0.20) 0.45 
Linear mixed models include random subject specific random intercept and slope, and were adjusted for gestational age at time of sample collection/delivery, maternal age, 
race/ethnicity, body mass index (BMI) at initial study visit, insurance provider, parity, and fetal sex. 
aln(ratio + 1)             
bln(ratio) 
cVariability ratio = within-woman variance/between-women variance 




CHAPTER VI. Conclusions 
 
SUMMARY OF FINDINGS 
This dissertation presents findings from four studies aimed at investigating the 
relationships between environmental phthalate exposure, maternal thyroid function parameters, 
and adverse birth outcomes. Coupled with previous research on this topic, these results provide 
valuable insight into the possible role of subclinical thyroid dysfunction in mediating the 
relationships between environmental phthalate exposure and preterm birth and fetal growth. 
While additional epidemiological investigations are required, the present dissertation work has 
potential implications for medical and public health policies aimed at reducing the social and 
economic burdens of endocrine-related adverse birth outcomes.  
Environmental Phthalate Exposure and Maternal Thyroid Hormones. The preliminary 
investigation of Aim 1 explored the relationships between urinary phthalate metabolites and 
maternal thyroid hormone concentrations in 106 pregnant women from Northern Puerto Rico. In 
the repeated measures analysis that included biomarker measurements collected at up to two time 
points in pregnancy, we observed that MCPP, a nonspecific metabolite of several long-chain 
phthalates, was inversely associated with FT3 (the principal bioactive thyroid hormone). We also 
found that study visit of sample collection significantly modified the relationships between 
certain urinary phthalate metabolites and maternal thyroid hormone concentrations. Specifically, 
we detected stronger inverse associations for both FT3 and FT4 at median 26 weeks of gestation 
compared to those observed at median 18 weeks, with significant negative estimates observed 
between FT3 and MCPP and MCOP as well as between FT4 and metabolites of DEHP. No 




 Results from the follow-up study conducted among the larger, dissertation cohort of 439 
pregnant women in Boston, MA support the previous investigation showing the potential for 
environmental phthalate exposure to disturb circulating levels of thyroid hormones in pregnant 
women. However, compared to the inverse associations observed in the Puerto Rico cohort, 
phthalate metabolites were largely positively associated with free and total thyroid T4 in the 
subsequent repeated analysis using biomarker measurements collected at up to 4 time points in 
pregnancy. While no relationships were observed for TSH in the earlier study, we found inverse 
associations between this hormone and DEHP metabolites as well as MiBP and MCPP. Due to 
sample volume constraints, we did not measure FT3 concentration in the Boston cohort.  The 
discrepant results observed between these two analyses of Aim 1 may be due to differences in: 
population size, number of serial biological samples available as well as the timing of sample 
collection in pregnancy, phthalate exposure levels, laboratory methods used to measure free 
hormones (chemiluminescence immunoassay vs. radioimmunoassay), and/or population 
demographic characteristics. 
 While these repeated measures analyses conducted among two disparate cohorts of 
pregnant women provide suggestive evidence of the possible thyroid-altering effects of 
phthalates in gestation and represented some of largest studies on this topic to date, our analyses 
have potential limitations. For example, we did not assess the iodine status of our participants; 
notably, this trace element is essential for normal thyroid function.1 However, we have no reason 
to believe that iodine status would influence phthalate exposure (and vice versa) and thus, iodine 
concentrations would not be a confounder in the phthalate-thyroid hormone relationship. 
Notably, in a study conducted among a representative sample of U.S. adult men and women, 
iodine excretion had a negligible impact on the significant relationships observed between 
phthalate metabolites and thyroid hormone levels.2 Additionally, as previously mentioned in 
Chapter III, the evaluation of circulating thyroid hormones as a sole indicator of thyroid toxicity 
may have also posed an additional limitation to our analyses.3 Measurements of peripheral 
thyroid hormones may not fully capture the phthalate-induced effects on thyroid homeostasis 
since blood levels of thyroid hormones do not always correspond to actions at the receptor, such 
as regulation of gene expression and the developmental processes in which they are involved.3-5  




specific markers during pregnancy, levels of circulating thyroid hormone measurements may 
serve as the most appropriate biomarker of thyroid disruption in large-scale, epidemiological 
investigations among pregnant women. Finally, these two studies were conducted among 
pregnant women in Northern Puerto Rico as well as predominately white women in Boston, MA, 
which may have implications for the generalizability of results.  
Overall, the findings for Aim 1 call for additional human health and animal studies to 
resolve the direction of the specific relationships between urinary phthalate metabolites and 
maternal thyroid hormone concentrations, to further elucidate periods of vulnerability in 
pregnancy to phthalate exposure, and to reveal the specific biological pathways of phthalate 
action on thyroid function in pregnant women. Furthermore, the implications of these findings on 
maternal and fetal health need to be determined. 
Maternal Thyroid Hormones and Preterm Birth. The analysis of Aim 2 assessed the effects of 
subclinical alterations in thyroid function parameters on the risk of preterm birth in 439 pregnant 
women without clinical thyroid disease participating in a nested case-control study of preterm 
birth in Boston, MA. In our characterization of the hormonal patterns across gestation, we 
observed temporal differences in the trends of TSH and FT4 in early pregnancy between women 
who delivered preterm (cases) vs. at term (controls). Specifically, at approximately median 10 
weeks of gestation we found higher concentrations of TSH and lower concentrations of FT4 in 
cases compared to controls. In particular, the hormonal trajectories in women delivering at term 
were consistent with what has been reported in the medical literature. As mentioned previously 
in Chapter IV, the observed variations in the hormonal patterns between the two groups may 
indicate a lack of thyroidal response to human chorionic gonadotropin (hCG; the pregnancy 
hormone) in women delivering preterm.6 However, additional studies are required to confirm 
these findings and to identify the mechanisms involved. 
Our stratified analysis by study visit of sample collection revealed potential windows of 
susceptibility for preterm birth, especially in early pregnancy. In samples collected at median 10 
weeks of gestation, we observed that a unit decrease in FT4 was associated with a twofold 
increase in the odds of overall preterm birth. Additionally, we observed positive associations 




did not detect any significant associations for TSH. One of the strengths of this study was our 
investigation of these relationships by subtype of preterm birth (spontaneous preterm birth vs. 
preterm birth due to aberrant placentation [“placental” preterm birth]). Here, we observed odds 
ratios that were greater in magnitude and more precise in models of spontaneous preterm alone, 
specifically for FT4 and total T3. While these findings may be due to differences in sample size 
between the two stratified analyses (N=49 for spontaneous vs. N=33 for placental preterm birth), 
our results for spontaneous preterm birth suggest that changes in these hormone concentrations 
during gestation may have particular consequences for spontaneous preterm labor and/or preterm 
premature rupture of the membranes (PPROM). 
Results from our nested case-control study add to the body of literature, which to date 
lacks data on the effects of trimester-specific subclinical alterations in individual parameters of 
thyroid function, especially in late gestation, on the risk of preterm birth. However, potential 
limitations of this investigation should be noted. Due to volume constraints of the biological 
samples, we did not assess the thyroid autoimmunity of our study participants. The presence of 
anti-thyroid autoantibodies have been found to modify the relationships between circulating 
thyroid hormone concentrations and adverse birth outcomes.7,8 Furthermore, our analysis of 
associations by subtype of preterm birth is limited by sample size. Additional studies in larger, 
prospective birth cohorts are required to more confidently determine the extent to which these 
associations differed by obstetric presentation of preterm birth, which would provide insight into 
the potential biological pathways involved.  
While we observed consistently elevated odds of preterm birth for total T3 in our 
analyses, it is possible that these results may be due to unmeasured or residual confounding. That 
is, conceivably, these observed relationships may be due to the effects of other biological factors 
(e.g., deiodinase enzyme activity or thyroid transport proteins) that are physiologically relevant 
to both preterm birth as well as circulating levels of maternal T3. Published studies on this topic 
to date have predominately assessed TSH and free hormones (FT4 and FT3) as these are 
sensitive markers of thyroid dysfunction.9 We are aware of no studies that have previously 
explored the effects of total hormones on the risk of preterm birth (or any adverse birth 
outcomes). While both unbound T4 and T3 initiate biological responses, FT3 is considered the 




Given our findings from this study, further research in qualitatively disparate populations of 
pregnant women is necessary to tease out the relationships between total hormones, in particular 
T3, and preterm birth. 
In conclusion, our results for Aim 2 support previous studies showing the potential for 
subclinical changes in thyroid hormone concentrations in pregnancy to influence the risk of 
preterm birth. Our stratified analyses suggest that these effects may vary by gestational age and 
clinical presentation of preterm birth. Additional human health and animal studies may consider 
taking these findings into account in their investigations of the mechanism(s) by which 
subclinical thyroid dysfunction influences the pathogenesis of preterm birth. 
Maternal Thyroid Hormones and Fetal Growth. Aim 3 examined the extent to which thyroid 
function parameters, collected at up to four times points in pregnancy, were associated with birth 
weight and repeated measurements of fetal growth in 439 pregnant women without clinical 
thyroid disease. In this prospective study, we observed consistent inverse associations between 
FT4 and fetal growth indicators. Specifically, FT4 was inversely associated with birth weight in 
stratified analysis by study visit as well as with estimated fetal weight and head and abdominal 
circumferences in repeated measures models. We observed weaker inverse associations for total 
T4, and a positive relationship between total T3 at median 26 weeks of gestation and birth 
weight. No significant associations were observed for TSH. In contrast to what has been reported 
previously,11 we did not detect any different effects by fetal sex, although the lack of an 
interaction may be due to sample size limitations. Finally, we did not find a significant difference 
in birth weight between women with subclinical hypothyroidism (TSH > 4 μIU/mL with normal 
FT4; N=10) vs. those without (N=426). Due to the small sample size, we did not pursue this 
investigation in additional analyses. 
 While the data on the influences of subclinical thyroid dysfunction on intrauterine and 
delivery indices of fetal growth are conflicting, the inverse associations we observed for FT4 are 
consistent with those previously reported in generally euthyroid women.11-14 A novel finding 
from our analysis was the effects of FT4 in early pregnancy on fetal growth across gestation. As 
mentioned in Chapter V, the underlying physiology behind our observed inverse associations 




placental function, deiodinase activity, and/or maternal metabolism. However, it is also possible 
that these findings can be explained by other factors determining thyroid hormone bioavailability 
in utero (e.g., transporters or receptors), lack of thyroidal response to other pregnancy hormones 
such as hCG, and/or additional thyroid hormone-dependent processes involved in fetal growth. 
Undoubtedly, future research is required to identify the underlying mechanisms that drive the 
inverse relationships observed between FT4 and fetal growth in euthyroid pregnant women. 
 The analyses of Aim 3 included the largest number of repeated thyroid hormone and 
ultrasound measurements on this topic to date, and the standardization of fetal growth indices to 
a larger population of pregnant women in Boston, MA15 allowed us to combine measurements to 
analyze these associations longitudinally. Despite the novelty of our research, this investigation 
was not without limitations. As previously noted for analyses of Aim 2, we did not assess thyroid 
autoimmunity in our study population. Notably, anti-thyroid autoantibodies may increase the risk 
of adverse maternal and birth outcomes independent of thyroid function.16 Additionally, the 
inclusion of visits 3 (median 26 weeks) and 4 (median 35 weeks) ultrasound measurements, 
which were not routine and requested if gestational abnormalities were suspected, may impact 
the generalizability of these results. However, we did not observe differences in the mean 
concentrations of the four thyroid function parameters between women with scans at these visits 
versus those without, thereby limiting the potential for differential bias in our results. 
 Overall, this Aim 3 investigation was consistent with prior studies showing the potential 
for subclinical alterations in maternal thyroid function parameters to influence fetal growth. 
Furthermore, as noted in Chapter V, our findings showing smaller intra-individual variability of 
thyroid hormones compared to inter-individual variability across pregnancy have implications 
for study design (i.e., recruiting additional subjects vs. collecting more repeated measurements) 
as well as for trimester-specific reference intervals (i.e., population-level reference intervals may 
not accurately capture thyroid dysfunction at the individual-level). Since our results may be more 
generalizable to pregnant women who have medical indications that require ultrasounds later in 





Integration of dissertation findings. Together, the results from the three aims of this dissertation 
research suggest that subclinical changes in maternal thyroid function attributable environmental 
exposure to phthalates influence the risk of preterm birth and impact ultrasound and delivery 
indices of fetal growth. Specifically, we found that certain phthalate metabolites, including 
DEHP metabolites, were associated with decreased levels of FT4. In turn, we found that a unit 
decrease in FT4 was associated with nearly two times the odds of preterm birth in women 
without diagnosed thyroid disease. Thus, even slight changes in unbound T4 may have 
deleterious effects on birth outcomes. While additional studies are required to confirm these 
findings in qualitatively disparate populations of pregnant women, placental metabolism of 
maternal thyroid hormones may be underlying these observed relationships. The placenta 
regulates both the quantity and composition of thyroid hormones transported to the fetus via 
activating and deactivating deiodinase enzyme activity.17 In thyroid deficiencies, however, the 
placenta lacks complete compensatory mechanisms necessary to optimize placental transfer of 
maternal thyroid hormones to the growing fetus.17 It is also possible that these findings from 
Aims 1 and 2 may be due to other biological mechanisms involved in both the pathology of 
preterm birth as well as thyroid dysfunction, such as inflammation. Notably, in a separate 
analysis within this dissertation cohort of pregnant women, phthalate exposure was associated 
with increased cytokines, including IL-6, a marker of peripheral inflammation.18 Additional 
research is necessary to elucidate the biological processes involved in relationships between 
phthalate-induced thyroid hormone disruption and preterm birth. 
 Interestingly, in both Aims 2 and 3 we observed consistent significant associations 
between total T3 (free plus unbound) and preterm birth as well as fetal growth indices. In Aim 2, 
total T3 was associated with more than three times the odds of preterm birth, and results from 
Aim 3 showed that total T3 measured at median 26 weeks of gestation was associated with an 
approximate 149-gram increase in birth weight. Since TSH and FT4 are the predominant markers 
of thyroid function measured in clinical settings, studies investigating the effects of total T3 on 
birth outcomes are lacking. However, it is possible that dysfunctional placental metabolism or 
issues in the upstream conversion of T4 to T3 by deiodinase enzymes may be contributing to the 




 Finally, in this research we performed a number of statistical comparisons, and there is 
the potential that some of the observed associations may be due to chance. We did not adjust for 
multiple comparisons (i.e., Type I error) using methods such as Bonferroni correction because 
our outcomes and exposures were correlated and these methods would have been too 
conservative. Furthermore, these studies were conducted to explore novel hypotheses utilizing 
repeated measures designs – representing some of the first of such studies in the field – and were 
conducted for discovery purposes. Correcting for multiple comparisons would have masked 
subtle associations and thus, would have precluded the exploration of these relationships in 
studies aimed to confirm and/or replicate our findings. 
PUBLIC HEALTH IMPACT  
Endocrine-disrupting chemicals contribute substantially to disease and dysfunction, and 
can have transgenerational effects.17-19 In the United States, the annual economic burden 
attributable to diseases associated with endocrine-disrupting chemical exposure was estimated at 
over 2% of the gross domestic product (GDP) or $340 billion.17 The cost associated with 
phthalate exposure was approximately $56 billion – second behind the $240 billion contributed 
by polybrominated diphenyl ether (PBDE) exposure.17 This is likely a conservative estimate as 
the analysis for phthalates did not include the cost of hormone-related adverse pregnancy 
outcomes such as preterm birth and impaired fetal growth. In response to increasing scientific 
research and subsequent public concern about the toxicity of phthalates, various regulatory 
actions directed at restricting the use of certain phthalates in consumer products, particularly 
those concerning infants and children, have been recommended and/or enacted in the United 
States and abroad.20,21 Despite the reformulation of products within the last decade, there are still 
significant gaps in the data regarding the human toxicity of phthalate alternatives.22 Nonetheless, 
reduction of exposure to phthalates and increased production of alternative chemicals can 
decrease the staggering healthcare costs as well as alleviate the lifelong consequences of disease 
and dysfunction associated with these low-dose, ubiquitous exposures.  
In 2012, the United Nations Environment Programme (UNEP) in conjunction with the 
World Health Organization (WHO) published a report on the state of the science of endocrine 




of endocrine-related diseases and disorders, including adverse birth outcome such as preterm 
birth and low birth weight, the document highlighted the significant gaps in research necessary to 
identify possible environmental causes of disease.23 Specifically, it was noted that at the 
time,“[t]here [wa]s very little epidemiological evidence to link [endocrine-disrupting chemical] 
exposure with adverse pregnancy outcomes…”(p. ix).23 While additional epidemiological 
investigations on this topic have been published since the release of this report,18 including two 
investigations conducted among the main dissertation cohort,24,25 few human health studies have 
explored the potential mechanisms through which endocrine disruptors may influence pregnancy 
outcomes. Characterizing biological pathways of chemical action will aid the scientific and 
medical communities in identifying and developing interventions necessary to reduce the burden 
of adverse maternal and neonatal outcomes caused by ubiquitous environmental chemical 
exposure.  
The current dissertation fills a crucial gap in the literature regarding the potential 
mechanisms by which phthalates may affect birth outcomes. Our results in two disparate cohorts 
of pregnant women showed that phthalates have subtle effects on the biochemical markers of 
thyroid function in gestation. Our follow-up studies in the main dissertation cohort revealed that 
even slight changes in these thyroid function parameters – akin to those attributable to phthalate 
exposure – may have deleterious effects on birth outcomes among generally euthyroid pregnant 
women.  
Thyroid dysfunction is common in women of reproductive age, especially pregnant 
women.9 Despite the potential adverse effects of overt and subclinical disease in pregnancy and 
studies showing the cost-effectiveness of universal screening,9,26 testing all women for thyroid 
disease remains a controversial topic.27 Our results from Aim 3 showing greater inter-individual 
variability than intra-individual variability in thyroid hormone concentrations across pregnancy 
coupled with our findings of positive associations between within-woman variability in total T4 
and fetal growth, may have implications for the creation of trimester-specific reference intervals. 
That is, current reference intervals based on population data may not be sensitive markers of 
thyroid dysfunction at the individual-level.28 Currently, the American Thyroid Association 
(ATA) recommends screening only for high-risk pregnant women with certain risk factors (e.g., 




Opposing views of screening stem from uncertainties in the effectiveness of thyroxine treatment 
in pregnancy as well as the heterogeneous results from studies investigating the maternal and 
neonatal health effects of subclinical thyroid disease.29 Potentially complicating these medical 
decisions based on the synthesis of epidemiological literature are the varied cutoff points (i.e., 
concentration vs. percentile) used to define subclinical disease, differences in the timing of 
sample collection, dissimilarities in the iodine status of study populations, as well as 
discrepancies in the laboratory assay methods. Utilizing the largest number of repeated hormone 
and ultrasound measurements to date and implementing analytically accurate free hormone 
assays, the results from this dissertation research necessitate future studies aimed at investigating 
the health and economic benefits of universal screening as well as subsequent treatment of 
subclinical thyroid disease in pregnant women. 
OVERALL CONCLUSIONS 
The increasing incidence in endocrine-related disorders coupled with the exponential rise 
in the global development and use of high production volume chemicals, many of which have 
known endocrine disrupting properties,30 call for policies aimed at reducing exposure to these 
chemicals among susceptible populations such as pregnant women. The present dissertation 
provides additional data on the possible pathways through which one class of chemicals, in 
particular phthalates, may act to influence downstream birth outcomes. More specifically, these 
results suggest that environmental phthalate exposure in pregnancy may influence neonatal 
outcomes via thyroid hormone disruption. Additional longitudinal and multigenerational studies 
are required to identify the particular biological mechanisms involved in phthalate-induced 
thyroid hormone disruption (i.e., actions at the receptor or metabolic effects); quantify the extent 
to which thyroid disruption, in concert with other biological mechanisms such as inflammation, 
mediates these relationships; and to identify the appropriate screening and medical interventions 
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